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Biomimetic agents are synthetic compounds devised to resemble structures and 
properties of natural biomolecules with the aim to solve complex human problems. 
Glycomimetics, nucleoside analogues (NAs) and modified oligonucleotides (MOs) 
represent biomimetic agents that have found various pharmacological applications and 
constitute the topic of the three main sections in which this PhD thesis has been 
organized. The design, the synthesis and then the biological evaluation of such molecules 
have been undertaken in these years; in all cases the aim was the development of new 
agents with targeted pharmacological activity or improved biological selectivity in 
several medicinal chemistry contexts (FIGURE 1). 
 
 
FIGURE 1. Biomimetic agents and enzymatic selectivity. 
GLYCOMIMETICS 
The term glycomimetics refers to molecules that mimic the structure and the activity of 
natural carbohydrates improving their biological, pharmacological or drug-like 
properties. Among a variety of glycomimetics of synthetic or natural origin an important 
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position is occupied by iminosugars.1 Iminosugars (“nitrogen in the ring”- containing 
carbohydrate analogues), also called erroneously azasugars, represent the most 
important class of glycomimetics discovered so far and have received great attention2 in 
the last four decades as therapeutic agents against many diseases due their great ability 
to act as inhibitors3 or enhancers (e.g. pharamacological chaperones)4 of glycosidases 
and glycosyltransferases. Their pharmacological application is however significantly 
hampered by their limited in vivo selectivity. Thus, they can be used for a plethora of 
therapeutic purposes, but they are always accompanied by a wide variety of side effects 
due to their activities against other cellular enzymes. On the other hand, L-iminosugars5 
(unnatural enantiomers) have displayed in several contexts more efficient 
pharmacological properties than their D-antipodes and, especially, improved enzymatic 
selectivity.6 In this context, inspired by these observations, we have first tuned up a 
synthetic strategy to prepare by a de novo stereocontrolled method (starting by the 
synthetically available enol thioether 2 and the Garner aldehyde, 3) enantiomerically 
pure L-DNJ ent-1,7 e.g. L-deoxynojirimycin (to the best of our knowledge never reported 
before) (FIGURE 2). Then, since lipophilicity has been postulated to enhance the 
selectivity of iminosugars, we have developed an alternative route to the existing 
methods for N-alkylation of iminosugars and alkyl chain assembly. Particularly, the 
strategy relies on the combined use of polymer-bound triphenylphosphine (PS-
DPP)/iodine8 as a “clean” and potentially recyclable iodination reagent by an iterative 
procedure not requiring extractive work-up and chromatographic purification steps 
(FIGURE 2). 
 
FIGURE 2. Synthesis and pharmacological applications of L-iminosugars. 
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With the target compounds 4-9 and ent-4-9 in hand, the analysis of their glycosidase 
inhibition properties was extensively explored, in collaboration with Dr Massimo Aureli, 
Prof. Marco Moracci first and then, during a period spent abroad at Department of 
Pharmacology of Oxford University supervised by Dr David Priestman and Prof. 
Frances Platt. Finally, the chaperoning potential of ent-4 in the context of PCT applied 
to Pompe Disease was preliminarily explored (in collaboration with Prof. Giancarlo 
Parenti). 
NUCLEOSIDE ANALOGUES 
Nucleoside analogues (hereafter NAs) are synthetic, chemically modified compounds 
developed to mimic the physiological counterparts to exert their cellular functions.9 They 
have become cornerstones of treatment of viral infections and today many efforts are 
still made to discover more potent, selective and less toxic antiviral NAs. 
In this context three classes of NAs have been herein explored. 
β-L-2′-Fluoro-3′-thiacytidine (F-3TC) stereoisomers: for a long period, it was assumed 
that only D-configured nucleoside analogues (NAs) in analogy with the natural ones, 
could be recognized by suitable enzymes to exhibit their biological activity. After the 
discovery of an unusual nucleoside, 2’,3’-dideoxy-3’-thiacytidine ((+)-BCH-189, 10) 
(FIGURE 3) and of its more potent and less toxic β-L-isomer (Lamivudine, (-)-3TC, 11) 
this paradigm has been challenged. Since then, many L-configured NAs10 have been 
synthetized and the molecular basis for their therapeutic activation, as antiviral or 
anticancer agents, have been elucidated. In efforts to improve 3TC pharmacological 
properties, a great deal of modifications has been explored over the past decades. 
However, no synthetic endeavours have been devoted to the preparation of 3TC 
derivatives having a fluorine atom in the “sugar” backbone at the C2′-position. Thus, 
considered that the selective introduction of fluorine atom into a bioactive nucleoside 
has become an important strategy in the design and discovery of novel drug candidates, 
we explored the synthesis of 2'-fluorinated 3TC derivatives having either (1'S,2'S,4'R) or 
(1'S,2'R,4'R) configuration [i.e. (2'S)-F-3TC (12) and (2'R)-F-3TC (13)] (FIGURE 3).11 
As depicted in the retrosynthetic pathway, the asymmetric sulfoxidation of 3TC afforded 
14 and its Pummerer rearrangement allowed us to obtain 15, suitable substrate to 
stereoselectively introduce the fluorine atom in the desired position. 
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FIGURE 3. Synthesis and antiviral activity of β-L-2′-Fluoro-3′-thiacytidine 
 (F-3TC) stereoisomers. 
 
The nucleoside 13 has been evaluated in vitro as antiviral agent against Hepatitis C Virus 
(HCV), Respiratory Sinctial Virus (RSV) and HIV. The experiments have been 
performed at Gilead Sciences. 
Piperidinyl Nucleosides: in recent times, the fusion of two principal concepts behind the 
research areas of glycomimetics and biomimetic agents has resulted in the development 
of a new class of molecules, defined as iminosugar-based nucleosides.12 On one hand, 
the structural mimicking of carbohydrates (the sugar oxygen atom is replaced by an 
amino function), achieved by iminosugars, has enabled to identify highly efficient 
modulators of the activity of carbohydrate processing enzymes. On the other hand, the 
conformational mimicking of natural nucleosides, achieved with sugar modified 
nucleoside analogues, revealed as a winning strategy for the treatment of viral infections 
(e.g. DNA viruses). Accordingly, iminosugar-based nucleosides have been conceived to 
exploit the efficiency of enzyme inhibition of the iminosugar core for the modulation of 
the activity of nucleoside processing enzymes. In this context, with the aim to expand 
the repertoire of such compounds, we have herein explored the synthesis of piperidinyl 
nucleosides 16 and 17 (FIGURE 4). Learning from the lesson of anti-HHV hexitol 
nucleosides,13 compounds 16 and 17 are conceived to act as conformational 
preorganized nucleosides, exploiting the rigidity of the piperidinyl core with the aim to 
further improve inhibition potency and selectivity and to act as mutagenic antiviral 
agents. 
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FIGURE 4. Novel piperidinyl iminosugar-based nucleosides as selective pharmacological tools. 
As depicted in the retrosynthetic analysis, our synthetic approach starts from the well-
known glucosidase inhibitor 1-deoxynojirimycin (D-DNJ, 1) prepared on large scale 
from 19. Through studied protection and functionalization reactions, C-3 deoxygenated 
key intermediates 18a-c are readily synthetized and the nucleobase insertion is then 
performed by nucleophilic displacement of a good leaving group (from 18b) or by 
Mitsunobu procedure (from 18c, obtained by 18a), leading to the target piperidinyl NAs 
16 and 17. A conformational analysis devoted to study of preferred chair conformation 
(e.g. 4C1→1C4 inversion owing to occurring 1,3-diaxial interactions) of 16 has been 
undertaken. Finally, preliminary biological in vitro assays of 16 against a variety of DNA 
viruses (HSV-1 and 2, VZV, HCMV, Vaccinia Virus and Adenovirus) has been 
performed at Rega Institute for Medical Research (KU Leuven, Belgium). 
D- and L-Cyclohexenyl Nucleosides: as highlighted above, replacement of the 
(deoxy)ribose core of natural nucleosides with conformationally restricted bioisosteric 
moieties has demonstrated to greatly improve the thermodynamic stability of enzyme-
substrate recognition processes, while providing molecules able to be selectively 
recognized by viral enzymes over their natural counterparts. In this area, nucleosides 
bearing cyclohexenyl scaffolds have deserved considerable attention over the last 
years.14 Indeed, the peculiar nature of the cyclohexenyl ring (fluctuating between low 
energy 2H3 and 3H2 conformations, see FIGURE 5) allows the corresponding nucleosides 
(remarkably, in both enantiomeric series) to closely resemble the bioactive 
conformations adopted by natural deoxynucleosides while interacting with host/viral 
kinases and polymerases. 
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FIGURE 5. Asymmetric synthesis of D- and L-cyclohexenyl nucleosides. 
With the aim to expand the repertoire of bioactive cyclohexenyl nucleosides, we have 
herein explored the synthesis and the antiviral potential of novel cyclohexenyl 
nucleosides 20a,b and ent-20a,b, lacking the OH group at C5' position and therefore 
being conceived as chain terminators (FIGURE 5). The synthetic path involves an 
enantioselective organocatalytic aldol addition of cyclohexanone 22, to set the chirality 
of target nucleosides, and a stereoconvergent Tsuji-Trost rearrangement of carbonates 
21, to set the relative cis configuration of the substituents. Nucleosides 20a,b and  
ent-20a,b are currently undergoing extensive in vitro assays aimed at determining their 
potential against a variety of DNA viruses and retroviruses. 
MODIFIED OLIGONUCLEOTIDES 
The challenge of chemists in this field is the construction of modified oligonucleotides 
(MOs) with deep structural changes compared to natural oligonucleotides (ODNs), able 
to keep their potential for selective cross communication but, on the other hand, able to 
enhance nuclease stability, target binding affinity, enzyme interaction, hybridization 
properties, cellular uptake and pharmacokinetic/pharmacodynamic properties.15 Among 
MOs, those having aptameric properties (ability to bind a molecular target with high 
affinity and specificity) represent the new frontier of their medicinal use.16 Looking for 
the preparation of novel selective aptamers, the attention has been focused on NU17217 
(FIGURE 6), a 26-mer whose structure has been hypothesised and, on the basis of the 
sequence (5’-CGCCTAGGTTGGGTAGGGTGGTGGCG-3’), seems to belong to the 
class of bimodular oligonucleotides that adopt a so called duplex/quadruplex 
conformation. Particularly, NU172 is able to bind the thrombin (a trypsin-like serine 
protease involved in the coagulation cascade) at very low concentration (Kd = 100 pM) 
and it is currently in Phase II of clinical trials as anticoagulant agent. The project arises 
in the frame of a scientific collaboration with Prof. P. Herdewijn (Rega Institute for 
Medical Research, KU Leuven) and has concerned the replacement of several residues 
of NU172 sequence with hNA (1',5'-anhydro-D-arabino-hexitol nucleotides) in order to 
study the influence of hexitol nucleosides 23 and 24 in the ability of resulting MOs 
(NU172A-E0618) to bind the thrombin acting as its aptamers and as anticoagulant 
agents (FIGURE 6). 
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FIGURE 6. Synthesis of modified thrombin aptamers  
as potential anticoagulant agents. 
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PREFACE 
BIOMIMETICS AND BIOLOGICAL SELECTIVITY 
Organic synthesis, medicinal chemistry and drug discovery represent today the main 
direction toward which the modern organic chemistry is reorienting. Drug discovery 
needs indeed basic study into the medicinal and chemical nature of the diseases to treat 
and, with this aim, the synthesis of newer organic molecules with more favourable 
therapeutic properties or their conversion into derivatives which show optimum 
medicinal activity, is necessary. The role of organic synthesis, and particularly of 
asymmetric synthesis, results central in this context considering that a minor change in 
the molecule chemical structure (i.e. change in stereochemistry, geometry, functional 
group, removal of groups, chelate formation, salt formation) may strongly modify its 
medicinal activity. The drug discovery usually progresses through several standard 
stages; these include: the selection of the biological target; identification of the starting 
building block and/or leads; compound design and synthesis; SAR studies; computers 
and computational chemistry; screening of the synthesised compound in biological in 
vitro assay and finally, pharmacokinetic and in vivo studies. Several of the above 
described stages have been the principal phases of the research projects undertaken in 
the last three years and fully described in the present PhD thesis; they were aimed to the 
study of the selectivity associated to biomolecular recognition processes in which novel 
synthetized biomimetic agents with potential pharmacological applications have been 
involved. The term “biomimetics” refers to human-made (unnatural) systems that 
imitate the natural ones. In the context of drug discovery, nucleoside analogues (NAs), 
glycomimetics and modified oligonucleotides (MOs) are examples of biomimetic agents 
that found over the years pharmacological application and represent the three sections 
of the following PhD thesis. On the basis of the scientific concept introduced by Paul 
Ehrlich (Physiology Nobel Prize in 1908) about the development of substances that 
would seek out specific disease-causing agents, called “magic bullets”, the attention has 
been focused, as mentioned above, on the development of such biomimetic agents with 
targeted pharmacological activity or improved biological selectivity in several 
medicinal chemistry contexts. To this aim, the role of conformation and configuration of 
such molecules has been deeply investigated. 
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GLYCOMIMETICS 
The term "glycomimetics" refers to natural or synthetic molecules that mimic the 
structure and the activity of natural carbohydrates. The need to synthesize glycomimetics 
derives from the fact that the carbohydrates themselves are often degraded too rapidly 
in vivo and because they weakly bind the proteins. Therefore, a research line is focused 
on the design of carbohydrate analogues with shapes and polarities resembling natural 
sugars and able to mimic, alter or replace native carbohydrate moieties, for improving 
their biological, pharmacological or drug-like properties. Glycomimetics are indeed 
able to inhibit the activity of carbohydrate-processing enzymes, especially glycosidases 
and glycosyltransferases; these are ubiquitous enzymes involved, respectively, in the 
breakdown of oligo- and polysaccharides and in their biosynthesis from smaller 
oligosaccharide sequences or even starting from single monosaccharides. These 
processes are of key importance, inter alia, for the synthesis of glycoproteins, which play 
a role in cell communication processes. In most cases, the inhibition capacity of 
glycomimetics against glycosidases and glycosyltransferases is due to their aptitude to 
mimic the transition state of the process of cleavage or formation of a glycosidic bond. 
Glycomimetic research has thus so far progressed in numerous fields of investigation, 
developing structures alternative to native carbohydrate buildings for the treatment of a 
broad range of inflammatory and infectious diseases. In Figure 1 are reported several 
prominent examples of glycomimetic-based drugs. 
 
Figure 1. Examples of glycomimetic-based drugs on the market. 
Among the most effective and studied glycomimetics (as seen in Figure 1), an important 
position is occupied by iminosugars. Iminosugars (“nitrogen in the ring”- containing 
carbohydrate analogues), also called erroneously azasugars, represent the most 
important class of glycomimetics discovered so far and have received considerable 
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attention over the last four decades as therapeutic agents against many diseases. Their 
pharmacological application is however significantly hampered by their limited 
selectivity in vivo. Thus, they can be used for a plethora of therapeutic purposes, but 
they are always accompanied by a wide variety of side effects due to their activities 
against other cellular enzymes.  
During this PhD research project that is aimed at exploring the stereoselectivity of 
biomolecular recognition processes, great attention has been focused on the 
stereoselective synthesis of the unnatural enantiomer of the well-known glycosidase 
inhibitor DNJ and of its N-alkylated congeners. The aim was to study those 
configurational and structural features of iminosugars (chirality and lipophilicity) 
useful to reach an improvement of their selectivity toward glycosidases, either in the 
inhibition of their biological activity or in the enhancement of their catalytic function, 
with specific applications in medicinal chemistry. 
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1.1.1 INTRODUCTION 
1.1.1.1 IMINOSUGARS: CHEMICAL STRUCTURE AND NATURAL OCCURRENCE 
Iminosugars are naturally occurring or synthetic small organic compounds that mimic 
carbohydrates but contain a nitrogen atom instead of oxygen in the ring system 
template.1 The iminosugar motif is present in several classes of monocyclic and bicyclic 
compounds, leading to a large and structurally diverse class of molecules (FIGURES 1-
4). However, the wide diversity of natural occurring iminosugars suggests, undoubtedly, 
that further structures can be identified in the next future. 
 
FIGURE 1. Main structural (monocyclic and bicyclic) motifs of iminosugars commonly available 
by synthetic methods or from natural sources. 
The template is typically substituted with hydroxyls, but many other functional groups 
are found in nature and easily introduced by synthetic approaches. Among iminosugar 
pyrrolidine analogues, DMDP ((2R,3R,4R,5R)-2,5-dihydroxymethyl-3,4-
dihydroxypyrrolidine) is a naturally occurring glycomimetic2 and it is one of the most 
widespread of secondary metabolite sugar mimics. DMDP can be viewed as a nitrogen-
containing β-fructose mimic and it is related to another natural product D-AB-1 by the 
removal of one of the two hydroxymethyl groups (FIGURE 2).3 
 
FIGURE 2. Some pyrrolidine iminosugars. 
In 1966 NJ (Nojirimycin) was discovered as a first natural glucose mimic isolated from 
a Streptomyces roseochromogenes filtrate; manno-NJ (Nojirimycin B) and galacto-NJ 
(Galactostatin) were isolated soon after (FIGURE 3).4 Despite their remarkable biological 
activity, they are fairly unstable due to the lability of hemiaminal function that rapidly 
gives the corresponding dehydration by-product. Therefore, they are stored as bisulfite 
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adducts or reduced as 1-deoxy-derivatives. DNJ (1; 1-deoxynojirimycin) was for the first 
time prepared by NJ reduction5 and then isolated from the roots of mulberry trees as well 
as from Streptomyces cultures. FAG (Fagomine) is the 1,2-dideoxy analogue of DNJ and 
was isolated from the seeds of Japanese buckwheat and then in the leaves and roots of 
Xanthocercis zambesiaca.6 α-HNJ (α-homonojirimycin) was the first discovered, 
naturally occurring C1-branched DNJ derivative;7 however, before its isolation, its β-D-
glucoside has been designed as a potential drug for the treatment of diabetes mellitus 
and only subsequently it was isolated from natural sources (FIGURE 3). 
 
FIGURE 3. Some piperidine iminosugars. 
As highlighted in FIGURE 1, there are three groups of bicyclic polyhydroxy-heterocyclic 
compounds, in which two five-membered rings (pyrrolizidines) or one five-membered 
ring and one six-membered ring (indolizidines and nortropanes) are fused together. 
These molecules have less obvious structural similarity toward monosaccharides but in 
each case the hydroxyl substituent configurations can be correlated to those of sugars. 
Castanospermine can be viewed as a bicyclic derivative of DNJ, with an ethylene bridge 
between the hydroxymethyl group and the ring nitrogen (FIGURE 4). 
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FIGURE 4. Some bicyclic iminosugars. 
1.1.1.2 NITROGEN IN THE RING: STRUCTURAL BASIS TO EXPLAIN THE 
VERSATILE IMINOSUGAR BIOLOGICAL POTENTIAL 
An attractive approach devoted to developing novel compounds able to selectively and 
potently interact with target enzymes relies on the design of mimics of their reaction 
(enzyme catalysed) transition state. The Transition State Theory is the rationale behind 
this method; it states that the reaction point in which the reactants have equal probability 
of going forward to products or reverting to reactants, is called transition state (TS) and 
the binding constant (Kd) with which the enzyme interacts with the TS is proposed to be 
1010-1015 fold more high then to the reactants. Therefore, ideally, chemically stable 
analogues of TS are expected to be efficient enzymatic competitive inhibitors. 
Iminosugars are sometimes defined “powerful glycomimetics” because of their great 
ability to interact as transition state analogues of carbohydrates processing enzymes, 
glycosidases and glycosyltransferases (FIGURE 5). In both cases, the TS is supposed to 
be quite close to a cation/oxocarbenium ion with a sp2 character at the anomeric carbon 
(as deduced by isotope effects measurements) and spatially oriented in a half-chair 
conformation.8 Therefore, it is easy to understand why the protonated forms of 
iminosugars, resembling in terms of charge such oxocarbenium TS, are able to 
efficiently interact with such enzymes, resulting their inhibitors9 or enhancers. The 
resulting ammonium ion indeed would be expected to mimic the partial positive charge 
developing on the endocyclic oxygen and bind to the enzymatic anionic residues.10 It 
must be noted that piperidinyl iminosugar such as NJ or DNJ typically adopt a chair-like 
conformation and, therefore, they cannot be expected to be perfect TS analogues 
(FIGURE 5). This assumption may be true, but as these derivatives bind 103-104 times 
more strongly to such enzymes than glucose, the protonated nitrogen must play an 
important role in the binding process.11  
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FIGURE 5. Reaction mechanism involving catalysis of glycosidases and glycosyltransferases. GD 
= Glycosyl Donor; GA = Glycosyl Acceptor; TS = Transition State. 
Since glycosidases and glycosyltransferases are involved in a wide range of anabolic and 
catabolic processes (i.e. GSLs biosynthesis, lysosomal catabolism of glycoconjugates, 
glycoprotein biosynthesis, ER quality control and ER-associated degradation of 
glycoproteins) their in vivo modification or block by use of inhibitors or enhancers is of 
a great interest from a therapeutic point of view. 
 
FIGURE 6. Conformational preferences of piperidinyl iminosugars and TS. 
1.1.1.3 PHARMACOLOGICAL APPLICATIONS 
The initial pharmaceutical interest in these compounds was related to their inhibitory 
activity toward a wide range of carbohydrate processing enzymes (as underlined in the 
above paragraph); thus, extensive efforts devoted to their isolation from natural sources 
or their synthetic preparation were made. However, over the last ten years, it has become 
clear that they can exploit biological function not only as enzyme inhibitors but also as 
their active-site chaperones and/or allosteric modulators. The difficult aim of the present 
section is to describe the main emerging and promising pharmacological applications12 
of this class of molecules, giving attention to those in which the iminosugars have 
displayed great efficacy and specificity. 
1.1.1.3.1 IMINOSUGARS AS GLYCOSIDASE INHIBITORS 
1.1.1.3.1.1 GAUCHER DISEASE: GCS INHIBITION 
Lysosomal Storage Diseases (LSDs) are a collection of genetic disorders that typically 
occur in infancy or early childhood.13 Over 40 different LDSs have been identified and 
are characterized by the accumulation of storage molecules in late 
 10 
 
endosomes/lysosomes. Most of these disorders results from mutations in the genes that 
encode the catabolic enzymes of lysosome14 leading to lysosomal storage of GSLs 
(glycosphingolipids);15 Gaucher disease belongs to this specific subgroup. It is caused 
by the deficiency of β-glucocerebrosidase (acid β-glucosidase GBA1 or GCase; EC 
3.2.1.45) and leads to accumulation of GlcCera (GlucosylCeramide; see FIGURES 7 and 
9). 
 
FIGURE 7. Glycosphingolipid catabolism and associated LSDs (adapted from ref. 15). 
The ERT (Enzyme Replacement Therapy)16 is one of the two approved clinical treatment 
for Gaucher disease; it consists in frequent intravenous infusions of the recombinant 
forms of wild-type enzymes (Cerezyme®). However, despite the remarkable efficacy of 
ERT in treating patients with Gaucher disease, lysosomal enzymes do not cross the 
blood-brain barrier; moreover, the high costs of ERT limit its global access. The only 
alternative approved therapy for LSDs is an oral, small-molecule approach termed 
Substrate Reduction Therapy (SRT) and it was applied for the first time in the treatment 
of Gaucher disease type 1. N-butyl-D-deoxynojirimycin (2, NBDNJ, Miglustat, 
Zavesca®; Actelion Pharmaceuticals Ltd) is the small molecule (see FIGURE 8) able to 
inhibit the first step in GSL biosynthesis – the conversion of Ceramide to GlcCer, 
catalysed by GlcCer Synthase, GCS (Ceramide glucosyltransferase, GlcCerT; EC 
2.4.1.80). NBDNJ, because its structural homology with ceramide may in part explain 
its competitive inhibitory activity toward GCS (TABLE 1).17 During their studies, 
Overkleeft et al. developed selective and potent inhibitors of GBA1, GBA2 and GCS, 
finding that N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimicyn (AMPDNM, 
8) was a 100-fold more potent GCS inhibitor than NBDNJ. However, 8 also strongly 
inhibited GBA1, GBA2 as well as intestinal lactase, sucrase and isomaltase resulting in 
                                                 
a GlcCer is substrate either of GBA1 and of GBA2 (as specified in the next paragraph). 
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a not selective compound; moreover, replacement of the adamantanemethyl group with 
linear alkyl substituents (butyl up to nonyl) led to comparable strong inhibition but not 
to selectivity (FIGURE 8 and TABLE 1).18 
 
FIGURE 8. N-alkyl-D-iminosugars. 
TABLE 1. IC50 (µM) of N-alkyl-D-iminosugars toward various enzymes. 
Compound GCS GBA1 GBA2 Sucrase Lactase Maltase 
2 50 400 0.23 0.6 750 9 
3 >20 500 0.4 2 >1000 10 
4 >20 80 0.11 1 700 10 
5 40 18.5 0.045 0.5 500 10 
6 4 4 0.020 0.75 300 8 
7 4 1.5 0.007 0.4 200 8 
8 0.2 0.2 0.001 2.5 35 4 
9 4 30 0.06 2 300 8 
10 2 705 0.04 1.2 300 4 
11 1 205 0.008 2 200 5 
12 0.3 1.75 0.015 0.8 250 7 
13 0.2 0.5 0.010 1 200 10 
14 0.1 0.5 0.040 1 350 25 
 
1.1.1.3.1.2 CYSTIC FIBROSIS: GBA2 INHIBITION 
Cystic Fibrosis (also referred as CF) is a genetic (inherited) disease caused by mutations 
in the gene which encodes for the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) protein.19 The main CF severe symptoms and complications, due to 
 12 
 
the chronic lung inflammation, are treated with antibiotics, non-steroidal anti-
inflammatory drugs or glucocorticoids.20 
 
FIGURE 9. GlcCer metabolism. 
Ceramideb-enriched membrane platforms have been identified as central to the host’s 
cellular and tissue responses to P. aeruginosa infection in CF patients. These findings 
have suggested the possibility to correct the infection by modulating (reducing) ceramide 
levels to their physiological range opening the possibility of targeting Cer metabolism 
as new therapeutic strategy for CF lung disease.21 Similarly to GBA1, also the neutral 
GBA2,22 a non-lysosomal glucosylceramidase (β-glucosidase) residing in the cytoplasm, 
is able to degrade glucosylceramide (GlcCer) into Cer and glucose (FIGURE 9). N-
alkylated iminosugars employed in several medicinal chemistry studies (e.g. SRT, 
Substrate Reduction Therapy) also inhibit GBA2 (TABLE 1). Particularly, D-NBDNJ (2, 
Miglustat, see FIGURE 8) inhibits GBA2 with IC50 values in the nanomolar range, 
whereas it inhibits GlcCerT and GBA1 at µM concentrations.23 These values indicate 
that Miglustat holds a higher affinity to GBA2, compared with GlcCerT and GBA1. 
DeChecchi et al. have recently demonstrated that Miglustat reduces the P. aeuriginosa-
dependent transcription of IL-8 in human bronchial epithelial cells in vitro and 
downmodulates neutrophil chemotaxis in murine lungs in vivo, providing clinical 
evidence to support the use of Miglustat in treating CF lung inflammation.24,25 
1.1.1.3.2 IMINOSUGAR CHAPERONING ACTIVITY 
As above mentioned for Gaucher Disease, most of the LSDs originate from the arrest of 
GSLs metabolism (the critical step at which it blocks depends by the specific disease), 
thus reactivation of the substrate hydrolysis with pharmacological chaperones could 
represent a valid strategy to rescue the precise defected glycosidase without interfering 
with any other enzymatic process.26 This is the concept behind the Pharmacological 
Chaperone Therapy (PCT) applied for the first time in the treatment of Pompe disease 
(see PARAGRAPH 1.1.1.3.2.1) and then, successfully, for other LDSs (see for example 
PARAGRAPH 1.1.1.3.2.2). The main advantage in its formulation relies on the possibility 
to choose the glycomimetic chaperone tuning its configurational properties depending 
                                                 
b The cell membrane contains domains enriched with sphingolipids (SLs) and glycosphingolipids 
(GSLs); ceramide (Cer) (FIGURE 9) represents the SL metabolism cornerstone.  
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by its glycosidase discrimination capabilities (enzymes acting on gluco or galacto, - or 
-pyranosyl substrates). Pompe and Fabry diseases are perfect examples to well explain 
the latter concept. 
1.1.1.3.2.1 POMPE DISEASE: GAA REACTIVATION 
Acid α-glucosidase (GAA; EC 3.2.1.20) is a lysosomal enzyme enabling the degradation 
of glycogen to glucose (glycosyl hydrolase family, GH31).27 A deficiency in GAA 
activity leads to intralysosomal glycogen storage, causing extensive and progressive 
damages to cardiac and skeletal muscles.28 The genetic disorder due to mutations-
induced functional defects of GAA is known as Pompe disease (PD; glycogen storage 
disease type II) and represents one of the most common lysosomal storage disorders 
(LSDs).29 To date, the only clinically approved strategy for the treatment of the disease 
is the enzyme replacement therapy (ERT) based on intravenous administration of 
recombinant human GAA (rhGAA, Myozyme).30 Even though ERT has shown to 
stabilize the disease course, use of rhGAA has some major limitations, regarding, inter 
alia, its adequate delivery to lysosomes and the stability to nonacidic conditions. 
Looking for alternative approaches, the identification of small molecule chaperones able 
to restore functions and properties of the mutated enzyme (the core of the so-called 
Pharmacological Chaperone Therapy, PCT) is representing an emerging strategy and a 
formidable challenge of the modern biomedical research.31 According to PCT, the use 
of suitable GAA ligands enables stabilization of protein conformation, inhibits 
premature misfolding and facilitates enzyme translocation into the lysosome, thereby 
preventing ER-associated degradation processes. Among pharmacological chaperones,32 
the iminosugar drug33 N-butyl-D-deoxynojirimycin (D-NBDNJ, 2) currently represents 
one of the most promising candidates under development for the treatment of Pompe 
Disease. In early studies, Miglustat has been found to improve residual activity and 
lysosomal trafficking of mutated GAA in cultured fibroblasts from Pompe patients.34 
Even more remarkably, the chaperone has subsequently demonstrated to enhance the 
physical stability and therapeutic efficacy of rhGAA itself.35 This finding has represented 
the first documented example of a synergistic effect deriving from the combined use of 
PCT and ERT, which has opened the way to the so-called “combination therapy” for the 
treatment of various LSDs. Higher lysosomal GAA levels in blood as resulting from co-
administration of rhGAA and Miglustat have been recently found in animal models and 
in PD patients.36 
1.1.1.3.2.2 FABRY DISEASE: α-Gal A REACTIVATION 
Fabry Disease is a LSD caused by mutations in the GLA gene that encodes for lysosomal 
α-galactosidase A (α-Gal A; EC 3.2.1.22); α-Gal A cleaves α-linked galactopyranosyl 
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moieties of neutral GSLs, mainly GL-3 (glotriaosylceramide, FIGURE 10). Deficiency 
in α-Gal A activity results in the accumulation of GL-3, which gives rise to a variety of 
clinical manifestations such as cardiomyopathy, renal disfunction, stroke and 
neurological symptoms.37 ERT using recombinant human α-Gal A has been available 
since 2001; two preparations are marketed: Replagal® (produced by Shire Human 
Genetic Therpies, Cambridge, MA) approved in the European countries and Fabrazyme® 
(produced by Genzyme Corporation, Cambrdige, MA) approved in the United States. 
Adverse effects of ERT include fever, rigors and chills; moreover, during ERT, disease 
progression may occur due to low physical stability of recombinant enzyme, a short 
circulating half-life and variable uptake in different tissues. Thus, novel therapeutic 
strategies are needed to treat patients with Fabry disease. 
 
FIGURE 10. Gb3 and Migalastat. 
Recently, 1-deoxygalactonojirimycin (DGJ, Migalastat, Galafold®) has been designed 
as orphan drug by FDA (2004) and then it has been approved by European Commission 
as drug for the treatment of Fabry disease (2016). The molecule is able to inhibit α-Gal 
A (it mimics the terminal galactose of Gb3, see FIGURE 10), but at sub-inihibitory 
concentration it is able to act as pharmacologic chaperone of the defected enzyme 
restoring its biological functions.38 Furthermore, co-administration improves the 
pharmacological properties of recombinant human α-Gal A preventing its denaturation 
and activity loss.39 
1.1.1.4 PHARMACEUTICAL ADVANTAGES AND DISADVANTAGES IN THE 
CLINICAL USE OF IMINOSUGARS 
• Advantageous properties: iminosugars have several intrinsic positive properties 
useful to their candidature as potential drugs. Many potent small molecules have 
only marginal solubility and enormous resources and efforts are be made to 
address this issue both in medicinal chemistry and formulation. The iminosugars, 
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because of their polar nature, have instead adequate water solubility. The entry of 
iminosugars into cells appears to work by passive, non-facilitated diffusion, or by 
flip-flop across the membrane.40 The rate of entry seems be independent of N-
alkyl chain length but increasing lipophilicity results in more protein and 
membrane binding.c In vivo studies have also revealed a correlation between 
increasing N-alkyl-iminosugar hydrophobicity and tissue access and 
sequestration; for example a greater liver and brain penetration was observed for 
NNDNJ (7) (containing a 9-carbon chain) than for NBDNJ (2) (containing 4-
carbon chain).41 These factors, if extrapolated to humans, offer considerable 
potential benefit for treating the neuronopathic disorders where ERT is of 
marginal efficacy due to lack of blood–brain barrier access. Iminosugars are 
chemically and metabolically stable molecules; they are typically excreted 
unchanged in urine.42 Such properties and others distinguish iminosugars from 
other small polar molecules and increase the attraction of using them as drug 
molecules. 
• Disadvantageous properties: despite their enormous potential as therapeutics, to 
date very few iminosugars have reached the pharmaceutical market. In fact, their 
pharmacological applications are significantly hampered by the limited selectivity 
in vivo. Thus, they can be used for a plethora of therapeutic purposes, as seen 
above, but they are always accompanied by a wide variety of side effects due to 
their activities against other cellular enzymes. Adverse effects are: abdominal 
bloating, flatulence, diarrhoea (due to the inhibition of intestinal glucosidases), 
transient tremor, weight loss, axonal and peripheral neuropathy.43 In order to 
overcome these problems, the effect of either the lipophilicity or the configuration 
of iminosugars has been explored over the last years. 
1.1.1.5 STRATEGIES DEVELOPED TO IMPROVE IMINOSUGAR ENZYMATIC 
SELECTIVITY 
1.1.1.5.1 THE ROLE OF THE ALKYL CHAIN 
Lipophilicity has been postulated to enhance the selectivity of an iminosugar since 
lipophilic moieties can only be hosted by enzymes having lipophilic character. Studies 
have been conducted to determine some of the molecular features of N-alkylated 
iminosugars that contribute to enhance their selective recognition by GCS in comparison 
with ER α-glucosidase I.44 The presence of an alkyl chain is obligatory for the transferase 
inhibition and, moreover, there is a direct correlation between inhibition potency and 
                                                 
c The effect of the alkyl chain lenght on the binding and inhibition potency exhibited by N-alkyl 
iminosugars toward glycosidases will be discussed in detail in the next paragharphs. 
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chain length, probably due to the greater ceramide mimicry (FIGURE 11a). On the other 
hand, the α-glucosidase inhibition is independent of the N-alkyl chain and changes in 
chain length; the inhibition seems mediated in this case by the close resemblance to the 
charged character of the oxocarbenium TS (FIGURE 11b). These studies offer the 
possibility to develop inhibitors able to selectively interact with one or the other enzyme 
leading to compounds for the potential treatment of LSDs and viral infections, 
respectively.45 
 
FIGURE 11. a) Overlay between NBDNJ (2) and Ceramide; b) Superposition of NBDNJ (2) and 
the terminal glucose residue of Glc3Man9GlcNAc2 which is removed by α-glucosidase I (figure 
adapted from ref. 44). 
As another example explaining the role of the alkyl chain, Sussman et al. solved the 
crystal structures of the complexes of both NBDNJ (2) and NNDNJ (7) bound to GBA1 
(FIGURE 12).46 NNDNJ clearly shows a stronger and more stable interaction with the 
enzyme than NBDNJ, due to the additional interactions with the hydrophobic residues 
in the active site of the enzyme. NNDNJ has in fact demonstrated to keep inhibitory 
properties only toward specific glycosidases (see TABLE 1). Therefore, this approach 
represents an interesting opportunity to increase the selectivity in glycosidase inhibition. 
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FIGURE 12. NBDNJ and NNDNJ in complex with GBA1 (taken from ref. 46). 
1.1.1.6 LOOKING-GLASS GLYCOMIMETICS: L-IMINOSUGARS 
As widely reported, the pharmacological interest around iminosugars is principally 
devoted to those belonging to D-series but, in recent times, their unnatural mirror images, 
i.e. L-iminosugars, have been completely re-evaluated.47 Asano et al. reported48 the first 
comparative inhibition study of D- and L-deoxyiminosugars toward various glycosidases 
revealing that L-DNJ (ent-1) and L-DGJ (FIGURE 13) are, surprisingly, inhibitors of  
α-glucosidases and of α-galactosidase respectively (L-DNJ: IC50 = 4.3 µM;  
L-DGJ: IC50 = 13 µM), even if with less potency showed by the corresponding natural 
enantiomers. L-allo-DNJ is an inhibitor of α-mannosidases (IC50 = 30 µM) despite D-
allo-DNJ and, more interestingly, it is able to inhibit the same enzymes better then D-
manno-DNJ (D-DNM: IC50 = 840 µM). 
 
FIGURE 13. L-iminosugars. 
L-DGJ is a less potent inhibitor of α-galactosidases but is strong inhibitor of  
α-L-fucosidase (IC50 = 0.63 µM) (FIGURE 13). In more recent times, Overkleeft et al. 
identified49 in various C-5 gluco epimers (L-ido congeners) potent, but especially, 
 18 
 
strongly selective GCS inhibitors; they observed, moreover, that the ether oxygen atom 
positioned at C5’ leads to much more potent GCS inhibitors when compared to the N-
alkyl series50 (TABLE 2). From this extensive study, ent-27 has resulted the most potent 
and selective iminosugar-based GCS inhibitor and might be considered in the treatment 
of Gaucher disease in the frame of SRT. It is difficult to soon understand why  
L-iminosugars are able to act as inhibitors and in some cases able to mimic the transition 
state of glycosidase and glycosyltransferase catalysed reactions, but some exceptions 
may occur. 
 
FIGURE 14. Stereochemical correlation between L-ido congeners and D-glucose. 
As an example, FIGURE 14 shows the structure of the iminosugars with L-ido 
configuration, whose conformation fluctuates between the 1C4 and 4C1 forms. In the latter 
conformation, L-ido-DNJ partially resembles the structure of natural D-glucose; this 
stereochemical correlation could explain the inhibitory potency showed by L-ido-
congeners. On the other hand, when no stereochemical correlation can be found, the 
inhibitory character can be related to a non-competitive mechanism, additionally only 
toward specific, non-enantioselective glycosidases. Because of these collected data and 
considerations, it is easy to understand the reasons why the synthesis of  
N-alkyl-L-iminosugars currently represents a challenging task in this field. Some 
selected and innovative procedures devoted to this aim are briefly reported in the next 
paragraph. 
  
 19 
 
 
TABLE 2. IC50 (µM) of N-Alkyl-L-ido-iminosugars toward various enzymes. 
1.1.1.7 SYNTHETIC APPROACHES TO N-ALKYL-L-IMINOSUGARS 
The access to L-iminosugars is clearly hampered by their poor availability from natural 
sources. Accordingly, a variety of innovative strategies, including those aiming at 
obtaining the whole series of compounds, has been devised over the past few years. In 
one of these approaches, Kato et al.48 prepared DNJ epimers with L-altro, L-ido, L-
galacto and L-gulo configurations as single compounds under highly stereoselective 
conditions; on the other hand, L-gluco-DNJ, L-allo-DNJ and L-manno-DNJ were 
prepared as diastereoisomeric mixtures. The procedure involved the use of 
dioxanylpiperidine 30 as starting material; the latter was obtained (as depicted in 
retrosynthetic path, SCHEME 1a) from L-Garner aldehyde. The crucial step is the 
conversion of the diolefin product 29 to give 30 through a ring closing methatesis (RCM) 
in presence of Grubbs’ catalyst.51,52 
Compound GCS GBA1 GBA2 Sucrase Lactase Maltase 
ent-15 20 >1000 1 >1000 >1000 >1000 
ent-16 15 >1000 0.25 >1000 >1000 >1000 
ent-17 40 >1000 0.14 600 700 10 
ent-18 40 18.5 0.045 0.5 500 >1000 
ent-19 4 25 0.02 60 100 600 
ent-20 2 50 0.01 >1000 >1000 >1000 
ent-21 2 >1000 0.09 >1000 400 >1000 
ent-22 0.15 100 0.015 >1000 200 >1000 
ent-23 0.1 95 0.025 >1000 200 >1000 
ent-24 0.05 40 0.015 >1000 250 >1000 
ent-25 0.05 15 0.015 >1000 300 >1000 
ent-26 <0.05 012 0.045 >1000 350 >1000 
ent-27 0.1 2 0.03 >1000 >1000 >1000 
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SCHEME 1. a) De novo strategy to prepare L-iminosugars; b) carbohydrate-based route to prepare 
L-iminosugars. 
The procedures proposed by Overkleeft et al. to prepare the L-ido and L-altro 
congeners,53 differently from the previous strategy, are carbohydrate-based routes. 
Particularly, L-ido and L-altro congeners were synthetized starting from 2,3,4,6-tetra-O-
benzyl-D-glucitol or from 2,3,4,6-tetra-O-benzyl- 
D-galactitol respectively (SCHEME 1b). 
More recently, Guaragna et al. finely tuned a highly stereocontrolled de novo strategy54 
to obtain enantiomerically pure D- and L-iminosugars (SCHEME 2). The synthesis 
involves the use of an heterocyclic synthon, the 5,6-dihydro-1,4-dithiin-2-yl- [(4-
methoxybenzyl)oxy]methane55 31, a reagent capable of three-carbon homologation of 
electrophiles, such as the Garner aldehyde 32. As depicted in the retrosynthetic scheme, 
the two synthons (the reaction conditions were tuned in order to “pre-establish” the C4 
chirality) were useful to afford the bicyclic compound 33, from which, by dithioethylene 
bridge removal, the key olefin 34 could be obtained. Then, syn or anti dihydroxylations 
of 34 allowed us to obtain six of the eight possible  
L-epimers (SCHEME 2).54,56 
 
SCHEME 2. De novo stereocontrolled method to prepare L-iminosugars. 
The introduction of the alkyl chain is generally performed by typical reductive amination 
conditions (CH3(CH2)nCHO/NaBH3CN/AcOH in MeOH). Overkleeft et al. developed a 
simple strategy to this aim which involves the use of alkylbromides as electrophiles in 
the coupling reaction with the iminosugar core. The same procedure can be easily 
applied also to prepare alkoxypentyl iminosugars (SCHEME 3). 
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SCHEME 3. Synthetic strategy to prepare N-alkyl and N-alkoxypentyl-L-iminosugars. 
L-AMP-congeners were prepared by condensation (via reductive amination) of the 
iminosacaridic core with 5-(adamantan-1-yl-methoxy)-pentanal 39. In this regard, 
Overkleeft et al. developed a pilot-scale procedure57 to prepare 39 in five steps starting 
by 1,5-pentandiol (35) with a 47% of overall yield (SCHEME 4a). 
 
SCHEME 4. Synthetic strategies to obtain 39. 
Since this procedure was affected by difficult purification procedures, a more 
expeditious method to afford 39 with higher yield (55% o.y.) was later conceived by 
Cooper et al. (SCHEME 4b).58 
 
SCHEME 5. Industrial synthetic procedure to prepare 8. 
However, this method also required optimization before large scale applications. In the 
same paper58 the authors reported the direct production of AMPDNM (8) by an economic 
and scalable method that involves the three-step synthesis of 39 with high yield and 
purity by selective cleavage of an endocyclic C-O bond of a THP ether using 
borane/THF as the key step. The subsequent coupling of 39 with DNJ gave 8 in 50% 
o.y. (SCHEME 5).  
 22 
 
1.1.2 RESULTS AND DISCUSSION 
On the basis of the data discussed in the previous section, one of the main topic of this 
PhD research program was focused on the study of the role of chirality on the activity 
and selectivity of N-alkyl iminosugars in various research areas with therapeutic 
relevance. Particularly, a highly stereocontrolled de novo synthesis of L-DNJ (ent-1) was 
efficiently accomplished (FIGURE 15).56 Synthetic efforts were also aimed to the 
assembly of a variety of alkyl chains, leading to the target N-alkyl iminosugars (FIGURE 
15). 
 
FIGURE 15. Synthetic approaches developed to prepare 
enantiopure N-alkyl-D- and L-iminosugars. 
With D- and L- N-alkyl-iminosugars in hand, the analysis of their glycosidase inhibition 
properties was extensively performed; furthermore, the chaperoning potential of ent-2 in 
the context of PCT applied to Pompe Disease was preliminarily explored. 
1.1.2.1 DE NOVO SYNTHESIS OF L-DNJ 
To the best of our knowledge, the synthesis of ent-1 has never been reported before.59 
More generally, as mentioned above, the access to L-iminosugars is often problematic 
due to the limited commercial availability of almost all  
L-hexoses, which hampers their use as starting materials. Alternatively, in an extension 
of a long studied60 de novo methodology, already devised to obtain unnatural 
carbohydrates and biomimetic agents61 including iminosugars52 and their precursors,62 
the synthesis of ent-1 was explored from the synthetically available alcohol 45 (SCHEME 
6). 
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SCHEME 6. sec-Alcohol 45 elaboration. 
In early attempts, inspired by previous results on L-glucose synthesis,63 the preparation 
and stereoselective functionalization of 1,6- anhydro-iminosugar was considered 
(SCHEME 6). sec-Alcohol 45 was first benzylated under common conditions (NaH, 
BnBr). The resulting benzyl ether 46 was then treated with a DCE/ MeOH solution of 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), directly providing, after 48h at rt 
and then 8 h at 60 °C, the bicyclic compound 47. Spontaneous cyclization of 47 into  
1,6-anhydro-iminosugar precursor 48 was even observed during chromatographic 
purification procedures. In spite of the synthetic utility of the reaction, 48 could not be 
further functionalized, as the subsequent double-bond unmasking step (Ra−Ni) did not 
provide the expected olefin 49 (SCHEME 6). 
Looking for alternative strategies, we then investigated the reactivity of oxirane 53, 
obtained from alcohol 45 as previously described54a (SCHEME 7). 
 
SCHEME 7. Synthetic route to oxirane 53 (ref 54a). 
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Particularly, the synthetic problem at this stage was the introduction of the two remaining 
stereocenters at C2 and C3 positions, having a trans-diequatorial orientation of the 
substituents. Indeed, as depicted in SCHEME 8, the trans-diaxial opening of oxirane 
would allow us to obtain, depending on the adopted conformation 4C1 or 1C4, two 
different stereoisomers, the desired L-gluco epimer and the undesired L-altro epimer, 
respectively. 
 
SCHEME 8. Synthetic problem to stereoselectively obtain ent-1. 
Treatment of 53 with refluxing NaOH directly produced the unprotected iminosugar 
with L-altro configuration ent-54 (altro:gluco > 20:1; SCHEME 9). Conversely, 
treatment of bis-MOM acetal 56 (from 53: MeONa, then MOMCl/DIPEA) under the 
same conditions gave, after the subsequent HCl addition to the crude mixture, the desired 
gluco epimer ent-1 as the only detected stereoisomer (dr > 99:1). 
 
SCHEME 9. Stereocontrolled de novo synthesis of ent-1. 
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The stereodivergent outcome of the reactions was assumed to rely on the conformational 
preferences of epoxides 53 and 56 depending by the nature of C4 and C6 substituents. 
We observed54a that diacetate 53 adopts a 3S1 sugar conformation having both C4 and 
C6 substituents in pseudodiaxial orientations (SCHEME 10). 
 
SCHEME 10. Basic treatment of 53 to afford L-altro-DNJ. 
In line with previous findings, this behaviour was judged to be a consequence of the 
steric clash occurring between the N-Boc and the pseudoequatorially oriented C6 acetate 
group. Accordingly, the formation of altro-DNJ from 53 was hypothesized to take place 
via the base-labile cyclic carbamate64 intermediate 57 (SCHEME 10). In agreement with 
literature data,65 an energy-minimized structure of 57 suggested that it was firmly locked 
in a quasi-planar conformation close to a 5E form with a pseudo-equatorially oriented 
methyleneoxy moiety (SCHEME 10). The conformational inversion from epoxide 53 to 
57 justified the formation of altro-DNJ after trans-diaxial epoxide ring opening of 57. 
Conversely, when the Ac group was replaced by the base-stable MOM group, the oxirane 
ring cleavage of bis-acetal 56 only provided the gluco-configured diol 58 (SCHEME 11). 
Even though the broadness of most NMR signals of epoxide 56 hampered the 
identification of its preferred conformation, NMR analysis of diol 58 (obtained by NaOH 
treatment of 56) indicated a conformation with all substituents in near axial orientations 
(J1,2 = 2.5 Hz; J3,4 = 1.8 Hz; J4,5 = 2.6 Hz). Close agreement between these calculated J 
values and those obtained from an energy-minimized structure66 (SCHEME 11) suggested 
that a 4C1 chair was adopted in this case. Eventually, the “all-equatorial” L-DNJ‧HCl ent-
1 was obtained by the concurrent removal of N-Boc and MOM groups, enabling as 
expected a conformational inversion from 4C1 to 1C4 chair. 
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SCHEME 11. Stereoselective synthesis of L-DNJ. 
1.1.2.2 SYNTHESIS OF N-ALKYL-L-DEOXYIMINOSUGARS 
With L-DNJ in hand, the access to the corresponding ent-2 (L-NBDNJ) was achieved 
under standard N-alkylation conditions (SCHEME 11). The synthesis of other N-alkyl-L-
deoxyiminosugars ent-7, ent-8, ent-11, ent-14 and ent-44 was instead accomplished 
exploring alternative routes, aimed first to the assembly of the alkyl chains and then to 
their insertion into L-DNJ by N-alkylation. Particularly, we studied expeditious 
procedures to obtain alkyl or alkoxypentyl iodides (to be used as electrophiles in the 
subsequent alkylation reaction with L-DNJ) using the established method67 of 
triarylphosphine and iodine (SCHEMES 12-14). In early studies, we devised a procedure 
to convert alcohols 59a-c into alkoxypentyl iodides 62a-c by iodination of 59a-c, 
subsequent coupling reaction of 60a-c with 1,5-pentandiol (35) and eventual iodination 
of alcohols 61a-c. While the synthetic protocol was tuned at first using TPP/I2 (TPP: 
triphenylphosphine) as the iodination reagent (SCHEME 12, Method A), TPP was later 
replaced by the recyclable polystyryl diphenylphosphine (PS-DPP, Method B). Indeed, 
given the efficiency of the reactions, the synthetic conditions were optimized to obtain a 
sequence of steps not requiring extractive work-up and chromatographic purifications. 
As a result, NMR analysis of the crude mixtures of 62a-c demonstrated that high-
yielding conversions (70-88% o.y.) could be obtained in all cases, with virtually no side 
products attributable to the limiting reagents (SCHEME 12). 
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SCHEME 12. Iterative iodination reactions to prepare alkyl and alkoxypentyl iodides 62a-c. 
The strategies reported in SCHEME 12 represent faster alternatives to most procedures 
devised for the preparation of alkyl and alkoxypentyl chains. In search for an even more 
expeditious protocol, in subsequent studies an alternative synthetic route was conceived, 
involving a double iodination of 1,5-pentandiol (35), to provide 1,5-diiodopentane (63, 
see TABLE 3), followed by coupling reactions with alcohols 59a-c (SCHEME 13). In this 
case, the use of PS-DPP was only examined. 
TABLE 3. Reaction conditions for the double  
iodination of 1,5-pentandiol (35). 
 
Entry Solvent T (°C) t (h) Yield (%) 
1 1,4-Dioxane reflux 12 46 
2 1,4-Dioxane 50  3 52 
3 ACN 25 12 86 
4 DCM 25 1 95 
The efficiency of the double iodination reaction to obtain 63 was markedly influenced 
by the reaction conditions: over a variety of solvents tested (TABLE 3), the most 
convenient conversion (95%) involved the use of DCM for 1h at rt (entry 4). The 
subsequent coupling reaction of 63 with alcohols 59a-c proceeded smoothly with 
hexanol (59a) and nonanol (59b), providing, after 48h at rt, the corresponding 
alkoxyalkyl iodides 62a,b in 65 and 64% yields, respectively (SCHEME 13). On the other 
hand, the reaction with adamantane-methanol (59c) was slower, and the corresponding 
iodide 62c was obtained with a 62% yield after 72h at rt (SCHEME 13). 
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SCHEME 13. A more expeditious route to prepare iodides 62a-c. 
With 62a-c in hand, their eventual reaction with L-DNJ was carried out under standard 
conditions. Treatment of L-DNJ (ent-1) with nonyl iodide 60b (K2CO3) smoothly 
provided ent-7 in 80% yield. Under the same conditions, the reaction of ent-1 with 
iodides 62a-c gave the corresponding N-alkyl L-DNJ derivatives ent-8, ent-11 and ent-
14 in satisfactory 75-80% yields (SCHEME 14). The same N-alkylation reactions using 
D-DNJ as the nucleophile afforded the corresponding natural enantiomers 7, 8, 11 and 
14. 
 
SCHEME 14. Coupling reactions to afford to ent-7, ent-8, ent-11 and ent-14. 
Compounds 44 and ent-44 were instead prepared as depicted in SCHEME 15. The 
reaction of iodomethane with monoalcoholate of 1,9-nonandiol (64) afforded alcohol 65 
(90%), whose subsequent iodination reaction to provide 66 (TPP/I2) was unfortunately 
unsuccessful.68 Other studies are currently ongoing to explore more efficient strategies 
to this aim. Alternatively, 65 was treated under typical Swern conditions to give aldehyde 
67; the subsequent condensation reaction with D- or L-DNJ eventually provided 44 and 
ent-44, respectively. 
 
SCHEME 15. Synthetic route to 44 and ent-44. 
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1.1.3 BIOLOGICAL ASSAYS 
The biological studies of this project were at first focused on the comparative analysis 
of the inhibition potential of 1, 2, 7, 8, 11, 14, 44 and ent-1, ent-2, ent-7, ent-8, ent-11, 
ent-14, ent-44 as well as of the corresponding racemic mixtures against a variety of 
glycosidases, including the pharmacologically relevant rhGBA1 (Cerezyme®, β-
glucosidase) and GAA (acid α-glucosidase). The experiments were performed under the 
supervision of Dr David Priestman and Prof. Frances Platt at Department of 
Pharmacology (University of Oxford) and by the research group of Prof. Marco Moracci 
at the National Council of Research (CNR) of Naples. In subsequent studies (in 
collaboration with Prof. G. Parenti), a preliminary evaluation of the potential of L-
iminosugars, especially of ent-2, as enhancer of GAA activity was performed, with 
concrete applications in the treatment of Pompe disease. 
1.1.3.1 GLYCOSIDASE INHIBITION STUDIES 
In preliminary assays, the comparative analysis of the inhibition properties of D- and L-
iminosugars were tested using D- and L-NBDNJ (2 and ent-2) as model inhibitors, while 
selected glycosidases were chosen as representative examples of various GH families 
(TABLE 4). The enzymatic assays rely on the use of 4-methylumbelliferyl-D-
glycopyranoside as substrate (SCHEME 16), exploiting the fluorescent properties of 4-
MU to evaluate the residual activity of the glycosidases. 
 
SCHEME 16. Fluorescence assay of 4-MU. 
No inhibitory effect up to 1 mM was found for ent-2 in most cases, except for the very 
weak inhibition of intestinal sucrase/isomaltase (38% inhibition, IC50 2 mM, entry 2), 
lactase (30% inhibition, IC50 > 5 mM, entry 4) and α-fucosidase (19%, entry 13). Instead, 
rhGAA (Myozyme) and β-glucosidases from Pyrococcus furiosus and Sulfolobus 
solfataricus P2 even showed a 20−25% activation even though no significant 
enhancement in the melting temperature (Tm) of rhGAA by ent-2 was indicated by 
differential scanning fluorimetry experiments (FIGURE 16). 
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TABLE 4. Residual activities (%) of various glycosidases after 
treatment with either 2 or ent-2. 
 
Addition of 0.1 or 1 mM D-NBDNJ 2 to a phosphate buffer (pH 7.4) containing 
Myozyme significantly enhanced the melting temperature (Tm) of the latter (0.1 mM: 
ΔTm = +12°C; 1 mM: ΔTm = +14.8°C). 
 
FIGURE 16. Stabilization of rhGAA (MyozymeTM) by D-NBDNJ and  
L-NBDNJ as suggested by differential scanning fluorimetry. 
Conversely, no significant stabilizing effect was observed with L-NBDNJ ent-2 under 
the same conditions (0.1 mM: ΔTm= +0.3°C; 1 mM: ΔTm = +1.4°C). Conversely, 2 
displayed inhibition of rice α-glucosidase (IC50 = 275 μM, entry 1), sucrase/isomaltase 
(IC50= 1.5 μM, entry 2) and recombinant human β-glucocerebrosidase (rhGBA1 or 
Entry Enzyme GH family 2 ent-2 
1 Rice α-glucosidase GH31 17 98 
2 Intestinal sucrase/isomaltase GH31 3 62 
3 rh-GAA (MyozymeTM) GH1 19 125 
4 Intestinal lactase GH1 62 70 
5 β-glucosidase (P. furiosus) GH1 81 120 
6 β-glucosidase (S. solfataricus P2) GH1 94 124 
7 rh-GBA1 (Cerezyme) GH30 35 97 
8 Human β-hexosaminidase GH20 98 98 
9 α-galactosidase (T. maritima) GH36 82 100 
10 rh-Gal A GH27 100 104 
11 β-galactosidase (A. acidocaldarius) GH42 98 102 
12 Human β-galactosidase GH35 87 98 
13 α-fucosidase (S. solfataricus) GH29 83 81 
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Cerezyme: IC50=0.3 mM, entry 7). Inhibition of rhGAA was also observed (IC50=158 
μM, entry 3). In subsequent studies, the comparative analysis of glycosidation inhibition 
was extended to a number of N-alkyl-D- and L-iminosugars and focused on the inhibition 
of some pharmacologically relevant glycosidases, including lysosomal 
glucocerebrosidase 1 (GBA1) and acid α-glucosidase (GAA). These enzymes are 
involved in the onset of specific lysosomal storage disorders, including Gaucher’s 
disease (GBA1) and the Pompe disease (GAA). The compounds were tested individually 
first and then as racemic mixtures in the search for potential synergistic effects. Their 
inhibitory activities toward the easily accessible recombinant form of GBA1, rhGBA1 
(Cerezyme®) are reported in FIGURE 17 and TABLE 5. As expected, FIGURE 17 
highlights a stronger inhibition by D-enantiomers than the corresponding L-enantiomers. 
Particularly, even though D- and L-DNJ had broadly same low activity (D-DNJ: IC50 = 
0.74 mM; L-DNJ: IC50 = 0.83 mM), the effect of alkyl chain was much more markedly 
beneficial for D-iminosugars: as an example, activity was increasingly higher from  
D-MONDNJ (44) (IC50 = 18 µM, entry 19) to D-AMPDNM (8) (IC50 = 1 µM, entry 10); 
on the other hand, L-AMPDNM (ent-8) was a moderate inhibitor of rhGBA1 (IC50 = 50 
µM, entry 11). 
 
FIGURE 17. rhGBA1 inhibition curves. 
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Noteworthy, L-NBDNJ showed, analogously to previous results (TABLE 4), an 
enhancing effect when co-incubated at concentrations in the range of 5-50 µM (see 
FIGURE 17). 
TABLE 5. IC50 (µM) of D- and L-iminosugars and of the corresponding 
racemates toward rhGBA1. 
Entry Sample IC50 (µM) 
1 D-DNJ (1) 830 
2 L-DNJ (ent-1) 740 
3 D-DNJ + L-DNJ (rac-1) 870 
4 D-NBDNJ (2) >1000 
5 L-NBDNJ (ent-2) / 
6 D-NBDNJ + L-NBDNJ (rac-2) >1000 
7 D-NNDNJ (7) 5 
8 L-NNDNJ (ent-7) 125 
9 D-NNDNJ + L-NNDNJ (rac-7) 4 
10 D-AMPDNM (8) 1 
11 L-AMPDNM (ent-8) 50 
12 D-AMPDNM+ L-AMPDNM (rac-8) 7 
13 D-HPDNJ (11) 5.5 
14 L-HPDNJ (ent-11) 180 
15 D-HPDNJ + L-HPDNJ (rac-11) 9 
16 D-NPDNJ (14) 1 
17 L-NPDNJ (ent-14) 100 
18 D-NPDNJ + L-NPDNJ (rac-14) 3.6 
19 D-MON DNJ (44) 18 
20 L-MON DNJ (ent-44) >1000 
21 D-MON DNJ + L-MON DNJ (rac-44) 26 
 
The same assays were performed using equimolar mixtures of enantiomeric 
iminosugars. The enzymatic residual activities and the IC50 values are summarized in 
FIGURE 18 and TABLE 5. In any case, the combination of the two enantiomers did not 
lead to an increase of the inhibitory activity showed by the single enantiomers. As the 
only exception, the combined use of D- and L-NNDNJ (rac-7) led to a slight 
enhancement of the inhibitory activity (IC50 = 4 µM, entry 9), approaching that of the D-
enantiomer (7: IC50 = 5 µM, entry 7), while it was far higher than that of ent-7 (IC50 = 
125 µM, entry 8). 
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FIGURE 18. rhGBA1 inhibition curves in the presence of racemates. 
The most interesting result is the strong enhancement of rhGBA1 residual activity in the 
presence of DNJ racemate, which is totally absent when the enzyme is co-incubated with 
the single enantiomers. The observed phenomenon could be explained in terms of 
positive cooperativity between the two enantiomers, allowing an extra stabilization of 
the enzyme. In FIGURE 19 and TABLE 6 the inhibitory activities of the same compounds 
against GAA are summarized. The curves obtained (FIGURE 19) show that the inhibition 
was exerted by the only D-enantiomers, while L-iminosugars were substantially inactive. 
Furthermore, in this case the inhibition potency seems independent from the alkyl chain 
(length and structure), since D-DNJ was endowed with the strongest potency (IC50 = 4 
µM; entry 1, TABLE 6). 
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FIGURE 19. Inhibition curves of D- and L-iminosugars toward GAA.  
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TABLE 6. IC50 (µM) of D- and L-iminosugars and of the  
corresponding racemates toward GAA. 
ENTRY SAMPLE IC50 
(µM) 
1 D-DNJ (1) 4 
2 L-DNJ (ent-1) / 
3 D-DNJ + L-DNJ (rac-1) 10 
4 D-NBDNJ (2) 24 
5 L-NBDNJ (ent-2) / 
6 D-NBDNJ + L-NBDNJ (rac-2) 37 
7 D-NNDNJ (7) 7.3 
8 L-NNDNJ (ent-7) / 
9 D-NNDNJ + L-NNDNJ (rac-7) 10 
10 D-AMPDNM (8) 14 
11 L-AMPDNM (ent-8) >1000 
12 D-AMPDNM+ L-AMPDNM (rac-8) 39 
13 D-HPDNJ (11) 9 
14 L-HPDNJ (ent-11) >1000 
15 D-HPDNJ + L-HPDNJ (rac-11) 28 
16 D-NPDNJ (14) 10 
17 L-NPDNJ (ent-14) / 
18 D-NPDNJ + L-NPDNJ (rac-14) 25 
19 D-MON DNJ (44) 8 
20 L-MON DNJ (ent-44) / 
21 D-MON DNJ + L-MON DNJ (rac-44) 14 
 
As for GBA1, the analysis of the racemates tested against GAA suggested that no 
synergistic effect deriving by the combination of the two enantiomers occurred (TABLE 
6). 
1.1.3.2 L-NBDNJ AS ALLOSTERIC ENHANCER OF α-GLUCOSIDASE ACTIVITY 
FOR THE TREATMENT OF POMPE DISEASE 
The results reported so far underline a weak propensity of N-alkyl- 
L-iminosugars to act as glycosidase inhibitors; conversely, in a number of examples the 
increase in the enzymatic activity of α- and β-glucosidases suggests a potential role of 
these compounds as enhancers (e.g. pharmacological chaperones) of carbohydrate 
processing enzymes, with a perspective application in the treatment of LSDs. As an early 
evaluation of the chaperoning potential of N-alkyl-L-iminosugars, the role of iminosugar 
chirality was explored evaluating the increase of the levels of lysosomal glucosidase 
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(GAA) deriving from patients with Pompe disease (PD), using  
D- and L-NBDNJ as model chaperones. As mentioned above, the corresponding D-
enantiomer was an established pharmacological chaperone for this enzyme, which is 
currently undergoing clinical evaluation. In a first set of experiments, PD fibroblasts 
from a patient carrying the mutation p.L552P/p.L552P (homozygous mutation) were 
incubated in the absence or in the presence of 20 μM ent-2 or its D-enantiomer69 (FIGURE 
20). The administration of ent-2 actually increased the residual activity of mutated GAA 
(FIGURE 20). The activating effect (1.5-fold increase) was slightly higher than that 
observed for 2 under the same experimental conditions ( 
1.3-fold increase). 
 
FIGURE 20. Effect of D- and L-NBDNJ (20 μM) on residual activity of mutated GAA in 
fibroblasts from a PD patient carrying the p.L552P/p.L552P mutation. 
Potential synergistic effects deriving from co-administration of ent-2 and rhGAA in PD 
fibroblasts were also considered. PD fibroblasts from three patients carrying various 
mutations (FIGURE 21) were incubated with rhGAA and ent-2 or its D enantiomer (20 
μM). 
 
FIGURE 21. Synergy between rhGAA and D- or L-NBDNJ in PD fibroblasts. 
In all cases, co-incubation of ent-2 and rhGAA provided a higher increase in GAA levels 
than those provided by rhGAA when incubated singularly. Especially when PD 
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fibroblasts carrying the mutation p.L552P/p.L552P were evaluated, a 2-fold increase of 
GAA activity was found; this value was the same observed by treatment of the cells with 
2/rhGAA. In the remaining cases, the enhancing effect was less marked (and lower than 
that found for 2/rhGAA) (FIGURE 21). Western blot analysis was eventually performed 
in ent-2 treated and untreated fibroblasts carrying the mutation p.L552P/p.L552P 
(FIGURE 22) to provide first clues on the mechanisms enabling the observed 
enhancement of GAA activity. 
 
FIGURE 22. Western blot analysis of rhGAA processing in Pompe fibroblasts carrying the 
p.L552P/p.L552P mutation incubated with rhGAA alone, rhGAA + 
 D-NBDNJ, or rhGAA + L-NBDNJ. 
In this case, density scans of rhGAA bands indicated that the mature 76 kDa isoform 
was more represented in the presence of both enantiomers, even though the increase with 
rhGAA/ent-2 was less marked with respect to that observed in cells treated with 
rhGAA/2.   
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1.1.4 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
One of the main topics of this PhD project is focused on the study the role of chirality of 
N-alkyl iminosugars in glycosidase inhibition/activation. From a synthetic standpoint, 
we were able to gain access to ent-1, the unnatural enantiomer of D-DNJ, accomplished 
by a highly stereocontrolled de novo strategy, exploiting the different reactivity and 
conformational preferences of epoxide intermediates 53 and 56. Then, with the aim to 
prepare the corresponding N-alkylated derivatives, we explored expeditious approaches 
enabling the assembly of the bioactive alkyl or alkoxyalkyl chains onto the iminosugar 
core. All the explored methods rely on the combined use of triphenylphosphine (either 
solvent-soluble or polymer bound phosphine: PS-DPP) and iodine as the iodination 
system of alkyl or alkoxyalkyl alcohols 59a-c and 61a-c. With target compounds in hand, 
an exhaustive comparative analysis of the inhibition properties of D- and L-iminosugars 
was performed using D- and L-NBDNJ (2 and ent-2) as model substrates. In addition, 
the remaining D- and L-iminosugars were evaluated in the potential inhibition of 
pharmacologically relevant GBA1 and GAA. In all cases, differently from the D-
enantiomers, L-iminosugars were not found to act as glycosidase inhibitors. On the other 
hand, either as single enantiomers (e.g. L-NBDNJ) or as racemic mixtures (D- and L-
DNJ), L-iminosugars were able to enhance the activity of both β- and α-glucosidases. 
This has suggested a potential role of L-iminosugars as pharmacological chaperones. 
Indeed, when tested in cell lines deriving from Pompe disease, ent-2 was found to 
enhance the activity of lysosomal α-glucosidase. In addition, when co-incubated with 
rhGAA, we found a synergistic enhancing effect, which was comparable to that observed 
for rhGAA/2. It’s worthy to underline that the chaperoning activity of an L-piperidine 
iminosugar has been reported only seldom before; in addition, to the best of our 
knowledge, the higher enhancing effect of an L-piperidine iminosugar compared to that 
of the corresponding natural enantiomer is even unprecedented. The lack of inhibition 
of the deficient enzyme and of the other glycosidases further augments the activating 
potential of ent-2, especially if compared with its enantiomer. It’s also worth noting that, 
unexpectedly, ent-2 seems not to affect the stability of the enzyme, while enhancing the 
activity of the latter in cells. Thus, although the molecule cannot be considered a 
conventional pharmacological chaperone of GAA, it represents a promising new 
candidate for the combination therapy of Pompe disease. Further studies aimed at 
elucidating the nature of the enhancing effect of ent-2 are currently ongoing. 
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1.1.5 EXPERIMENTAL SECTION 
L-DNJ SYNTHESIS 
 
Diol 55. Zemplén deacetylation was accomplished by treatment of a solution of 53 (0.24 
g, 0.76 mmol) in MeOH (5 mL) with MeONa (41 mg, 0.76 mmol) for 4 h at room 
temperature. The mixture was neutralized with few drops of acetic acid and then the 
volatiles were removed under reduced pressure. The crude residue was dissolved in 
CHCl3 and filtered through a short pad of silica gel. The resulting filtrate was eventually 
concentrated to dryness, giving 55, which was used in the following step without further 
purification; oily. 1H NMR (400 MHz, DMSO-d6), δ: 1.39 (s, 9H), 3.14 (bs, 1H), 3.35 
(bs, 1H), 3.41−3.57 (m, 1H), 3.87 (bt, J = 7.2 Hz, 1H), 3.91−3.98 (m, 1H), 4.02−4.13 (m, 
1H), 4.14−4.23 (m, 1H), 4.62 (bt, J = 4.9 Hz, 1H). 1H NMR (400 MHz, 55 °C, DMSO-
d6), δ: 1.40 (s, 9H), 3.11−3.20 (m, 2H), 3.32−3.41 (m, 2H), 3.46−3.55 (m, 1H), 3.84−3.96 
(m, 2H), 4.13 (bs, 1H), 4.47 (t, J = 5.7 Hz, 1H), 5.19 (d, J = 5.2 Hz, 1H). 13C NMR (100 
MHz), δ: 28.4, 43.1, 50.2, 53.6, 60.0, 61.1, 63.1, 81.2, 156.9. Anal. Calcd for C11H19NO5: 
C, 53.87; H, 7.81; N, 5.71. Found: C, 53.94; H, 7.79; N, 5.73. HRMS: m/z [M + Na]+ 
calcd 268.1155, found 268.1144. 
 
Bis-Acetal 56. To a stirring solution of the crude diol 55 (26 mg, 0.1 mmol) in DCM (2 
mL), DIPEA (35 μL, 0.2 mmol) and MOMCl (15 μL, 0.2 mmol) were sequentially added 
at room temperature. The resulting mixture was stirred at the same temperature for 48 h 
and then the reaction was quenched by the addition of H2O (1 mL). The mixture was 
diluted with DCM and washed with brine (pH 7). The organic phases were dried 
(Na2SO4), filtered, and concentrated under reduced pressure. Chromatography of the 
crude residue gave bis-acetal 56 (25 mg, 76% yield) as a colourless oil. 1H NMR (400 
MHz, CDCl3), δ: 1.45 (s, 9H), 3.31 (bs, 1H), 3.45 (s, 3H), 3.37−3.46 (m, 4H), 3.56−3.70 
(m, 4H), 4.18 (bs, 1H), 4.30 (bd, J = 13.3 Hz, 1H), 4.54−4.68 (m, 2H), 4,71 (d, J = 6.7 
Hz, 1H), 4.79 (d, J = 6.7 Hz, 1H). 1H NMR (400 MHz, CDCl3, 45 °C), δ: 1.53 (s, 9H), 
3.31−3.35 (m, 2H), 3.38 (t, 3H), 3.45 (t, 3H), 3.47−3.53 (m, 1H), 3.60−3.64 (m, 1H), 
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3.68 (t, J = 7.9 Hz, 2H), 4.20−4.45 (m, 2H), 4.61 (d, J = 6.6 Hz, 1H), 4.63 (d, J = 6.7 Hz, 
1H), 4.73 (d, J = 6.6 Hz, 1H), 4.82 (d, J = 6.8 Hz, 1H). 13C NMR (100 MHz, CDCl3), δ: 
28.3, 50.4, 51.1, 53.8, 55.2, 55.7, 65.1, 69.7, 72.8, 80.2, 96.0, 155.5. Anal. Calcd for 
C15H27NO7: C, 54.04; H, 8.16; N, 4.20. Found: C, C, 54.20; H, 8.14; N, 4.19. 
 
L-altro-Deoxynojirimycin (ent-54). Acetate 53 (33 mg, 0.1 mmol) was suspended in a 
1 M NaOH solution (3 mL). The suspension was warmed to reflux and stirred at the 
same temperature for 1 h. Temperature was then cooled to rt and the mixture was eluted 
through a short pad containing a Dowex 50WX8 (H+ form) resin. The resulting filtrate 
was concentrated, and chromatography of the crude residue provided ent-54 (9.0 mg, 
55% yield) as an oil. NMR data of ent-54 were consistent with those reported elsewhere. 
HRMS: m/z [M + H]+ calcd 164.085, found 164.0902. 
 
L-Deoxynojirimycin hydrochloride (ent-1). Oxirane 56 (25 mg, 75 μmol) was 
suspended in a NaOH 1 M solution (2 mL). The reaction mixture was warmed to reflux 
for 1 h and then temperature was cooled to rt. The mixture was eluted through a short 
pad containing a Dowex 50WX8 (H+ form) resin. The resulting filtrate was concentrated, 
acidified with HCl 2 M (3 mL), and refluxed for 1 h. Removal of the volatiles under 
reduced pressure yielded ent-1 (15 mg, 91% over two steps) as a white solid. 1H NMR 
(400 MHz, D2O), δ: 3.03 (dd, J = 11.6, 12.6 Hz, 1H), 3.26 (ddd, J = 3.2, 5.2, 10.5 Hz, 
1H), 3.56 (dd, J = 5.4, 12.6 Hz, 1H), 3.65 (dd, J = 9.3, 10.5 Hz, 1H), 3.77−3.87 (m, 2H), 
3.93 (dd, J = 5.2, 12.8 Hz, 1H), 4.00 (dd, J = 3.2, 12.8 Hz, 1H). 13C NMR (100 MHz, 
D2O), δ: 41.5, 53.6, 55.8, 62.8, 63.7, 72.2. Anal. Calcd for C6H14ClNO4: C, 36.10; H, 
7.07; N, 7.02. Found: C, 36.22; H, 7.05; N, 7.00. HRMS: m/z [M + H]+ calcd 164.0917, 
found 164.0910. 
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Diol 58. A small amount of the crude residue deriving from oxirane ring cleavage of 56 
was purified by column chromatography (hexane:EtOAc, from 100:0 to 70:30), to 
provide the pure 58 as a pale-yellow oil. 1H NMR (400 MHz, CDCl3), δ: 1.47 (s, 9H), 
3.36 (s, 3H), 3.39 (bd, J = 14.3 Hz, 1H), 3.43 (s, 3H), 3.71 (bd, J = 2.5 Hz, 1H), 3.77 (dd, 
J = 4.8, 10.3 Hz, 1H), 3.85 (dd, J = 5.5, 10.3 Hz, 1H), 3.88 (bt, J = 1.8 Hz, 1H), 3.91 (bt, 
J = 2.6 Hz, 1H), 4.07 (dd, J = 2.5, 14.3 Hz, 1H), 4.47 (bt, J = 5.1 Hz, 1H), 4.62 (d, J = 
6.6 Hz, 1H), 4.65 (d, J = 6.6 Hz, 1H), 4.71 (d, J = 7.0 Hz, 1H), 4.74 (d, J = 7.0 Hz, 1H). 
13C NMR (100 MHz, acetone-d6), δ: 27.8, 51.6, 51.8, 54.3, 55.0, 64.8, 69.3, 69.6, 74.3, 
78.7, 95.4. 95.9, 155.3. Anal. Calcd for C15H29NO8: C, 51.27; H, 8.32; N, 3.99. Found: 
C, 51.40; H, 8.30; N, 3.98. HRMS: m/ z [M + Na]+ calcd 374.1785, found 374.1769. 
N-ALKYL-L-DNJ SYNTHESIS 
 
N-Butyl-L-deoxynojirimycin (ent-2). Butanal (16.4 μL, 0.18 mmol) was added to a 
stirring solution of L-DNJ·HCl (11, 28 mg, 0.14 mmol) in an acetic acid/methanol (2 
mL, 1:200 v/v) solution. After a few minutes, NaBH3CN (8.8 mg, 0.14 mmol) was 
added. The resulting mixture was stirred at the same temperature for 16 h and then the 
volatiles were removed under reduced pressure. Flash chromatography of the crude 
residue (DCM:MeOH:NH4OH = 70:28:2) and subsequent filtration though a short pad 
containing a Dowex 1X8 (chloride form) resin yielded the pure ent-2 (30 mg, 96% yield) 
as a colourless oil; [α]D +17.0, c 0.27, H2O (2: −15.9, c 0.77, H2O).70 1H NMR (400 
MHz, D2O), δ: 0.92 (t, J = 7.3 Hz, 3H), 1.31 (sext, J = 7.3 Hz, 2H), 1.47−1.59 (m, 2H), 
2.40−2.55 (m, 2H), 2.68−2.80 (m, 1H), 2.82−2.95 (m, 1H), 3.10−3.21 (m, 1H), 3.32 (t, J 
= 9.3 Hz, 1H), 3.45 (t, J = 9.5 Hz, 1H), 3.61 (ddd, J = 10.7, 9.3, 4.9 Hz, 1H), 3.89 (dd, J 
= 12.9, 2.5 Hz, 1H), 3.94 (dd, J = 12.9, 2.5 Hz, 1H). 13C NMR (100 MHz, CD3OD), δ: 
14.2, 21.4, 27.0, 53.7, 56.5, 57.7, 67.4, 69.6, 70.8, 79.6. Anal. Calcd for C10H21NO4: 
C, 54.77; H, 9.65; N, 6.39. Found: C, 54.88; H, 9.62; N, 6.37. HRMS: m/z [M + H]+ 
calcd 220.1471, found 220.1533. 
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TPP/I2 as the iodination reagent. Iodination of alcohols 59a-c: general procedure. 
Alcohol 59 (1.0 equiv.) was dissolved in anhydrous toluene (35 mL); then 
triphenylphosphine (59a and 59b: 1.5 equiv; 59c: 2.0 equiv.) was added. The mixture 
was warmed to 60°C and iodine (59a and 59b: 1.5 equiv; 59c: 2.0 equiv.) was quickly 
added. The reaction was then stirred at reflux temperature for the appropriate time (59a: 
0.5 h; 59b: 1h and 59c: 12h). Toluene was removed under diminished pressure; the crude 
was dissolved in DCM, washed with saturated aqNa2S2O3 and brine. DCM was removed 
under reduced pressure and the compound was used in the subsequent step without 
further purification. 1-Iodohexane (60a) and 1-iodononane (60b): 1H and 13C NMR 
spectra were fully in line with those reported in the literature.71 Adamantanemethyl 
iodide (60c). 1H NMR (500 MHz, CDCl3), δ: 1.51 (d, J = 2.5 Hz, 6H), 1.64-1.67 (m, 
3H), 1.72-1.75 (m, 3H), 1.99 (s, 3H), 3.20 (s, 2H). 13C NMR (125 MHz, CDCl3), δ: 27.1, 
28.8, 36.7, 42.2. 
 
Reaction of iodides 60a-c with 1,5-pentanediol: general procedure. 1,5-pentanediol 
(5.0 equiv.) was dissolved in anhydrous DMF (35 mL) and NaH (60% dispersion in 
mineral oil; 5.0 equiv.) was added. The mixture was stirred for 30 min at room 
temperature. Then a solution of the crude iodide 60 (1.0 equiv.) in DMF (15 mL) was 
added. The reaction was warmed to the appropriate temperature (60a: 70°C; 60b and 
60c: 140°C) and stirred at the same temperature for an appropriate time (60a and 60b: 
16h; 60c: 48h). The mixture was then dissolved in DCM, washed with sat NH4Cl and 
brine. DCM was eventually removed under reduced pressure; column chromatography 
of the crude (petroleum ether/EtOAc) gave the pure alcohol 61. 5-Hexyloxyl-1-pentanol 
(61a): 22% o.y. from 60a. 1H NMR (400 MHz, CDCl3), δ: 0.88 (t, J = 6.4 Hz, 3H), 1.25-
1.35 (m, 6H), 1.41-1.47 (m, 2H), 1.52-1.64 (m, 6H), 3.40 (q, J = 6.7 Hz, 4H), 3.65 (t, J = 
6.5 Hz, 2H). 13C NMR (100 MHz, CDCl3), δ: 14.20, 22.69, 22.78, 26.01, 29.59, 29.87, 
31.86, 32.67, 63.04, 70.89, 71.22. 5-Nonyloxyl-1-pentanol (61b): 31% o.y. from 60b. 
1H NMR (400 MHz, CDCl3), δ: 0.87 (t, J = 6.6, 3H), 1.21–1.36 (m, 12H), 1.38–1.46 (m, 
2H), 1.51–1.65 (m, 6H), 3.39 (q, J = 6.6, 4H), 3.65 (t, J = 6.5 Hz, 2H). 13C NMR (125 
MHz, CDCl3), δ: 14.2, 22.5, 22.7, 26.3, 29.3, 29.5, 29.6, 29.6, 29.8, 32.0, 32.6, 63.0, 
70.8, 71.1. 5-Adamantanemethoxypentanol (61c): 55% o.y. from 60c. 1H NMR (500 
MHz, CDCl3), δ: 1.39-1.45 (m, 2H), 1.52-1.53 (m, 6H), 1.56-1.61 (m, 4H), 1.63-1.72 (m, 
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6H), 1.95 (bs, 3H), 2.96 (s, 2H), 3.39 (t, J = 6.5 Hz, 2H), 3.66 (t, J = 6.6 Hz, 2H). 13C 
NMR (125 MHz, CDCl3), δ: 22.6, 28.5, 29.4, 32.7, 34.3, 37.4, 39.9, 63.1, 71.7, 82.1. 
 
Iodination of alcohols 61a-c: general procedure. Alcohol 61 (1.0 equiv.) was 
dissolved in anhydrous toluene (10 mL), then triphenylphosphine (1.5 equiv.) was 
added. The mixture was warmed to 60°C and iodine (1.5 equiv.) was added. The reaction 
was stirred to reflux for 1h. The mixture was then dissolved in DCM, washed with 
saturated Na2S2O3 and NaHCO3 solutions and with brine. DCM was removed under 
reduced pressure; column chromatography of the crude residue (petroleum ether/EtOAc) 
gave the pure iodide 62. 1-Iodo-5-hexyloxyl-pentane (62a): 64% yield. 1H NMR (400 
MHz, CDCl3), δ: 0.89 (t, J = 6.7 Hz, 3H), 1.25-1.37 (m, 5H), 1.42-1.50 (m, 2H), 1.52-
1.63 (m, 5H), 1.82-1.89 (m, 2H), 3.19 (t, J = 7.0 Hz, 2H), 3.39 (t, J = 5.0 Hz, 2H), 3.41 
(t, J = 4.4 Hz, 2H). 13C NMR (100 MHz, CDCl3), δ: 7.1, 14.2, 22.7, 26.0, 27.4, 28.8, 
29.9, 31.9, 33.5, 70.6, 71.2. 1-Iodo-5-nonyloxyl-pentane (62b): 37% yield. 1H NMR 
(500 MHz, CDCl3), δ: 0.88 (t, 3H, J = 6.8 Hz),1.25-1.34 (m, 12H), 1.43-1.49 (m, 2H), 
1.53-.63 (m, 4H),1.82-1.88 (m, 2H, J = 7.1 Hz), 3.19 (t, 2H, J = 7.0 Hz), 3.4 (q, J = 6.4 
Hz, 4H). 13C NMR (125 MHz, CDCl3), δ: 7.3, 14.5, 23.1, 26.6, 27.7, 29.1, 29.7, 29.9, 
30.0, 30.2, 32.3, 33.8, 70.9, 71.5. 1-Iodo-5-adamantanemethoxyl-pentane (62c): 45% 
yield. 1H NMR (500 MHz, CDCl3), δ: 1.41-1.50 (m, 2H), 1.50-1.54 (m, 6H), 1.54-1.60 
(m, 2H), 1.60-1.74 (m, 6H), 1.80-1.89 (m, 2H), 1.92-1.99 (m, 3H), 2.94 (s, 2H), 3.19 (t, 
J = 7.1 Hz, 2H), 3.37 (t, J = 6.3 Hz, 2H). 13C NMR (125 MHz, CDCl3), δ: 7.2, 27.4, 28.4, 
28.5, 28.6, 28.7, 29.8, 31.4, 32.2, 33.5, 34.2, 37.4, 37.5, 39.9, 71.4, 82.1. 
PS-DPP/I2 as the iodination reagent: general procedure for the conversion of 
alcohols 59a-c into 1-iodo-5-alkyloxyl-pentanes 62a-c. Step 1: alcohol 59 (1.0 mmol) 
was dissolved in the appropriate anhydrous solvent (59a and 59b: ACN; 59c: toluene), 
then polystyryldiphenylphosphine (PS-DPP; 100-200 mesh, extent of labelling: ~3 
mmol/g triphenylphosphine loading) (3.5 equiv.) was added. The mixture was warmed 
to 40 °C and was added I2 (2.0 equiv.). After warming the reaction to reflux and leaving 
the suspension for the appropriate time (59a: 0.5h; 59b: 1h; 59c: 4h), the mixture was 
filtered, and the solvent was removed at rt under reduced pressure, affording iodide 60. 
Step 2: an appropriate amount of 1,5-pentandiol (60a and 60b: 1.0 equiv.; 60c: 5 equiv.) 
was dissolved in dry DMF (60a and 60b: 1.0 mL; 60c: 5.0 mL) and NaH (60% dispersion 
in mineral oil; 60a and 60b: 1.2 equiv.; 60c: 5 equiv.) was added. The mixture was stirred 
for 30 min at room temperature. Then a solution of the crude iodide 60 in dry DMF (0.5 
mL) was added dropwise. After 16h at 100 °C, the mixture was concentrated under 
reduced pressure to furnish 61. In the case of 61c, the reaction was washed with hexane 
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repeatedly in order to remove the excess of 1,5-pentandiol. Step 3: alcohol 61 was 
dissolved in the appropriate anhydrous solvent (61a and 61b: ACN, 2.5 mL; 61c: 
toluene, 5 mL), then PS-DPP (2.0 equiv.) was added. The mixture was warmed to 40 °C 
and I2 was added (2.0 equiv.). After warming the reaction to reflux and leaving the 
suspension under stirring at the same temperature for the appropriate time (61a and 61b: 
16h; 61c: 6h), the mixture was filtered, and the filtrate was evaporated under reduced 
pressure giving the pure iodide 62 (62a: 70 % o.y.; 62b: 88% o.y.; 62c: 80% o.y.–
deduced by NMR analysis of the crudes). 
 
1,5-Diiodopentane (63). To a solution of PS-DPP (100-200 mesh, extent of labeling: ~3 
mmol/g triphenylphosphine loading) (4.0 equiv.) and iodine (4.0 equiv.) in anhydrous 
DCM, 1,5-pentandiol (1.0 equiv.) was added dropwise. The reaction was stirred at room 
temperature for 1h; the mixture was then filtered, and the filtrate was evaporated under 
reduced pressure. The resulting crude was dissolved in DCM, washed with saturated aq 
Na2S2O3 and brine. DCM was removed under diminished pressure. Column 
chromatography of the crude residue (petroleum ether) gave the pure 1,5-diiodopentane 
(63) as a pale-yellow oil (95% yield). 1H NMR (500 MHz, CDCl3), δ: 1.49-1.55 (m, 2H), 
1.82-1.88 (m, 4H), 3.19 (t, J = 7.0 Hz, 4H). 13C NMR (100 MHz, CDCl3), δ: 6.3, 31.1, 
32.5. 
General procedure for the preparation of iodides 62 from 63. NaH (60% dispersion 
in mineral oil; 1.0 equiv.) was added to a stirring solution of alcohol 59a-c (1.5 equiv.) 
in dry THF (1.5 mL) at 0°C. The reaction mixture was stirred at the same temperature 
for 2h. Bis-iodide 63 (0.70 mmol) was then added and the mixture was warmed to rt. 
After the appropriate time (59a and 59b: 48h; 59c: 72h) the mixture was diluted with 
DCM and washed with aq NH4Cl and brine. The organic layer was dried with Na2SO4 
and the solvent evaporated under reduced pressure. Chromatography of the crude residue 
over silica gel provided the pure iodide 62 (62a: 65% yield; 62b: 64% yield; 62c: 62% 
yield). 
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L-N-nonyl DNJ (ent-7). Iodide 60b (0.21 g, 0.83 mmol) was dissolved in anhydrous 
DMF (2 mL) and added dropwise to a solution of L-DNJ (ent-1; 0.10 g, 0.613 mmol) 
and K2CO3 (0.25 g, 1.84 mmol) in DMF (2 mL). The reaction was warmed to 70 °C and 
stirred at the same temperature for 16h. Afterwards, the solvent was removed under 
diminished pressure. Chromatography of the crude residue over silica gel 
(acetone/MeOH = 80:20) afforded ent-7 as an oil; the compound, dissolved in water, 
was further purified with Dowex® 1X8, 50-100 mesh, ion-exchange resin (0.14 g, 80% 
yield). 1H NMR (400 MHz, MeOD), δ: 0.90 (t, 3H, J = 7.0 Hz), 1.22-1.38 (m, 12H), 
1.45-1.57 (m, 2H), 2.18-2.20 (m, 1H), 2.24 (t, J = 10.9 Hz, 1H), 2.60-2.66 (m, 1H), 2.81-
2.87 (m, 1H), 3.02 (dd, J = 4.8, 11.3 Hz, 1H), 3.15 (t, J = 9.1 Hz, 1H), 3.37 (t, J = 9.3 
Hz, 1H), 3.49 (dt, 1H, J= 4.9, 5.3 Hz), 3.86 (bs, 2H). 13C NMR (100 MHz, CDCl3), δ: 
14.4, 23.7, 24.5, 27.9, 30.3, 30.4, 30.6, 33.0, 54.1, 55.5, 56.4, 67.4, 68.6, 69.7, 78.7. LC-
TOF MS: m/z [M + H]+, calcd: 290.23; found: 290.23. 
 
L-N-Adamantanemethoxypentyl-DNJ (L-AMP-DNM) (ent-8). Iodide 62c (0.30 g, 
0.83 mmol) was dissolved in anhydrous DMF (2 mL) and added dropwise to a solution 
of ent-1 (0.10 g, 0.61 mmol) and K2CO3 (0.25 g, 1.83 mmol) in DMF (2 mL). The 
reaction was warmed to 80 °C and stirred at the same temperature for 16h. Afterwards, 
the solvent was removed under reduced pressure. Chromatography of the crude residue 
over silica gel (acetone/MeOH = 80:20) afforded ent-8 as an oil; the compound, 
dissolved in water, was further purified with Dowex® 1X8, 50-100 mesh, ion-exchange 
resin (0.19 g, 80% yield).  1H NMR (MeOD, 500 MHz): δ 1.31-1.40 (m, 2H), 1.50-1.64 
(m, 10H), 1.69 (bd, J = 11.9 Hz, 3H), 1.76 (bd, J = 12.0 Hz, 3H), 1.95 (bs, 3H), 2.09-
2.15 (m, 1H), 2.16-2.22 (m, 1H), 2.55-2.63 (m, 1H), 2.77-2.83 (m, 1H), 2.97 (s, 2H), 2.99 
(dd, J = 4.8, 11.3 Hz, 1H), 3.13 (t, J = 9.1 Hz, 1H), 3.35 (t, J = 8.9 Hz, 1H), 3.39 (t, J = 
6.2 Hz, 2H), 3.45-3.50 (m, 1H), 3.84 (dd, J = 1.7, 12.0 Hz, 1H), 3.87 (dd, J = 2.3, 12.2 
Hz, 1H). 13C NMR (100 MHz, CDCl3), δ: 24.2, 24.7, 29.7, 30.2, 33.4, 38.3, 40.8, 55.1, 
55.7, 67.4, 68.1, 69.2, 72.2, 72.6, 78.4, 831. LC-TOF MS: m/z [M + H]+, calcd: 398.29; 
found: 398.29. 
 46 
 
 
L-N-[5-(Hexoxy)pentyl]-DNJ (ent-11). Iodide 62a (0.25 g, 0.83 mmol) was dissolved 
in anhydrous DMF (2 mL) and added dropwise to a solution of ent-1 (0.1 g, 0.61 mmol) 
and K2CO3 (0.25 g, 1.84 mmol) in DMF (2 mL). The reaction was warmed to 70 °C and 
stirred at the same temperature for 16h. Afterwards, the solvent was removed under 
reduced pressure. Chromatography of the crude residue over silica gel (acetone/MeOH 
= 80:20) afforded ent-11 as an oil; the compound, dissolved in water, was further purified 
with Dowex® 1X8, 50-100 mesh, ion-exchange resin (0.16 g, 78% yield). 1H NMR (500 
MHz, MeOD), δ: 0.93 (t, J = 6.7 Hz, 3H), 1.31-1.39 (m, 8H), 1.52-1.65 (m, 6H), 2.15-
2.24 (m, 2H), 2.59-2.65 (m, 1H), 2.81-2.87 (m, 1H), 3.02 (dd, J = 4.9, 11.2 Hz, 1H), 3.15 
(t, J = 9.1 Hz, 1H), 3.37 (dd, J = 9.4, 12.0 Hz, 1H), 3.45 (q, J = 6.2 Hz, 4H), 3.49 (dt, J 
= 4.9, 10.3 Hz, 1H), 3.86 (dd, J = 2.7, 12.0 Hz, 1H), 3.89 (dd, J =2.6, 12.0 Hz, 1H). 13 
C NMR (500 MHz, MeOD), δ: 14.4, 23.7, 23.9, 24.5, 26.9, 30.1, 30.7, 32.8, 54.3, 54.9, 
54.9, 67.4, 67.8, 68.8, 71.4, 72.1, 78.1. LC-TOF MS: m/z [M + H]+, calcd: 334.26; found: 
334.25. 
 
L-N-[5-(Nonyloxy)pentyl]DNJ (ent-14). Iodide 62b (0.28 g, 0.83 mmol) was dissolved 
in anhydrous DMF (2 mL) and added dropwise to a solution of ent-1 (0.100 g, 0.61 
mmol) and K2CO3 (0.25 g, 1.84 mmol) in DMF (2 mL). The reaction was warmed to 70 
°C and stirred at the same temperature for 16h. Afterwards, the solvent was removed 
under reduced pressure. Chromatography of the crude residue over silica gel 
(acetone/MeOH = 90:10) afforded ent-14 as an oil; the compound, dissolved in water, 
was further purified with Dowex® 1X8, 50-100 mesh, ion-exchange resin (0.17 g, 75% 
yield). 1H NMR (500 MHz, MeOD), δ: 0.92 (t, J = 6.6 Hz, 3H), 1.29-1.41 (m, 14H), 
1.51-1.64 (m, 6H), 2.13 (bd, J = 9.5 Hz, 1H), 2.19 (dd, J = 6.7, 10.8 Hz, 1H), 2.57-2.63 
(m, 1H), 2.79-2.85 (m, 1H), 3.01 (dd, J = 4.9, 11.2 Hz, 1H), 3.14 (t, J = 9.1 Hz, 1H), 3.37 
(t, J = 9.0 Hz, 1H), 3.44 (q, J = 6.3 Hz, 4H), 3.49 (dt, J = 4.8, Hz, 1H), 3.85 (dd, J = 2.2, 
11.9 Hz, 1H), 3.89 (dd, J = 1.9, 11.9 Hz, 1H). 13C NMR (100 MHz, MeOD), δ: 14.4. 
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23.7, 24.0, 24.5, 27.3, 30.2, 30.4, 30.6, 30.7, 30.8, 33.0, 54.3, 54.8, 54.9, 67.4, 67.8, 68.8, 
71.4, 72.1, 78.2. LC-TOF MS: m/z [M + H]+, calcd: 376.31; found: 376.30. 
 
Mehoxyl 1-nonanol (65). To a solution of 1,9-nonandiol (0.57 g, 3.53 mmol) in dry 
DMF (5.0 mL), NaH (0.09 g, 3.53 mmol) was added at 0 °C. The mixture was stirred at 
the same temperature for 15 minutes and CH3I (0.1 g, 0.71 mmol) was then added 
dropwise. After 30 minutes the reaction was quenched with a saturated solution of 
NH4Cl. The mixture was then extracted with EtOAc and brine, the organic layers dried 
over Na2SO4 and concentrated under reduced pressure. Purification over silica gel of the 
crude (hexane:Acetone=80:20) afforded the pure 65 (0.11 g, 90% reaction yield) as 
colourless oil. 1H NMR (400 MHz, CDCl3), δ: 1.29 (bs, 10H), 1.52-1.58 (m, 4H), 3.32 
(s, 3H), 3.35 (t, J= 6.6 Hz, 2H), 3.62 (t, J= 6.6 Hz, 2H). 13C NMR (100 MHz, CDCl3), δ: 
25.8, 26.2, 29.5, 29.6, 29.7, 29.8, 33.0, 58.7, 63.1, 73.0. 
 
Mehoxyl 1-nonanal (67). The reaction flask contains oxalyl chloride (0.08 g, 0.63 
mmol) dissolved in dry DCM (1.7 mL), cooled to -78 °C. Once added DMSO (0.1 g, 
1.26 mmol) to dry DCM (0.6 mL) in another flask, its content was added to the reaction 
flask. After stirred the mixture for 30 minutes at the same temperature, 65 (0.1 g, 0.57 
mmol), dissolved in dry DCM (1.0 mL) was dropwise added. After 2h at -78 °C, 
triethylamine (0.29 g, 2.87 mmol) was added and the mixture was warmed to 0 °C. After 
2h the mixture was extracted with DCM and brine, the organic layers dried over Na2SO4 
and concentrated under reduced pressure. The crude was purified over silica gel 
(hexane:Acetone=95:5) affording the pure 67 (0.05 g, 48 % reaction yield) as white 
solid. 1H NMR (500 MHz, CDCl3), δ: 1.31 (bs, 8H), 1.53-1.63 (m, 4H), 2.41 (t, J= 7.3 
Hz, 2H), 3.33 (s, 3H), 3.36 (t, J =6.5 Hz, 2H), 9.76 (s, 1H). 13C NMR (125 MHz, CDCl3), 
δ: 25.8, 26.3, 29.3, 29.4, 29.5, 29.6, 36.1, 58.5, 73.9, 198.5. 
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L-N-[9-(Methoxyl)nonyl]DNJ (ent-44). L-DNJ ent-1 (0.035 g, 0.22 mmol) was 
dissolved in an acetic acid/methanol (1:200 v/v) solution (18 µL AcOH in 3.48 mL of 
dry MeOH), then the aldehyde 67 (0.044 g, 0.26 mmol) and NaBH3CN (0.014 g, 0.22 
mol) were added at room temperature. The mixture was stirred at the same temperature 
until TLC showed disappearance of the starting material (12h). The reaction mixture was 
concentrated under reduced pressure and the crude purified over silica gel 
(hexane:Acetone=80:20) affording the pure ent-44 (0.063 g, 91 % reaction yield) as 
white solid. 1H NMR (400 MHz, MeOD), δ: 1.33 (bs, 10H), 1.47-1.60 (m, 4H), 2.15-
2.32 (m, 2H), 2.64-2.70 (m, 1H), 2.84-2.91 (m, 1H), 3.05 (dd, J =4.8, 11.3 Hz, 1H), 3.16 
(t, J= 9.0 Hz, 1H), 3.34 (s, 3H), 3.38 (t, J= 6.5 Hz, 2H), 3.50 (dt, J= 4.8 Hz, 1H), 3.87 
(bs, 2H). 13C NMR (100 MHz, MeOD), δ: 25.1, 27.1, 28.5, 30.4, 30.5, 30.6, 30.7, 53.8, 
57.4, 58.7, 59.0, 67.4, 70.5, 71.8, 73.9, 80.3. 
GLYCOSIDASES INHIBITION STUDY 
Cerezyme assay: Cerezyme (Genzyme. Cambridge, MA) has been provided by courtesy 
of Department of Medicine, University of Cambridge, UK. The assay buffer was 50 mM 
citric acid, 176 Mm K2HPO4, pH 5.9, 0.01% Tween-20 and 10 mM sodium taurocholate. 
Cerezyme (40U/Ml) was diluted in the assay buffer in presence of 1% BSA (Bovine 
Serum Albumin) to reach the final concentration of 1:50000. The artificial substrate,  
4-methylumbelliferyl-β-D-glucopyranoside, was dissolved in the assay buffer (4.5 mM). 
The blank mixture (in triplicate) contains 10 µL of assay buffer, 10 µL of enzyme 
solution and 40 µL of substrate. Each incubation mixture (at different inhibitor 
concentrations, in triplicate) contains 10 µL of enzyme, 10 µL of inhibitor and 40 µL of 
substrate. The tubes containing the mixtures were incubated at 37° for 30 minutes; then 
the assay was stopped by the addition, in each tube, of a stop solution (0.4 mL, 0.5 M 
Na2CO3). The mixtures were transferred in a plate and the fluorescence was measured 
with a BMG Labtech CLARIOSTAR plate-reader (excitation λ= 365 nm; emission λ= 
450 nm). 
GAA assay: the enzyme source (0.020 g, liver extract) of acid α-glucosidase (GAA) has 
been suspended and homogenised in 2.0 mL of cold water. The assay buffer was 0.1 mM 
citric acid, 0.1 M phosphate, pH 4.0, 0.1% Triton X-100. The artificial substrate, 4-
methylumbelliferyl-α-D-glucopyranoside, was dissolved in the assay buffer (1.47 mM). 
The blank mixture (in triplicate) contains 10 µL of assay buffer, 10 µL of tissue extract 
and 60 µL of substrate. Each incubation mixture (at different inhibitor concentrations, in 
triplicate) contains 10 µL of enzyme, 10 µL of inhibitor and 60 µL of substrate. The 
tubes containing the mixtures were incubated at 37° for 30 minutes; then the assay was 
stopped by the addition, in each tube, of a stop solution (0.4 mL, 0.5 M Na2CO3). The 
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mixtures were transferred in a plate and the fluorescence was measured with a BMG 
Labtech CLARIOSTAR plate-reader (excitation λ= 365 nm; emission λ= 450 nm).  
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NUCLEOSIDE ANALOGUES 
Nucleosides are endogenous compounds involved in several cellular processes such as 
nucleic acids synthesis, cell signalling, enzyme regulation and metabolism. Nucleoside 
analogues (NAs) are synthetic, chemically modified compounds developed to mimic the 
physiological counterparts in order to exert their cellular functions. They have become 
cornerstones of treatment of viral infections and today many efforts are still made to 
discover in the next future more potent, selective and less toxic antiviral NAs. The 
metabolic pathway of NAs is the same of that exploited by endogenous ones; inside the 
cells, NAs are subsequently phosphorylated until triphosphate substrates (active form) 
are accumulated in virus-infected cells. This mechanism results easy for those NAs 
conceived to be inhibitors of DNA viruses (such as HHVs) that possess their own kinases 
characterized by obvious broader substrate specificity than mammalian counterparts; it 
is more difficult instead to develop new anti-HIV NAs because of the obligate recognition 
by cellular kinases to make them active. At this point, they can act as intracellular 
enzymes inhibitors, as well as they can be incorporated into newly synthetized DNA and 
RNA inducing termination of chain elongation, accumulation of mutations in viral 
progeny (lethal mutagenesis) or inducing cell apoptosis. The wide chemical diversity of 
NAs relies on the possibility to insert chemical modifications at different levels of their 
basic structure (Figure 1), that are the sugar moiety, the nucleobase or the phosphate 
groups (nucleotide analogues). The antiviral nucleosides currently on the market were 
discovered through the intuitive thinking of chemists as to which structural analogues of 
natural substrates might confound the viruses, or on the basis of already existing 
antiviral compounds. However, a nucleoside is more than the sum of carbohydrate plus 
nucleobase; there is still so much we do not understand about nucleosides and about 
their antiviral pathways or biological targets. This research field is thus still open and 
continuously in evolution. 
In the above described context, during this PhD research program, the attention has 
been focused on the synthesis and biological evaluation of three different class of NAs: 
2'-fluorinated oxathiolanyl nucleosides (2.1), piperidinyl nucleosides (2.2) and 
cyclohexenyl nucleosides (2.3). In the first case, the aim was to enhance (through the 
stereoselective introduction of a fluorine atom) the already well-known anti-HIV activity 
of (-)-3TC (L-NA) as terminator chain. In the other two cases (examples of NAs with a 
six-membered sugar core), the nucleoside conformational preferences have been 
considered and exploited with the aim to mimic the bioactive ones and at the same time 
to pre-organize the NAs in order to improve the selectivity associated to the host-guest 
recognition processes crucial for the viral replication. 
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Figure 1 (taken by Jordheim, L.P. et al. Nat. Rev. Drug Discovery 2013, 12, 447): structural 
and chemical modifications of NAs. 
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2.1.1 INTRODUCTION 
2.1.1.1 ANTIVIRALS AT MIRROR: L-NUCLEOSIDE ANALOGUES 
Louis Pasteur, some years after discovery that not only objects but also molecules and 
chemical reactions exhibit chirality, in his speech at French Academy of Sciences, said 
“l’Univers est dissymétrique”.1 The chirality in its biological meaning explains the 
reason why proteins are built up only with L-amino acids and nucleic acids with 
nucleotides whose sugar moiety is only in D-configuration (ensuring the formation of 
right-handed helices). The enantioselectivity characterizing the enzyme-substrate 
recognition processes (namely the property of enzymes to recognize and metabolize only 
one of the two enantiomers of chiral molecules), is dictates by the intrinsic chiral 
structure of the enzymes (due to three-dimensional folding of the polypeptide backbone 
and to amino-acids side chain orientation).2 In this context,  
L-nucleosides however represent a surprising exception to the mentioned rule (FIGURE 
1). For a long period, indeed, it was assumed that nucleoside analogues (NAs) having 
only a natural D-configuration, by analogy with the natural ones, could be recognized by 
enzymes to exhibit their biological activity. 
 
FIGURE 1. a) Mirror relationship between D- and L-nucleosides;  
b) (+)-BCH189 and (-)-3TC (Lamivudine). 
As a matter of fact, at the beginning of the 1990s, this paradigm has been challenged and 
unnatural L-nucleosides emerged as new class of therapeutic agents.3 Indeed, Schinazi 
et al.4 reported the synthesis and anti-HIV-1 activity of all possible stereoisomers of an 
unusual nucleoside, 2’,3’-dideoxy-3’-thiacytidine ((+)-BCH-189, 1) (FIGURE 1), and 
surprisingly the -L-isomer (Lamivudine, (-)-3TC, 2) resulted as the most potent and 
less toxic nucleoside. Since then, many L-NAs have been synthetized (FIGURE 2) and 
the molecular basis for their therapeutic activation as antiviral or anticancer agents have 
been elucidated. 
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FIGURE 2. L-NAs endowed with biological activity  
(approved drugs in the blue panel). 
2.1.1.2 LACK OF ENANTIOSELECTIVITY OF VIRAL AND HUMAN ENZYMES: 
MOLECULAR BASIS TO DEVELOP SELECTIVE ANTIVIRAL AGENTS 
In order to gain pharmacological activity, both D- and L-NAs require serial 
phosphorylation (SCHEME 1), via the mono- and diphosphate intermediates to the 
triphosphorylated form (NA-TP). This implies that, gives their inverted configuration, 
the pharmacological activity of L-nucleoside analogues is dependent on the capacity of 
all the enzymes of the activation pathway to phosphorylate enantiomers of opposite 
chirality, plus the ability of the L-NA-TP to successfully compete with physiological 
nucleoside triphosphates (NTPs) and to distinctively inhibit the viral target DNA (or 
RNA) polymerase.5 
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SCHEME 1. Metabolism of (+)-BCH 189 and (-)-3TC. 
The virus encoded enzymes often show properties similar to those exhibited by their 
cellular equivalents; for this reason, the design of selective antiviral agents able to not 
interfere with the host cells metabolism (harming the whole organism), is a difficult task 
to reach. HSV-TK (Herpes Simplex Virus Thymidine Kinase) represents a lucky case in 
which the viral enzyme, despite its similar functionality to the cellular counterpart (the 
human TK), possess unique catalytic properties being not enantioselective.2 Indeed, 
beside to its great ability to accept a wide range of modified NAs (e.g. acyclovir, 
idoxuridine, brivudine [BVdU] and ganciclovir [DHPG]),6,7  it is able to phosphorylate 
with similar efficiency both D- and L-enantiomers of idoxuridine and BVdU. Similar 
results were obtained for HSV-2 TK and Varicella Zoster TK, suggesting that the lack 
of stereospecificity could be a common feature shared by TKs encoded by HHVs 
(Herpes Human Viruses).6 
On the other hand, for those viruses, such as HIV (Human Immunodeficiency Virus) or 
HBV (Hepatitis B Virus), which do not possess their own kinases, the crucial 
phosphorylation step must be accomplished by host kinases such as thymidine kinase 1 
(TK1), deoxycytidine kinase (dCK), thymidine kinase 2 (TK2) and deoxyguanosine 
kinase (dGK). While TK1 is highly specific for thymidine (dT), dCK, TK2 and dGK are 
able to accept several substrates.8 As an example, 3TC and FTC (FIGURES 1 and 2) are 
both substrates of dCK, being converted to the corresponding MP-NAs (for 3TC, see 
SCHEME 1) more efficiently than the corresponding D-forms. Further phosphorylation 
leading to di- and triphosphate forms is then accomplished by UMP/CMP kinase and 3-
phosphoglycerate kinase, respectively. L-NA-TPs act as dCTP analogues, competitively 
inhibiting HIV Reverse Transcriptase (RT) and HBV DNA polymerase, by 
incorporation into viral DNA behaving as chain terminator.9 In order to understand the 
“relaxed” enantioselectivity showed by dCK-like enzymes,10 Sabini et al. solved the 
dCK three-dimensional structure in complex with D- or L-NAs. They concluded that the 
interaction between dCK and NAs is mediated by the overlay of “fingerprint” groups: 
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the nucleobase moiety (whose binding requires obligate changes of the sugar moiety) 
and the 5’OH group (FIGURE 3). 
 
FIGURE 3 (adapted from Chemical Synthesis of Nucleoside Analogues).3 Schematic 
representation of the structural features determining the biological activity of D- and L-NAs 
(cytidine analogues; X, Y = O, S, C). a) “Fingerprint” groups overlay. b) Phosphorylation of D- 
or L-NA by non-enantioselective viral/host kinases. c) Recognition of D- or L-NA by viral/host 
polymerases. 
Precisely, once established the interactions between polar atoms of the base and side 
chains of the enzyme active site, the structure of the L-nucleoside needs only of a small 
tilt of the base and a change in the glycosidic bond torsion angle to fit the plastic dCK 
active site. The FIGURE 3a clearly shows how the 5’-OH group positioning in the dCK 
active site is independent of chirality and how the mirror relationship still allows a nearly 
perfect overlay of the critical O5’ atoms.11 Therefore, if internal symmetry and intrinsic 
conformational flexibility of L-NAs are suitable to satisfy these structural changes, dCK 
will exert catalytic activity giving the corresponding MP-NA. 
It is worth noting that, despite the described enzymatic plasticity exerted by some 
examples of host/viral enzymes, other strictly enantioselective hydrolytic enzymes (e.g. 
deoxycytidine deaminase, see SCHEME 1) are not able to recognize unnatural L-NAs, 
resulting in their low displayed cellular/mitochondrial toxicity.12 
2.1.1.3 SYNTHESIS OF L-NUCLEOSIDES 
As a consequence of displayed dCK (and of other related kinases) peculiar 
enantioselectivity, the field of L-nucleosides holds promise for the identification of 
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efficient and selective drugs, whose increasing clinical request (especially as antiviral 
agents) justifies the development of a wide variety of synthetic approaches devoted to 
their preparation. Numerous are the sugar-modified L-NAs classes: ribose and 2’-
deoxyribose, 2’,3’-deoxyribose, carbocyclic, pyrrolidinyl, dioxolanyl and others. 
However, driven by the great antiretroviral activity displayed by 3TC and FTC,13 the  
L-nucleosides having a 1,3-oxathiolane sugar moiety as bioisoster of the 2’,3’-
deoxyribose unit, represent the most prominent examples among all existing nucleoside 
analogues equipped with a heterocycle sugar ring. Their preparation can be approached 
by either de novo strategies (involving small starting materials such as 1,4-dithiane-2,5-
diol) or by chiron strategies (using enantiomerically pure and commercially available 
starting materials such as carbohydrates) (SCHEME 2). All the methods share the 
synthesis of the 1,3-oxathiolanyl intermediate 3 that, in the following Vorbruggen N-
glycosidation reaction, leads to the target L-nucleosides (SCHEME 2a).14 
Among the possible oxathiolane nucleoside precursors 3, the acetate 4 has been widely 
used as electrophilic “sugar” in the stereoselective methods developed for the synthesis 
of both 3TC and FTC.15 In this context, recently, Guaragna et al. reported a novel highly 
stereoselective N-glycosidation procedure consisting in the combined use of I2 and 
silanes (TMS or PMHS) as substrate activators and glycosydation promoters (SCHEME 
2b).16 
 
SCHEME 2. a) Simplified scheme of the synthetic approaches used to prepare  
1,3-oxathiolanyl-L-nucleosides. b) Highly stereoselective synthesis of 3TC and FTC by a novel 
N-glycosylation procedure (ref. 16). 
2.1.1.4 THE ROLE OF FLUORINE IN THE DESIGN OF BIOACTIVE NAS 
Fluorinated NAs (namely nucleosides containing fluorine atom(s) or fluorine-containing 
groups in their sugar or base moiety) have drawn increasing attention in the last 30 
years;17 as a consequence, a wide number of important fluorinated pharmaceuticals have 
been discovered and developed by modifying the skeleton of biologically active 
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nucleosides (FIGURE 4).18 The advantages deriving from incorporation of fluorine 
atom(s) into biologically active molecules are based on its unique characteristics: (1) 
fluorine is the second smallest atom and closely mimics hydrogen without much 
distortion of the geometry;19 (2) fluorine is the most electronegative element and can act 
as an isopolar and isosteric mimic of a hydroxyl group (the C–F bond length, 1.35 Å, is 
close to the C–O bond length, 1.43 Å), as well as fluorine is a hydrogen-bond acceptor;20 
(3) the strength of C–F bond exceeds that of C–H bond resulting often in increased 
biological/chemical stability, improved lipophilicity and better pharmacokinetic and 
pharmacodynamic properties of the corresponding compounds.21 Therefore, the 
selective introduction of fluorine atom(s) into a bioactive nucleoside has become an 
important strategy in the design and discovery of novel drug candidates.22 
 
FIGURE 4. Examples of D- (in blue) and L- (in red) fluorinated 
NAs approved as drugs or in clinical trials. 
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2.1.1.4.1 FLUORINATION SYNTHETIC METHODOLOGIES 
Therefore, the synthesis of fluorinated NAs has required the development of novel 
fluorination methodologies and fluorinating reagents to allow the stereoselective 
introduction of one or more fluorine atoms. The fluorination reactions are mainly 
classified dependently by the chemical nature, electrophilic or nucleophilic, of the 
fluorine source reagent. 
a) Nucleophilic fluorinating reagents 
Depending on the reaction environment, the fluoride ion (F-) can act either as a poor 
nucleophile (in a protic solvent) or as a good nucleophile (in polar aprotic solvents, 
especially in presence of large lipophilic countercations). Activation of alcohols 
with good leaving groups, such as mesylate, tosylate or triflate, followed by a SN2 
substitution by a fluoride ion has become a standard method to replace OH with F. 
Commonly used nucleophilic fluorinating reagents are the Olah’s reagents (Py⸱nHF 
and iPr2NH⸱3HF) and DAST ([(diethylamino)sulfur trifluoride], Et2NSF3) (FIGURE 
5). The latter is a really versatile fluorinating agent; it is able to give the classical 
SN2 reaction (in presence of a suitably introduced good leaving group) but also: a) 
one-step exchange of a hydroxyl group (primary, secondary, tertiary and allylic OH) 
by fluorine in excellent yields, mainly with a complete inversion of configuration; 
b) conversion of most aldehydes and ketones to the corresponding gem-difluorides; 
c) sulphoxide conversion in the corresponding -fluoro-thioether by a modified 
Pummerer reaction.23 
 
FIGURE 5. Commonly used nucleophilic fluorinating reagents. 
b) Electrophilic fluorinating reagents 
When a fluorine atom binds to an electronegative nitrogen (F–X) it acts as a ‘real’ 
F+ source in reactions with electron-rich double bonds or in the replacement of a 
proton on aromatic systems. NFSI (N-fluorobenzenesulfonimide) and Selectfluor® 
(1-chloromethyl-4-fluoro-1,4-diazoniabicyclo [2.2.2] octanebis(tetrafluoroborate) 
are the most used and efficient electrophilic fluorinating agents (FIGURE 6). The 
latter is a stable, easily handled and solid electrophilic fluorinating agent, soluble in 
polar solvents, such as MeCN, DMF and H2O. Selecfluor® is an equivalent of F2, 
but much more effective and selective. Asymmetric fluorinations are also achieved 
with Selectfluor® in the presence of various chiral catalysts.24 
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FIGURE 6. Commonly used electrophilic fluorinating reagents.  
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2.1.2  RESULTS AND DISCUSSION 
2.1.2.1 SYNTHESIS OF -L-2′-FLUORO-3′-THIACYTIDINE (F-3TC) 
STEREOISOMERS 
In an effort to improve the pharmacological properties of 3TC (2), a great deal of 
modifications has been explored over the past decades.25 The most effective change in 
this area has been the formal replacement of a hydrogen by a fluorine atom at C5 position 
of cytosine, leading to Emtricitabine [(–)-2',3'-dideoxy-3'-thia-5-fluorocytidine or FTC] 
and Racivir [(±)-FTC or RCV] (FIGURE 7). Conversely, no synthetic endeavours have 
been so far devoted to the preparation of 3TC derivatives having a fluorine atom in the 
“sugar” backbone. If on the one hand, fluorine introduction at the C2′  
β-position is reported to increase the stability of the corresponding N-glycosidic bond26 
(keeping the antiviral potential), on the other hand the occurrence of up to three labile 
stereocentres in such a small molecule could potentially affect the stability of the 
molecule. 
 
FIGURE 7. Oxathiolane nucleosides 3TC (2), FTC, RCV and 2'-fluorinated 3TC congeners 
(2'S)-F-3TC (5) and (2'R)-F-3TC (6). 
Intrigued by these observations, the aim of the project herein reported has been the 
synthesis of 2'-fluorinated 3TC derivatives having either (1'S,2'S,4'R) or (1'S,2'R,4'R) 
configuration [i.e. (2'S)-F-3TC (5) and (2'R)-F-3TC (6)] (FIGURE 7).27 Furthermore, the 
nucleoside 6 has been evaluated in vitro as antiviral agent against Hepatitis C Virus 
(HCV), Respiratory Sinctial Virus (RSV) and HIV. The experiments have been 
performed at Gilead Sciences. 
2.1.2.2 PRELIMINARY ORGANOCATALYTIC ELECTROPHILIC FLUORINATION 
REACTIONS 
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In initial attempts, fluorine atom introduction was conceived at an early stage of the 
synthesis by an asymmetric, organocatalytic electrophilic fluorination of oxathiolanones 
10a,b (SCHEME 3 and TABLE 1). These last were prepared starting from ethylene glycol 
7 and glycerol 8 via aldehydes 9a,b respectively, as previously reported (SCHEME 
3).28,29,30,31 
 
SCHEME 3. Synthesis of fluorinated oxathiolanes 11a-b starting from 7-8. 
 
TABLE 1. Organocatalytic asymmetric fluorination of oxathiolanones 10a,b. 
All reactions were carried out at room temperature unless otherwise specified. ai-PrOH used as co-solvent 
(CH3CN:i-PrOH = 10:1 v/v). b Minor amounts (10-12%) of mercaptolactones 12a-b (FIGURE 8) were also 
detected. c The reaction was carried out at 0°C. dThe enantiomeric excess was determined by 1H NMR 
analysis of the major trans isomer using Eu(hfc)3 as shift reagent. eND: not detected (owing to broadness of 
NMR signals following Eu(hfc)3 addition). fThe (–)-enantiomer was obtained as deduced by polarimetric 
analysis. 
The fluorination reaction (TABLE 1) was studied using L-proline as chiral 
organocatalyst; Selectfluor® was chosen as the fluorine source in place of the more 
effective N-fluorobenzenesulfonimide (NFSI), since use of the latter rapidly altered the 
starting oxathiolanones 10a,b (releasing the parent aldehydes 9a,b). Treatment of 
mercaptolactones 10a,b with Selectfluor and proline in CH3CN32 smoothly provided 
(16h) the corresponding fluorination products 11a-b (50-55% yields; TABLE 1, entries 
1-2). In both cases, the reaction exhibited a high degree of diastereoselectivity (trans:cis 
>20:1). Considering that starting compounds 10a-b were racemic mixtures, this last 
result was invariably associated to an exceedingly poor enantioselectivity (<5% ee), as 
confirmed by 1H NMR analysis of the trans isomer of 11a-b following treatment with 
entry compound time 
(h) 
yield 
(%) 
trans:cis ee 
(%)d 
1 10a 16 50 >20:1 <5 
2 10b 16 55 >20:1 <5 
3 10aa,b 1 50 4:1 NDe 
4 10ba,b 1 47 4:1 52f 
5 10aa,c 10 65 4:1 NDe 
6 10ba,c 12 85 4:1 60f 
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Eu(hfc)3. In line with previous reports,33 in subsequent attempts, use of i-PrOH as co-
solvent (CH3CN:i-PrOH = 10:1 v/v) led to a significant improvement in the 
enantioselectivity of the reaction [e.g., 11b: trans:cis = 4:1; 52% ee (trans isomer)]. A 
preference for the (–)-enantiomer was found, as suggested by polarimetric analysis 
(entry 4). Furthermore, the reaction was much faster in this case (1h). The formation of 
minor amounts of byproducts 12a-b (10-12%) was also detected34,35 (FIGURE 8). When 
the same reaction was performed at 0°C, only traces of the last ones were found; in 
addition, a further improvement in the enantioselectivity (11b: 60% ee) and in the 
reaction yields (65-85%) was observed (entries 5-6). 
 
FIGURE 8. Byproducts 12a-b of the organocatalytic fluorination reactions. 
Despite the synthetic relevance of these first promising results, a more comprehensive 
study of oxathiolanone fluorination involving the use of other chiral organocatalysts36 
and methodologies37 was not performed. Indeed, α-fluorinated compounds 11a-b did not 
show any stability to the typical reduction conditions of the lactone group (DIBAL-H, 
DIBAL-H/Ac2O, DIBAL-H/MeI, Red-Al/Ac2O, NaBH4/Ac2O, BH3-THF, 
PTSA/Ac2O), required for the subsequent nucleobase insertion step. 
On the basis of described unsuccessful results, the synthetic strategy to obtain 5 and 6 
was then changed and alternative routes were explored trying to accomplish the 
fluorination step at the late stage of the synthesis, namely once performed the preparation 
of 3TC. 
2.1.2.3 EN ROUTE TO 2’-FLUORO-OXATHIOLANYL NUCLEOSIDES 
In an early approach aimed to prepare the nucleoside 16 (SCHEME 4), ketone group 
reduction of 10a and subsequent acetylation of the resulting hemiacetal function gave 
oxathiolanyl acetate 13 (71% o.y.; SCHEME 4), which was used as an achiral model 
substrate. Thioether oxidation of the latter (MCPBA) led to a 2:1 mixture of sulfoxides 
14 (66%), which were subjected to a Pummerer rearrangement (Ac2O, AcONa). Acetyl 
ester 15 was formed with slight stereoselectivity; a concurrent acetoxy group 
anomerization (α/β = 1/1) was also found under these conditions (69% o.y.). 
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SCHEME 4. Oxathiolanone 10a elaboration. 
The newly installed acetoxy ester function in 15 was conceived both as a stereodirecting 
moiety in the subsequent N-glycosidation step and as a leaving group for the nucleophilic 
fluorination reaction. However, 15 displayed limited synthetic utility: when treated 
under typical N-glycosidation conditions (CyNBz/BSA/SnCl4 or TfOTMS), it was 
converted into the desired nucleoside 16 only in traces (up to 4%); anhydrosugar 17 was 
instead recovered as the major reaction product (up to 52%), despite the known 
compatibility of the reagents with the TBDPS group (SCHEME 4). 
A further alternative route was then considered and unprotected Lamivudine (3TC, 2) 
was first of all prepared exploiting a highly stereoselective Et3SiH/I2-mediated N-
glycosidation method of menthyl oxathiolane 4, briefly described before (see 
PARAGRAPH 2.1.1.3).16 3TC was next converted into the bis-benzoylated derivative 18 
by treatment with BzCl in pyridine (95%). When 18 was subjected to common 
sulfoxidation conditions (MCPBA), a 7:3 mixture of (1'S,3'R,4'R) and (1'S,3'S,4'R) 
configured nucleosides 19 was attained (80%). Conversely, treatment of 18 under 
Kagan’s conditions38 [Ti-(O-i-Pr)4, L-DET, H2O, CuOOH] yielded protected 3TC 
sulfoxide 19 (64%) with a remarkably higher stereoselectivity [(3'R)-19:(3'S)-19 > 20:1]. 
Unexpectedly, the nucleophilic fluorination of 19, devised by treatment of the latter with 
diethylaminosulfur trifluoride (DAST) and ZnI2, restored the starting sulfide39 18 in 
place of the desired fluorinated nucleoside (SCHEME 5). 
 
SCHEME 5. Asymmetric sulfoxidation reactions to obtain 19. 
On the other hand, Pummerer rearrangement of 19 led to the corresponding 2'-O-acetyl 
ester 20 (SCHEME 6). When typical conditions were used (Ac2O, AcONa, 110°C, 8h), 
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no stereoselectivity was found (d.r. = 1:1) starting from an equimolar mixture of (3'R)-
19 and (3'S)-19; the displacement of the N-benzoyl group into a N-acetyl derivative 20a 
was also concurrently observed (73%). Interestingly, if a catalytic amount (0.2 equiv.) 
of Ti(O-i-Pr)4 was added to the reaction mixture, the rearrangement of (3’R)-19 
proceeded without formation of any side product and with very high stereoselectivity, 
obtaining nucleoside (2'S)-20b as the only detected reaction product (73%). When a 1:1 
mixture of diastereomeric sulfoxides (3'R)-19 and (3'S)-19 was engaged in the reaction, 
we even found that the only (3'R) isomer was converted, while the (3'S) congener was 
recovered unreacted (SCHEME 6). Direct fluorination of 20a with HF-pyridine40 did not 
give the desired fluorinated nucleoside, even after prolonged reaction times; the de-N-
acetylated nucleoside 21 was instead recovered (71%). 
 
SCHEME 6. En route to 2'F-oxathiolanyl nucleosides via Pummerer rearrangement. 
On the other hand, treatment of 20a-b with lithium trifluoroethoxide (CF3CH2OLi, 
obtained in situ by reaction of CF3CH2OH with BuLi)41 in CF3CH2OH led to a C2'-
selective de-O-acylation, providing hemithioacetals 22a-b in satisfying 60-63% yields 
(SCHEME 7). The reaction of 22a-b with DAST eventually enabled OH→F displacement 
by nucleophilic fluorination to give, already after 0.5h at 0°C, 2'-fluoronucleosides 23 
and 24 (23a-24a, R = Ac, 66% o.y.; 23b-24b, R = Bz, 72% o.y.). Relative configuration 
assignment was based on the observation of a NOE contact between H2' and H4' nuclei 
in 23a, which was therefore identified as the (2’R)-isomer. It should be however noted 
that a not negligible NOE signal between the same nuclei was also found in the 
corresponding (2’S) epimer 24a. Noteworthy, a strong interaction between distant F2' 
and H4' nuclei (4J = 7.2 Hz) was observed in 23b, while it was not detected in 24b. In 
line with literature data,42 the long-range hydrogen-fluorine coupling (LRHFC)41a was 
thought to be correlated with HOMO-LUMO interactions involving fluorine atom 
orbitals and those on C4'. The reaction proceeded with a slight stereoselectivity for the 
(2’S) isomer (d.r. = 3:1). Any attempt to improve or reverse the stereochemical outcome 
of the reaction was unsuccessful: as an example, replacement of DCM with THF gave a 
2.4:1 ratio of (2’S):(2’R); in addition, the use of DMF (6 equiv.) as stereodirecting 
agent43 increased the amount of (2’R) isomer only up to (2’S):(2’R) = 1.5:1. When the 
reaction was performed starting from the single isomer (2’S)-22b, an even equimolar 
amount of the two fluorinated nucleosides was obtained. 
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SCHEME 7. Nucleophilic fluorination reactions to nucleosides 23-24a,b. 
Protective groups removal of 24a (NH3/MeOH) eventually provided (92%) the first 2'-
fluorinated 3TC derivative 5 [(2’S)-F-3TC; SCHEME 8]. However, over time (2-4h) the 
latter underwent to a spontaneous cyclization, leading to the undesired cyclonucleoside 
25 (99%). The same compound was formed even faster when the crude was treated with 
Et2O/MeOH during recrystallization attempts. It’s worth noting that treatment of 25 with 
Ac2O/AcONa along with a catalytic amount of Ti(O-i-Pr)4 provided back triacetate 26 
in a high stereoselective manner [(2’S)(2’R) >20:1] (SCHEME 8). The fluorinated 3TC 6 
[(2’R)-F-3TC] was similarly obtained by ammonolysis of 23b (90%). In this case, we 
were glad to observe that 6 was stable throughout the deprotection process as well as 
during the subsequent purification procedures. 
 
SCHEME 8. Deprotected fluorinated 3TC congeners 5-6. 
With the aim to unambiguously determine the relative configuration of the fluorination 
products, our efforts were eventually devoted to the determination of their structure by 
X-ray analysis. Since crystals of either 23a-b, 24a-b or 6 were unsuitable to this end, the 
latter was protected as bis-4-bromobenzoyl derivative 27 (p-BrBzCl/DMAP, 69%). X-
ray analysis of the latter confirmed the cis orientation of the nucleobase, the fluorine 
atom and the hydroxymethylene group: indeed, the absolute configuration of the three 
stereogenic centres, established by X-ray anomalous dispersion effects, resulted to be 
(1'S,2'R,4'R) (SCHEME 9). 
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SCHEME 9. X-Ray analysis of 27 to confirm its stereocenters configuration.  
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2.1.3 BIOLOGICAL DATA 
In order to study the antiviral potential of 2'-fluorinated 3TC derivatives, nucleoside 6 
was evaluated for its in vitro antiviral activity. The experiments were performed under 
the supervision of Dr. Richard Mackman (Gilead Sciences). Particularly, compound 6 
was evaluated for its inhibitory effect on the cytopathicity of Respiratory Syncytial 
Virus, RSV (strain A2) in Hep2 cells using Ribavirin as reference compound (TABLE 
2). Nucleoside 6 was also evaluated for its ability to inhibit the replication of HIV-1 (3b) 
in MT4 cells (TABLE 2), using AZT as reference control. Finally, 6 was tested for wild-
type replicon potency and selectivity against HCV in 1b R-luc cells (harboring a 
genotype 1b replicon), in 1a R-luc cells (harboring a genotype 1a replicon) and in 
2aLucNeo-25 cells (harboring a genotype 2a JFH-1 replicon) (TABLE 2). In this case, 
2’C-methyl-adenosine (2’CMeA) was used as control compound. Unfortunately, 6 did 
not show measurable antiviral activities in all cases. In order to explain the lack of 
expected antiviral activity of 6, minimized energy structures of 6 and the parent anti-
HIV drug 3TC were preliminary obtained (HyperChem Software 8.0), with the aim to 
search conformational differences between the two compounds. We found that in both 
cases the C3’-endo (or North) conformation resulted the only adopted conformation as 
shown in FIGURE 9. This result is in line with previous crystallographic data5,11 and 
highlights the peculiarity of 3TC, which adopts a pseudo-sugar ring pucker opposite to 
the C3’-exo (or South) conformation adopted, inter alia, by both D- and L-dC when in 
complex with dCK (FIGURE 10). The conformational profile of 3TC represents thus an 
exception to the general rule about the conformational requirements of NAs for 
enzymatic (kinases and polymerases) recognition.44 
 
FIGURE 9. Overlay of the C3’-endo conformers of 2 and 6 (in green). 
Accordingly, data suggest that the occurrence of the fluorine atom at C2’ position does 
not affect the conformational preferences of the oxathiolane sugar moiety. However, 
even though the recognition between 6 and dCK is expected by conformational reasons, 
we can speculate that just the presence of a highly electronegative atom may make 
difficult this process. Indeed, considering that the fluorine atom is reported to also act as 
a OH mimic because of the similar electronic densities, the presence of fluorine in such 
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an unusual conformation could make 6 a poor substrate for dCK, as it could be regarded 
as a 2-OH (arabino) nucleoside. 
 
FIGURE 10. a) D-dC, L-dC, 3TC and β-2F’-3TC conformations recognized by kinases and 
polymerases; b) comparison of the binding of D-dC, L-dC, 3TC and FTC in the active site od dCK 
(adapted from ref. 5).  
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TABLE 2. Antiviral evaluation of 6 (EC50, µM). 
 
  
 6 Ribavirin AZT 2’CMeA 
RSV 
CC50 
>100 16.0 ND ND 
>100 88.7 ND ND 
HIV-1 
CC50 
>53 ND 0.047 ND 
>53 ND 27.5 ND 
GT 1b 
CC50 
>44.4 ND ND 0.78 
>44.4 ND ND >44.4 
GT 1a 
CC50 
>44.4 ND ND 0.67 
>44.4 ND ND >44.4 
GT 2a 
CC50 
>44.4 ND ND 0.67 
>44.4 ND ND >44.4 
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2.1.4 CONCLUSIONS 
This topic has concerned the development of a stereoselective synthetic methodology 
devoted to the preparation of novel class of 3TC derivatives,  
2'-fluorinated having either (1'S,2'S,4'R or F3TC, 5) or (1'S,2'R,4'R or F3TC, 6) 
configuration. The insertion of fluorine atom has been conceived on the basis of other 
reported examples of 2'-fluorinated D-NAs resulted antiviral agents (e.g.  and -
FddA)45 and with the aim to enhance the pharmacological properties already observed 
for 3TC, 2. Despite several encountered synthetic difficulties because of the presence of 
three labile centres in the same molecule, the target nucleosides have been efficiently 
synthetized; unfortunately, 5 showed remarkable instability affording the intramolecular 
cyclization byproduct 25. On the other side, 6, once confirmed the stereocenters chirality 
by X-ray diffraction of its derivative 27, has been tested as antiviral agent (anti-HCV, 
anti-HIV and anti-RSV) but did not show any interesting antiviral activity. A preliminary 
computational approach in order to explain the lack of expected activity has been 
conducted, and allowed us to detect for 6 and 2 the same unconventional conformational 
behaviour. In both cases a C3’-endo conformation (typically recognized by viral 
polymerases) is indeed adopted. This preliminary study led us to assume that the fluorine 
atom in C2’, due its electronic mimicking of a hydroxyl group, could give to 6 arabino 
nucleoside resemblance explaining thus its poor recognition by dCK. 
  
 76 
 
2.1.5 EXPERIMENTAL SECTION 
 
2-[(tert-Butyldiphenylsilyloxy)methyl]-1,3-oxathiolan-5-one (10a). Mercaptoacetic 
acid (0.61 mL, 8.72 mmol) was added to a stirred solution of aldehyde 9a (2.60 g, 8.72 
mmol) in toluene (18 mL) at rt. The mixture was warmed to reflux and stirred for 2 h, 
the H2O formed was removed by means of a Dean–Stark apparatus. The reaction was 
then concentrated under reduced pressure. Flash chromatography of the crude residue 
(hexane:Et2O=95:5) gave the pure oxathiolactone 10a (2.20 g, 68% reaction yield) as a 
pale yellow oil. 1H NMR (200 MHz, CDCl3), δ: 1.06 (s, 9 H), 3.59 (d, J = 16.4 Hz, 1 H), 
3.82 (dd, J = 16.4, 0.8 Hz, 1 H), 3.82 (dd, J = 11.2, 3.4 Hz, 1 H), 3.95 (dd, J = 11.2, 3.4 
Hz, 1 H), 5.82 (dt, J = 3.4, 0.8 Hz, 1 H), 7.37–7.52 (m, 6 H), 7.62–7.78 (m, 4 H). 13C 
NMR (50 MHz, CDCl3), δ: 19.1, 26.6, 31.2, 67.4, 81.2, 128.0, 130.0, 132.4, 135.6, 173.1. 
Anal. Calcd for C20H24O3SSi: C, 64.48; H, 6.49; S, 8.61. Found: C, 64.35; H, 6.52; S, 
8.60. 
 
2-[(Benzoyloxy)methyl]-1,3-oxathiolan-5-one (10b). Following the procedure for 10a 
using aldehyde 9b (2.36 g, 14.4 mmol) gave 10b (2.36 g, 69% reaction yield) as a pale-
yellow oil. 1H NMR (500 MHz, CDCl3), δ: 3.68 (d, J = 16.4 Hz, 1 H), 3.76 (d, J = 16.4 
Hz, 1 H), 4.59 (dd, J = 12.3, 4.1 Hz, 1 H), 4.61 (dd, J = 12.3, 4.9 Hz, 1 H), 5.79 (dd, J = 
4.9, 4.1 Hz, 1 H), 7.47 (t, J = 7.3 Hz, 2 H), 7.61 (t, J = 7.5 Hz, 1 H), 8.05 (d, J = 7.5 Hz, 
2 H). 13C NMR (50 MHz, CDCl3), δ: 30.8, 66.5, 78.4, 128.6, 129.0, 129.8, 133.5, 165.8, 
172.3. Anal. Calcd for C11H10O4S: C, 55.45; H, 4.23; S, 13.46. Found: C, 55.30; H, 4.20; 
S, 13.53. 
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2-[(tert-Butyldiphenylsilyloxy)methyl]-4-fluoro-1,3-oxathiolan-5-one (11a). L-
Proline (10 mg, 86 μmol) and Selectfluor (0.61 g, 1.72 mmol) were sequentially added 
to a cooled (0 °C) and stirred mixture of lactone 10a (0.32 g, 0.86 mmol) in MeCN/i-
PrOH (10:1, 2.16 mL). The mixture was stirred at this temperature for 10 h; then it was 
diluted with EtOAc and washed with sat. NaHCO3 until neutral. The organic layer was 
dried (Na2SO4) and the solvent evaporated under reduced pressure. Flash 
chromatography of the crude residue (hexane:EtOAc= 90:10) provided 11a (0.22 g, 65% 
reaction yield) as an oil; mixture of stereoisomers cis/trans, 1:4. 
trans-11a: 1H NMR (200 MHz, CDCl3), δ: 1.06 (s, 9 H), 3.87 (dd, J = 10.7, 5.1 Hz, 1 
H), 3.98 (dd, J = 10.7, 4.7 Hz, 1 H), 5.78 (q, J = 4.8 Hz, 1 H), 6.20 (d, J = 56.6 Hz, 1 H), 
7.27–7.52 (m, 6 H), 7.54–7.78 (m, 4 H). 13C NMR (50 MHz, CDCl3), δ: 19.2, 26.6, 65.3, 
81.4, 92.2 (d, J = 225.8 Hz), 127.8, 130.1, 132.2, 135.5, 167.6. MS (MALDI): m/z [M + 
Na]+ calcd: 413.11; found: 413.12. Anal. Calcd for C20H23FO3SSi: C, 61.51; H, 5.94; S, 
8.21. Found: C, 61.60; H, 5.96; S, 8.24. 
 
2-[(Benzoyloxy)methyl]-4-fluoro-1,3-oxathiolan-5-one (11b). Following the 
procedure for 11a using mercaptolactone 10b (0.24 g, 1.0 mmol) gave 11b (0.22 g, 85% 
reaction yield) as an oil; mixture of stereoisomers cis/trans, 1:4. 
trans-11b: 60% ee (NMR analysis, Eu(hfc)3 used as shift reagent). 1H NMR (500 MHz, 
CDCl3), δ: 4.63 (dd, J = 12.6, 5.2 Hz, 1 H), 4.66 (dd, J = 12.6, 4.2 Hz, 1 H), 6.02 (q, J = 
5.2 Hz, 1 H), 6.25 (d, J = 56.2 Hz, 1 H), 7.46 (t, J = 7.3 Hz, 2 H), 7.61 (t, J = 7.8 Hz, 1 
H), 8.04 (d, J = 7.6 Hz, 2 H). 13C NMR (125 MHz, CDCl3), δ: 64.3, 78.8, 92.1 (d, J = 
232.0 Hz), 128.6, 129.7, 133.6, 165.5, 166.7 (d, J = 25.2 Hz). MS (MALDI): m/z [M + 
Na]+ calcd: 279.02; found: 279.11. Anal. Calcd for C11H9FO4S: C, 51.56; H, 3.54; S, 
12.51. Found: C, 51.45; H, 3.56; S, 12.48. 
 
(1′S,4′R)-N4-Benzoyl-5′-O-benzoyl-2′,3′-dideoxy-3′-thiacytidine (18). Benzoyl 
chloride (1.27 mL, 11 mmol) was added to a cooled (0 °C) solution of lamivudine 2 
(1.00 g, 4.37 mmol) in anhydrous pyridine (3.0 mL). The resulting solution was warmed 
to rt and stirred for 16 h. The mixture was then concentrated under reduced pressure; the 
solid was partitioned between CH2Cl2 and brine. The organic layer was dried (Na2SO4) 
 78 
 
and concentrated under reduced pressure. Chromatography of the crude residue (silica 
gel, CH2Cl2:MeOH=95:5) provided 18 (1.8 g, 95% reaction yield) as a white solid. FT-
IR (KBr): 3056, 1718, 1694, 1671, 1670, 1262, 785 cm–1. 1H NMR (500 MHz, CDCl3), 
δ: 3.34 (dd, J = 12.8, 2.6 Hz, 1 H), 3.70 (dd, J = 12.8, 5.4 Hz, 1 H), 4.79 (dd, J = 12.6, 
2.7 Hz, 1 H), 4.90 (dd, J = 12.6, 4.3 Hz, 1 H), 5.55 (dd, J = 4.3, 2.7 Hz, 1 H), 6.41 (dd, J 
= 5.4, 2.6 Hz, 1 H), 7.46 (t, J = 7.3 Hz, 4 H), 7.60 (t, J = 7.3 Hz, 2 H), 8.12 (d, J = 7.4 
Hz, 4 H), 8.33 (d, J = 7.6 Hz, 1 H), 11.61 (br s, 1 H). 13C NMR (125 MHz, CDCl3), δ: 
39.3, 63.3, 85.5, 87.7, 96.7, 127.5, 128.5, 128.6, 128.7, 129.1, 132.6, 133.2, 133.7, 144.7, 
154.3, 162.4, 165.8. Anal. Calcd for C22H19N3O5S: C, 60.40; H, 4.38; N, 9.61; S, 7.33. 
Found: C, 60.48; H, 4.40; N, 9.58; S, 7.31. 
 
(1′S,3′R/S,4′R)-N4-Benzoyl-5′-O-benzoyl-2′,3′-dideoxy-3′ thiacytidine S-Oxide (19). 
Method A: a solution of MCPBA (0.23 g, 1.29 mmol) in anhydrous CH2Cl2 (3.0 mL) 
was added dropwise to a stirred and cold (–78 °C) solution of thioether 18 (0.43 g, 0.99 
mmol) in anhyd CH2Cl2 (10 mL). The resulting mixture was stirred at this temperature 
for 1 h; then it was warmed to rt, diluted with further CH2Cl2 and washed with sat. 
NaHCO3 solution and with brine. The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. Chromatography of the crude residue (silica gel, 
CH2Cl2:MeOH=98:2) provided 19 (0.36 g, 80% reaction yield) as a white solid; mixture 
of diastereomers dr (1′S,3′R,4′R)/(1′S,3′S,4′R) ~ 7:3). Method B: Ti(O-i-Pr)4 (0.29 mL, 
0.99 mmol) was added dropwise to a stirred solution of (+)-L-DET (0.33 mL, 1.98 mmol) 
in anhyd CH2Cl2 (7.0 mL) at rt. After 20 min, H2O (18.0 μL, 0.99 mmol) was added. 
After 10 min, temperature was cooled to –20 °C and a solution of nucleoside 18 (0.43 g, 
0.99 mmol) in anhydrous CH2Cl2 (13 mL) was added within 5 min. Cumyl 
hydroperoxide (0.29 mL, 1.98 mmol) was then added dropwise. The resulting solution 
was eventually warmed to 0 °C and stirred at this temperature for 48 h. Afterwards, H2O 
(10 mL) was added to the mixture. After 10 min, the resulting emulsion was filtered over 
a Celite pad, the solid was rinsed with further CH2Cl2 (2 × 60 mL). The collected filtrate 
was treated with 10% Na2S2O5 solution (30 mL), then with 5% NaOH solution (30 mL) 
until neutrality and finally with brine. The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. Chromatography of the crude residue (silica gel, 
CH2Cl2:MeOH=98:2) provided (3′R)-19 (0.29 g, 64% reaction yield) as a white solid; 
one main isomer dr (1′S,3′R,4′R)/(1′S,3′S,4′R) >20:1. 
(3′R)-19: FT-IR (KBr): 3020, 2924, 1734, 1714, 1636, 1252, 1068, 795 cm–1. 1H NMR 
(400 MHz, DMSO-d6), δ: 3.53 (dd, J = 13.9, 8.6 Hz, 1 H), 3.64 (dd, J = 13.9, 5.0 Hz, 1 
 79 
 
H), 4.82 (dd, J = 12.3, 5.1 Hz, 1 H), 4.88 (dd, J = 12.3, 5.0 Hz, 1 H), 5.12 (t, J = 5.0 Hz, 
1 H), 6.73 (dd, J = 8.5, 5.0 Hz, 1 H), 7.37 (d, J = 7.5 Hz, 1 H), 7.53 (t, J = 7.5 Hz, 2 H), 
7.56 (t, J = 7.6 Hz, 2 H), 7.64 (br t, J = 7.4 Hz, 1 H), 7.70 (br t, J = 7.5 Hz, 1 H), 7.98 
(br d, J = 7.8 Hz, 4 H), 8.19 (br d, J = 7.5 Hz, 1 H). 13C NMR (100 MHz, DMSO-d6), δ: 
54.9, 62.3, 88.9, 97.6, 102.9, 128.9, 129.0, 129.4, 129.7, 129.8, 133.3, 134.2, 146.0, 
154.3, 164.2, 165.7, 168.0. Anal. Calcd for C22H19N3O6S: C, 58.27; H, 4.22; N, 9.27; S, 
7.07. Found: C, 58.39; H, 4.20; N, 9.24; S, 7.04. 
 
(1′S,2′R/S,4′R)-N4-Acetyl-2′-O-acetyl-5′-O-benzoyl-3′-deoxy-3′-thiacytidine (20a). 
AcONa (0.20 g, 2.5 mmol) was added to a stirred solution of sulfoxides (3′R)- and (3′S)-
19 (0.11 g, 0.25 mmol) in Ac2O (10 mL) at rt. After 5 min, the suspension was warmed 
to 110 °C and stirred at this temperature for 7 h. The resulting solution was then cooled 
to rt, washed with sat. NaHCO3 until neutral and extracted with EtOAc. The organic 
layer was dried (Na2SO4) and concentrated under reduced pressure. Chromatography of 
the crude residue (silica gel, hexane:EtOAc=1:1) gave 20a (79 mg, 73% reaction yield) 
as a pale yellow oil; mixture of stereoisomers dr 1:1. FT-IR (KBr): 3076, 2919, 1737, 
1721, 1664, 1613, 1215, 792 cm–1. 1H NMR (500 MHz, CDCl3), δ: 1.85 (s, 1.5 H), 2.17 
(s, 1.5 H), 2.23 (s, 1.5 H), 2.26 (s, 1.5 H), 4.65 (dd, J = 12.2, 3.3 Hz, 0.5 H), 4.69 (dd, J 
= 12.2, 6.0 Hz, 0.5 H), 4.87 (dd, J = 12.5, 3.5 Hz, 0.5 H), 4.91 (dd, J = 12.5, 3.4 Hz, 0.5 
H), 5.59 (dd, J = 6.0, 3.3 Hz, 0.5 H), 5.84 (t, J = 3.1 Hz, 0.5 H), 6.24 (s, 0.5 H), 6.27 (d, 
J = 2.8 Hz, 0.5 H), 6.34 (d, J = 2.8 Hz, 0.5 H), 6.48 (s, 0.5 H), 7.47 (t, J = 7.7 Hz, 1 H), 
7.54 (t, J = 7.6 Hz, 1 H), 7.60 (t, J = 7.5 Hz, 0.5 H), 7.67 (t, J = 7.5 Hz, 0.5 H), 8.06 (d, 
J = 7.6 Hz, 1 H), 8.08 (d, J = 7.2 Hz, 2 H), 8.18 (d, J = 7.6 Hz, 1 H), 8.99 (br s, 1 H). 13C 
NMR (125 MHz, CDCl3), δ: 20.5, 24.8, 29.5, 62.4, 65.5, 79.2, 85.3, 86.4, 89.0, 91.9, 
96.3, 128.0, 128.5, 128.7, 129.7, 129.9, 133.5, 133.9, 144.0, 145.2, 163.0, 165.8, 168.7, 
170.9. 
 
(1′S,2′S,4′R)-2′-O-Acetyl-N4-benzoyl-5′-O-benzoyl-3′-deoxy-3′-thiacytidine (20b). 
Ac2O (0.27 mL, 2.9 mmol), AcONa (0.24 g, 2.9 mmol), and Ti(O-i-Pr)4 (17.0 μL, 0.06 
mmol) were sequentially added to a stirred solution of (3′R)-19 (0.13 g, 0.29 mmol) in 
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anhydrous toluene (9.0 mL) at rt. The resulting mixture was warmed to 110 °C and 
stirred at this temperature for 8 h. The solution was then cooled to rt, washed with sat. 
NaHCO3 until neutral and extracted with EtOAc. The organic layer was dried (Na2SO4) 
and concentrated under reduced pressure. Chromatography of the crude residue (silica 
gel, hexane:EtOAc=1:1) gave 20b (0.10 g, 73% reaction yield) as a white solid as the 
single (2′S)-isomer. FT-IR (KBr): 3062, 2924, 1733, 1704, 1698, 1622, 1221, 790 cm–1. 
1H NMR (500 MHz, CDCl3), δ: 2.19 (s, 3 H), 4.87 (dd, J = 12.7, 2.5 Hz, 1 H), 4.92 (dd, 
J = 12.7, 3.5 Hz, 1 H), 5.86 (t, J = 3.3 Hz, 1 H), 6.27 (s, 1 H), 6.54 (s, 1 H), 7.53 (t, J = 
7.7 Hz, 2 H), 7.56 (t, J = 7.5 Hz, 2 H), 7.63 (t, J = 7.5 Hz, 1 H), 7.68 (t, J = 7.6 Hz, 1 H), 
7.88 (br d, J = 7.7 Hz, 3 H), 8.10 (d, J = 7.8 Hz, 2 H), 8.23 (d, J = 7.7 Hz, 1 H), 8.67 (br 
s, 1 H). 13C NMR (125 MHz, CDCl3), δ: 20.9, 62.7, 85.4, 86.4, 96.8, 127.3, 128.7, 128.8, 
129.1, 129.6, 133.2, 133.9, 145.4, 154.0, 162.8, 166.0, 168.8. Anal. Calcd for 
C24H21N3O7S: C, 58.17; H, 4.27; N, 8.48; O, 22.60; S, 6.47. Found: C, 58.05; H, 4.28; 
N, 8.51; S, 6.45. 
 
(1′S,2′S/R,4′R)-N4-Acetyl-5′-O-benzoyl-3′-deoxy-2′-hydroxy-3′-thiacytidine (22a). 
A solution of acetyl esters (2′S)- and (2′R)-20a (0.10 g, 0.23 mmol) in CF3CH2OH (0.58 
mL) was added dropwise to a cold (0 °C) solution of 1.6 M BuLi in n-hexane (0.29 mL, 
0.47 mmol) in CF3CH2OH (1.2 mL). The mixture was stirred at this temperature for 3 h; 
then it was transferred to a separatory funnel, washed with a 10% NH4Cl solution until 
neutral and extracted with EtOAc. The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. Chromatography of the crude residue (silica gel, 
CH2Cl2:MeOH=98:2) gave 22a (57 mg, 63% reaction yield) as an oil; approx. equimolar 
mixture of (2′S) and (2′R) diastereomers. FT-IR (KBr): 3615, 3083, 2901, 1715, 1640, 
1621, 1233, 794 cm–1. 1H NMR (500 MHz, CDCl3), δ: 2.22 (s, 1.5 H), 2.25 (s, 1.5 H), 
4.59 (dd, J = 11.9, 3.2 Hz, 0.5 H), 4.80 (dd, J = 11.9, 7.4 Hz, 0.5 H), 4.86 (dd, J = 12.9, 
1.9 Hz, 0.5 H), 4.93 (dd, J = 12.9, 3.6 Hz, 0.5 H), 5.55 (br d, J = 7.3, 3.1 Hz, 0.5 H), 5.76 
(s, 0.5 H), 5.89 (br d, J = 2.3 Hz, 0.5 H), 5.99 (br t, J = 3.4 Hz, 0.5 H), 6.13 (br s, 0.5 H), 
6.27 (s, 0.5 H), 7.29 (d, J = 7.5 Hz, 0.5 H), 7.42–7.68 (m, 3.5 H), 8.07 (br d, J = 7.8 Hz, 
2 H), 8.15 (d, J = 7.5 Hz, 0.5 H), 8.24 (d, J = 7.4 Hz, 0.5 H), 9.13–9.50 (m, 1 H). 13C 
NMR (125 MHz, CDCl3), δ: 24.8, 62.8, 67.1, 76.5, 79.3, 86.6, 86.9, 91.6, 94.6, 96.3, 
96.8, 128.4, 128.7, 129.0, 129.4, 129.6, 129.7, 133.4, 133.8, 144.6, 146.7, 155.6, 155.7, 
162.6, 162.7, 166.0, 166.1, 170.5, 170.8. Anal. Calcd for C17H17N3O6S: C, 52.17; H, 
4.38; N, 10.74; S, 8.19. Found: C, 52.30: H, 4.36; N, 10.70; S, 8.22. 
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(1′S,2′S,4′R)-N4-Benzoyl-5′-O-benzoyl-3′-deoxy-2′-hydroxy-3′-thiacytidine (22b). 
A solution of acetyl ester (2′S)-20b (50 mg, 0.10 mmol) in CF3CH2OH (0.29 mL) was 
added dropwise to a cold (0 °C) solution of 1.6 M BuLi in n-hexane (0.14 mL, 0.23 
mmol) in CF3CH2OH (0.6 mL). The mixture was stirred at this temperature for 3 h; then 
it was transferred into a separatory funnel, washed with a 10% NH4Cl solution until 
neutral, and extracted with EtOAc. The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. Chromatography of the crude residue (silica gel, 
CH2Cl2:MeOH=98:2) provided 22b (30 mg, 65% reaction yield) as a mixture of 
stereoisomers (dr 1:1), recrystallization of the mixture gave (2′S)-22b (27.5 mg, 60% 
reaction yield) as the main stereoisomer; dr >20:1. FT-IR (KBr): 3607, 3068, 2909, 1702, 
1647, 1617, 1245, 789 cm–1. 1H NMR (400 MHz, CDCl3), δ: 4.85 (dd, J = 12.8, 2.7 Hz, 
1 H), 4.92 (dd, J = 12.9, 3.6 Hz, 1 H), 5.74 (s, 1 H), 6.00 (app t, J = 3.4, 2.9 Hz, 1 H), 
6.29 (s, 1 H), 7.42–7.56 (m, 5 H), 7.59 (t, J = 7.5 Hz, 1 H), 7.65 (t, J = 7.5 Hz, 1 H), 7.98 
(d, J = 7.5 Hz, 2 H), 8.07 (d, J = 7.5 Hz, 2 H), 8.33 (d, J = 7.6 Hz, 1 H). 13C NMR (100 
MHz, CDCl3), δ: 62.7, 77.1, 86.4, 86.7, 94.6, 96.5, 128.0, 128.7, 128.8, 129.0, 129.6, 
129.7, 132.3, 133.4, 133.8, 145.5, 153.5, 162.2, 165.9, 166.7. Anal. Calcd for 
C22H19N3O6S: C, 58.27; H, 4.22; N, 9.27; S, 7.07. Found: C, 58.40; H, 4.20; N, 9.30; S, 
7.05. 
 
(1′S,2′R,4′R)-N4-Acetyl-5′-O-benzoyl-3′-deoxy-2′- fluoro-3′-thiacytidine (23a) and 
(1′S,2′S,4′R)-N4-Acetyl-5′-O-benzoyl-3′-deoxy-2′-fluoro-3′-thiacytidine (24a). 
DAST (0.04 mL, 0.32 mmol) was carefully added to a stirred solution of hemithioacetals 
(2′S)- and (2′R)-22a (0.09 g, 0.24 mmol) in anhyd CH2Cl2 (9 mL) at 0 °C. The mixture 
was stirred at this temperature for 30 min, then sat. NaHCO3 (1 mL) was added in one 
portion. The resulting emulsion was washed with further NaHCO3 solution until neutral 
and extracted with CH2Cl2. The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. Flash chromatography of the crude residue (EtOAc) gave the 
two separated diastereomers (2′R)-23a (15 mg; white solid) and (2′S)-24a (45 mg; white 
solid) (66% total reaction yield). 
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23a: FT-IR (KBr): 2980, 2921, 1734, 675, 1679, 1647, 1316, 1279, 829 cm–1. 1H NMR 
(500 MHz, CDCl3), δ: 2.13 (s, 3 H), 4.68–4.76 (m, 2 H), 5.60–5.66 (m, 1 H), 6.26 (d, J 
= 15.1 Hz, 1 H), 6.38 (d, J = 60.0 Hz, 1 H), 7.26 (d, J = 7.8 Hz, 1 H), 7.48 (t, J = 7.8 Hz, 
2 H), 7.60 (t, J = 7.8 Hz, 1 H), 7.98 (d, J = 7.8 Hz, 1 H), 8.10 (d, J = 7.8 Hz, 2 H), 9.15 
(br s, 1 H). 13C NMR (125 MHz, CDCl3), δ: 25.0, 65.6, 79.4, 90.6 (d, J = 18.0 Hz), 95.4 
(d, J = 231.7 Hz), 96.8, 129.7, 129.8, 130.9, 135.6, 145.2, 154.7, 163.1, 166.0, 170.5. 
Anal. Calcd for C17H16FN3O5S: C, 51.90; H, 4.10; F, 4.83; N, 10.68; S, 8.15. Found: C, 
51.79; H, 4.12; N, 10.72; S, 8.12. 
24a: FT-IR (KBr): 2970, 2925, 1724, 689, 1673, 1634, 1315, 1276, 819 cm–1. 1H NMR 
(500 MHz, CDCl3), δ: 2.25 (s, 3 H), 4.90 (dd, J = 13.0, 2.4 Hz, 1 H), 4.98 (dd, J = 13.0, 
3.2 Hz, 1 H), 5.94 (br s, 1 H), 6.26 (d, J = 52.0 Hz, 1 H), 6.55 (d, J = 11.6 Hz, 1 H), 7.27 
(d, J = 7.0 Hz, 1 H), 7.54 (t, J = 7.7 Hz, 2 H), 7.67 (t, J = 7.5 Hz, 1 H), 8.07 (d, J = 7.3 
Hz, 2 H), 8.15 (d, J = 7.5 Hz, 1 H), 9.42 (br s, 1 H). 13C NMR (125 MHz, CDCl3), δ: 
25.0, 62.1, 87.4, 93.2 (d, J = 47.9 Hz), 96.5, 103.6 (d, J = 233.2 Hz), 124.9, 128.6, 129.6, 
133.9, 143.7, 154.5, 162.7, 165.7, 170.1. Anal. Calcd for C17H16FN3O5S: C, 51.90; H, 
4.10; N, 10.68; S, 8.15. Found: C, 51.76; H, 4.11; N, 10.72; S, 8.18. 
 
(1′S,2′R,4′R)-N4-Benzoyl-5′-O-benzoyl-3′-deoxy-2′-fluoro-3′-thiacytidine (23b) and 
(1′S,2′S,4′R)-N4-Benzoyl-5′-O-benzoyl-3′-deoxy-2′-fluoro-3′-thiacytidine (24b). 
Following the procedure for 23a and 24a using (2′S)- and (2′R)-22b (50.0 mg, 0.11 
mmol) gave fluoronucleosides 23b (9 mg; white solid) and 24b (27.1 mg; white solid) 
(72% total reaction yield). 
23b: FT-IR (KBr): 2955, 2923, 1735, 715, 1659, 1627, 1331, 1267, 814 cm–1. 1H NMR 
(400 MHz, CDCl3), δ: 4.72 (d, J = 4.6 Hz, 2 H), 5.64 (dt, J = 7.2, 4.5 Hz, 1 H), 6.33 (dd, 
J = 13.7, 1.9 Hz, 1 H), 6.39 (dd, J = 58.7, 2.3 Hz, 1 H), 7.48 (t, J = 7.7 Hz, 2 H), 7.54 (t, 
J = 7.5 Hz, 2 H), 7.58–7.67 (m, 3 H), 7.91 (d, J = 7.2 Hz, 2 H), 8.07 (d, J = 7.2 Hz, 1 H), 
8.09 (d, J = 7.9 Hz, 2 H), 8.03 (br s, 1 H). 13C NMR (100 MHz, CDCl3), δ: 65.6, 79.9, 
90.5 (d, J = 19.2 Hz), 95.4 (d, J = 235.8 Hz), 96.8, 127.6, 128.5, 128.9, 129.1, 129.7, 
132.8, 133.2, 133.4, 145.2, 154.3, 162.9, 165.9, 168.7. 19F {1H dec} NMR (376 MHz, 
CDCl3), δ: –158.1. Anal. Calcd for C22H18FN3O5S: C, 58.02; H, 3.98; F, 4.17; N, 9.23; 
O, 17.56; S, 7.04. Found: C, 58.19; H, 3.98; N, 9.23; S, 7.04. 
24b: FT-IR (KBr): 2951, 2919, 1733, 699, 1652, 1617, 1319, 1265, 805 cm–1. 1H NMR 
(400 MHz, CDCl3), δ: 4.92 (dd, J = 13.0, 2.2 Hz, 1 H), 5.01 (dd, J = 13.0, 3.3 Hz, 1 H), 
5.97 (br t, J = 2.5 Hz, 1 H), 6.30 (d, J = 52.0 Hz, 1 H), 6.60 (d, J = 11.7 Hz, 1 H), 7.44 
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(br d, J = 7.3 Hz, 1 H), 7.53 (t, J = 7.5 Hz, 2 H), 7.57 (t, J = 7.5 Hz, 2 H), 7.63 (t, J = 7.5 
Hz, 1 H), 7.70 (t, J = 7.5 Hz, 1 H), 7.90 (d, J = 7.4 Hz, 2 H), 8.10 (d, J = 7.6 Hz, 2 H), 
8.22 (d, J = 7.3 Hz, 1 H), 8.93 (br s, 1 H). 13C NMR (100 MHz, CDCl3), δ: 62.2, 87.5, 
93.2 (d, J = 42.4 Hz), 103.0 (d, J = 242.9 Hz), 127.7, 128.8, 128.9, 129.1, 129.7, 133.5, 
134.1, 144.3, 155.0, 161.9, 166.0, 170.0. 19F {1H dec} NMR (376 MHz, CDCl3), δ: –
158.2. Anal. Calcd for C22H18FN3O5S: C, 58.02; H, 3.98; N, 9.23; S, 7.04. Found: C, 
58.20; H, 3.99; N, 9.20; S, 7.01. 
 
(1′S,2′S,4′R)-2′,3′-Dideoxy-2′-fluoro-3′-thiacytidine [(2′S)-F-3TC, 5]. Nucleoside 
24a (40 mg, 0.10 mmol) was treated with 7 M NH3/MeOH solution (2.7 mL) at 0 °C. 
The resulting suspension was stirred at this temperature for 16 h. The volatiles were then 
removed under reduced pressure. Chromatography of the crude residue (silica gel, 
CH2Cl2:MeOH=90:10) provided (2′S)-F-3TC 5 (23 mg, 92% reaction yield) as a white 
solid. 1H NMR (400 MHz, CD3OD), δ: 3.96 (dd, J = 13.0, 3.0 Hz, 1 H), 4.12 (dd, J = 
13.0, 3.1 Hz, 2 H), 5.63 (br t, J = 3.0 Hz, 1 H), 5.87 (d, J = 7.5 Hz, 1 H), 6.31 (d, J = 53.8 
Hz, 1 H), 6.51 (d, J = 13.1 Hz, 1 H), 8.07 (d, J = 7.5 Hz, 1 H). 
As discussed in the previous section, an extensive characterization of 5 was hampered 
by the spontaneous, undesired cyclization of the latter, leading to cyclonucleoside 25 as 
a white solid (99% reaction yield). 
 
Cyclonucleoside 25: 1H NMR (400 MHz, CD3OD), δ: 3.44 (dd, J = 12.7, 2.6 Hz, 1 H), 
3.65 (dd, J = 12.7, 1.5 Hz, 1 H), 5.86 (t, J = 2.4 Hz, 1 H), 6.53 (d, J = 7.3 Hz, 1 H), 6.78 
(d, J = 5.8 Hz, 1 H), 7.00 (d, J = 5.8 Hz, 1 H), 8.15 (d, J = 7.4 Hz, 1 H). 13C NMR (100 
MHz, CD3OD), δ: 65.0, 93.5, 95.4, 96.5, 103.2, 141.1. Anal. Calcd for C8H9N3O3S: C, 
42.28; H, 3.99; N, 18.49; S, 14.11. Found: C, 42.39; H, 3.98; N, 18.42; S, 14.05. 
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(1′S,2′R,4′R)-2′,3′-Dideoxy-2′-fluoro-3′-thiacytidine [(2′R)-F-3TC, 
6]. Following the procedure for 5 using nucleoside 23a (26 mg) gave (2′R)-F-3TC 6 (14 
mg, 90% reaction yield) as a white solid. FT-IR (KBr): 3378, 3364, 2923, 1726, 1253 
cm–1. 1H NMR (400 MHz, CD3OD), δ: 3.83 (dd, J = 12.3, 4.2 Hz, 1 H), 3.87 (dd, J = 
12.3, 5.4 Hz, 1 H), 5.35 (dt, J = 7.7, 4.9 Hz, 1 H), 5.91 (d, J = 7.6 Hz, 1 H), 6.16 (dd, J= 
15.9, 2.0 Hz, 1 H), 6.32 (dd, J = 59.8, 2.0 Hz, 1 H), 7.80 (dd, J = 7.6, 2.1 Hz, 1 H). 13C 
NMR (100 MHz, CD3OD), δ: 66.5, 84.5, 92.2 (d, J = 19.0 Hz), 96.5, 98.3 (d, J = 231.0 
Hz), 143.8, 158.5, 168.7. 19F {1H dec} NMR (376 MHz, CD3OD), δ: –160.1. Anal. Calcd 
for C8H10FN3O3S: C, 38.86; H, 4.08; N, 17.00; S, 12.97. Found: C, 38.72; H, 4.09; N, 
17.06; S, 13.00. 
 
(1′S,2′R,4′R)-N4-(4-Bromobenzoyl)-5′-O-(4-bromobenzoyl)-3′-deoxy-2′-fluoro-3′-
thiacytidine (27). 4-Bromobenzoyl chloride (0.18 g, 0.82 mmol) and a catalytic amount 
of DMAP (5 mg, 0.04 mmol) were added to a cooled (0 °C) solution of nucleoside 6 (82 
mg, 0.33 mmol) in anhyd pyridine (3 mL). The resulting mixture was then warmed to rt 
and stirred at this temperature for 2 h. The mixture was then diluted with H2O, extracted 
with EtOAc and washed with brine. The organic layer was dried (Na2SO4), filtered and 
the solvent removed under reduced pressure. Chromatography of the crude residue 
(CH2Cl2:MeOH=90:10) provided pure 27 (0.14 g, 0.22 mmol, 69% reaction yield) as 
white crystals; mp 227.6–227.8 °C (Et2O/MeOH). FT-IR (KBr): 3053, 2920, 2847, 1720, 
1684, 1661, 1591, 1253, 1107, 784 cm–1. 1H NMR (200 MHz, DMSO-d6), δ: 4.87–4.99 
(m, 2 H), 5.73–5.80 (m, 1 H), 6.25 (d, J = 16.0 Hz, 1 H), 6.60 (d, J = 58.9 Hz, 1 H), 7.36 
(d, J = 7.7 Hz, 1 H), 7.71 (d, J = 8.7 Hz, 4 H), 7.91 (d, J = 8.7 Hz, 4 H), 8.11 (d, J = 6.7 
Hz, 1 H), 11.47 (br s, 1 H). 13C NMR (50 MHz, DMSO-d6), δ: 65.8, 79.8 (d, J = 22 Hz), 
90.1 (d, J = 18 Hz), 96.5 (d, J = 229 Hz), 96.9, 127.3, 128.2, 128.8, 131.1, 131.7, 131.9, 
132.4, 145.8, 154.1, 164.1, 165.2, 167.0. Anal. Calcd for C22H16Br2FN3O5S: C, 43.09; 
H, 2.63; N, 6.85; S, 5.23. Found: C, 43.22; H, 2.62; N, 6.82; S, 5.21. 
X-ray Crystallography of 27.  
Single crystals of 27 suitable for X-ray diffraction were obtained by slow evaporation of 
a Et2O/MeOH solution at rt. One crystal (colorless 0.50 × 0.06 × 0.01 mm) was selected 
and mounted at 173 K under N2 flow on a Bruker-Nonius KappaCCD diffractometer 
equipped with a graphite monochromated MoKα radiation (λ = 0.71073 Å, CCD rotation 
images, thick slices, ϕ and ω scans to fill asymmetric unit). Unit cell parameters were 
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determined by least squares refinement of the θ angles of 134 reflections in the range 
3.509° < θ < 18.771°. SADABS program was used for scaling and multiscan absorption 
corrections. The structure was solved by direct methods (SIR97 program) and 
anisotropically refined (SHELXL-97 program) by the full matrix least-squares method 
on F2 against all independent measured reflections in WinGX45 suite programs. 
Hydrogen atoms were introduced in calculated positions and refined according to a 
riding model. Absolute configuration R/R/S at C9/C10/C11 was established by 
anomalous dispersion effects due to the presence of strong scattered atoms. 
Crystal data for 27: empirical formula: C22H16Br2FN3O5S; formula weight: 613.26; 
crystal system: monoclinic; space group: P21; a = 10.234(3) Å; b = 6.692(2) Å; c = 
16.433(3) Å; β = 100.989(15)°; V = 1104.8(5) Å3; Z = 2; calculated density = 1.843 
g/cm3; abs. coeff. = 3.814 mm–1; θ range 3.30–25.10°; reflections/unique: 6828/3533 
(Rint = 0.1948); data/restraints/parameters: 3553/163/307; goodness of fit on F2: 1.029; 
R1/wR2 [I > 2σ(I)]: 0.0934/0.1469; R1/wR2 (all data): 0.2247/0.1932; abs. struc. param.: 
0.03(3); Largest diff. peak and hole 0.792, –1.071 e/Å3.  
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2.2.1 INTRODUCTION 
As described in the last chapter, viral diseases are the primary cause of death among 
human infectious diseases worldwide.1 Vaccination and antiviral chemotherapies are 
typically used to prevent or treat viral infections.2 While the vaccination is not available 
for viruses such as HIV or HCV (in the case of HHVs, an effective vaccine is today 
available only for Varicella Zoster Virus, VZV),3 the antiviral chemotherapy proven to 
be a successful choice in many cases. However, given the increasing emergence of drug-
resistant clinical isolates due to the viruses’ high mutation rate, the search of new 
antiviral therapies remains critical. The field of nucleoside analogues (NAs) represents, 
as already mentioned, a valid alternative to this aim. In this chapter, two novel concepts 
will be introduced: the possibility to conformationally preorganize the nucleoside in 
order to enhance the selectivity associated to the host-guest recognition process and 
then, the possibility to design mutagenic nucleosides that, together with the chain 
termination, constitutes one of the most used antiviral strategies in this context. Both 
concepts have been merged to synthetize a novel class of mutagenic piperidinyl 
nucleosides, subject of the following chapter. 
2.2.1.1 PREORGANIZED HOST-GUEST CHEMISTRY 
“The first step in enzymatic catalysis is the formation of highly selective molecular 
complexes that orient the reactants and catalysts. […] In host-guest chemistry, the host 
molecule is the larger and the guest molecule is the smaller of the two. The host molecule 
must recognize by complexing best those guest molecules that contain the array of 
binding sites and steric features that complement those of the host.”4 In this paper Donald 
Cram introduced for the first time the “preorganization” concept analysing several 
examples of small organic guest-host complexes.4 The formation of these kind of 
complexes is thermodynamically unlikely for two main reasons: first, three degrees of 
translational and rotational entropy are lost while forming a complex from two separate 
molecules, and second, if each molecule has free internal bond rotations (necessarily 
locked in the complex), several degrees of freedom for each bond will be lost and the 
“freezing out” of all such rotations will be entropically unfavourable. If the first effect 
results totally unavoidable, the second one could be easily addressed by chemists 
designing guest molecules “frozen” in the binding conformation before the recognition 
processes; then any entropy cost, due to fixing bond rotations, will not be necessary in 
binding.5 In few and easier words, reduction of all possible conformational states of a 
guest molecule to those fitting with the geometric and stereochemical requirements of a 
host molecule may lead to an entropic benefit of complex formation, and thus to 
enhanced complex stability. The concept of preorganization has been widely used to 
design nucleoside analogues (NAs) (and particularly, modified oligonucleotides, MOs; 
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this aspect will be extensively discussed in the Chapter 3.1) endowed with 
modifications able to restrict the number of conformations and to increase the desired 
complementarity between the parties. The main result is the strong improvement of the 
host-guest selectivity because of the drastic reduction of the possible mismatched host-
guest processes.6 
2.2.1.2  THE CENTRAL ROLE OF SUGAR CONFORMATION IN THE ANTIVIRAL 
ACTIVITY OF NUCLEOSIDE ANALOGUES 
The complete definition of the nucleoside conformation usually involves the 
determination of three groups of structural parameters: (a) the deviation from planarity 
of the sugar ring, measured by the phase angle of pseudorotation (P), (b) the orientation 
of the glycosylic bond (χ) and (c) the orientation of the hydroxymethyl group (γ). 
 
FIGURE 1 (taken from ref. 8). Structural parameters defining the conformation of a 
(deoxy)ribonucleoside. a) Phase angle of pseudorotation P (0°→360°): the nucleoside furanose 
ring fluctuates between the C3'-endo (approx., 0°< P <+40°) and the C2'-endo (approx., +140°< 
P <+180°) sugar ring conformations. b) Torsion angle χ (0°→±180°): the value ranges between 
two principal low energy domains, anti (-115°> χ > -180°), and syn (0< χ <90°). c) Orientation 
of the hydroxymethyl group (γ): γ typically ranges between antiperiplanar (ap, γ ~ 180°) and 
synclinal (sc, γ = ± 60°) conformations. 
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The first parameter has been introduced to describe the continuous interconversions 
among a (virtually) infinite number of puckered forms related to the furanose ring of 
natural (deoxy)ribonucleosi(ti)des. Thus, the nucleoside conformation can be 
conveniently described (summarized) by the P value (°) as showed in the conformational 
cycle (FIGURE 1).7,8 Conventionally, P = 0° describes a C-3'-endo puckering, while P = 
180° the C-2'-endo antipode; they are also generically defined as N (North) and S (South) 
conformations respectively (FIGURE 1). The N and S regions are nearly equally 
populated for ribonucleosides whereas for 2'-deoxyribonucleosides there is a clear 
preference for S type geometries (≈ 3:1 for the ratio of S versus N pseudorotamer 
populations). NMR studies have shown that the puckered geometries of the furanose 
moiety in nucleos(t)ides interconvert rapidly in solution (in the NMR timescale); this 
means that the activation energy barrier between the interconverting pseudorotamers in 
solution is significantly low (ΔG ~ 20 kJ mol-1). However, when the sugar rings of 
natural (deoxy)ribonucleotides are involved in polymeric structures (i.e. RNA and 
DNA), the energy differences between A- and B- right handed helical structures are 
magnified and the A-form prefers the N pseudorotamer while the B- form the S one 
(FIGURE 2).9 
 
FIGURE 2. Side and top view of A- and B-type duplexes. 
The preference for one or for another conformation seems to derive from the nature of 
the C-2' group. In the presence of a withdrawing group (e.g. OH), the C-3'-endo (N) 
pucker is the only conformation observed (such as in dsRNA, A-type helix), whereas in 
its absence the C-2'-endo (S) pucker is preferred (such as in dsDNA, B-type helix) 
(FIGURE 2). 
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What happen when a single nueoside(-tide) binds to an organized macromolecule (i.e. 
an enzyme)? It is expected that the architecture of the binding pocket will impose a 
specific conformational demand on the sugar ring (N or S) for an optimal fit.10 This 
means that even though a NA may show comparable populations of N and S conformers 
under equilibrium conditions, during the binding process, in order to exert biological 
activity, one conformer preferentially will interact with the enzyme itself. 
In the biochemical path leading to NA incorporation into a nucleic acid chain, two 
specific enzymatic systems are involved. On one hand, kinases convert nucleosides to 
their corresponding triphosphate forms. As widely described in the last chapter, some 
viruses (e.g. Herpes Simplex Viruses, HSV-1 and -2) use their own viral kinases (e.g. 
HSV-tk) to enable serial phosphorylation,11 otherwise, other viruses (e.g. Human 
Immunodeficiency Viruses HIV-1 and HIV-2) exploit cellular enzymes to this end (e.g. 
dCK and dGK).12 On the other hand, RNA or DNA polymerases [e.g., viral HSV-
DNApol for HHV13 and HIV-RT (reverse transcriptase) for HIV14 viruses] are 
responsible for the incorporation of the nucleotides into the growing RNA or DNA chain. 
Studies have been conducted in order to establish if these activating enzymes, select their 
substrates on the basis of conformational preferences of the individual nucleosides. To 
unambiguously address this question, locked NAs built on a rigid template, i.e. the 
bicyclo[3.1.0]-hexane scaffold (North and South methano-carbathymidine, N-MCT and 
S-MCT), were designed and biologically evaluated (FIGURE 3).15 
 
FIGURE 3. Bicyclo[3.1.0]hexane nucleosides locked in two 
non-equilibrating North and South conformations. 
In this novel structure, the cyclopentane ring mimics the deoxyfuranose and the fused 
cyclopropane ring locks the conformation of the cyclopentane in the North hemisphere 
of pseudorotational cycle or in the antipodean South area. These two isomers displayed 
opposite affinities for HSV-tk and DNA polymerases.15 With regards to the 
phosphorylation steps, S-MCT was the preferred substrate of the kinases. However, 
despite the high levels of S-MCT-5'-triphosphate formed, only negligible amounts were 
incorporated into DNA by polymerases. On the other hand, even if N-MCT resulted a 
poorer substrate for these kinases, N-MCT is recognized by DNA polymerases and it is 
a potent anti-HSV drug (EC50=0.02 M) while S-MCT was totally ineffective.15 
Thus, the conformational preferences by kinases and polymerases to recognize NAs as 
their natural counterparts have been unambiguously identified. Particularly, the overall 
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lesson learned from these studies was that while kinases recognize natural nucleosides 
and their analogues in a C2'-endo (S) pucker, polymerases require the C3'-endo (N) form 
of the corresponding nucleotide triphosphates for the subsequent incorporation process. 
Importantly, it was observed that while DNA polymerases (HSV-DNApol, HIV-RT) do 
not accept NAs-TP in the “wrong” S pucker, some viral kinases, such as HSV-tk, allow, 
although to a limited extent, phosphorylation of a nucleoside locked in an N pucker. The 
broad substrate specificity of some viral enzymes, which do not accurately discriminate 
on the basis of nucleoside structure and conformation owing to the need for a rapid virus 
replication, is one of the key elements for the development of novel NAs as antiviral 
agents. 
2.2.1.3 CONFORMATIONALLY CONSTRAINED NUCLEOSIDE ANALOGUES 
One of the most efficient approaches devised to probe the conformational requirements 
of NAs by cellular/viral enzymes for an effective interaction is to “freeze” the 
conformations of sugar backbone by synthetically creating conformationally restricted 
NAs, in which the sugar ring pucker is chemically locked in one of the two main 
conformations required for recognition. A leading example is represented by the 
replacement of the natural furanose ring with a six-membered sugar moiety in the 
nucleoside architecture16 in which the conformational flexibility is significantly reduced, 
thanks to the considerable energy required for chair flip between two conformations 
(1C4↔4C1). Therefore, the conformations will be restricted to those adopted on the basis 
of the energetic requirements of the substituents (FIGURE 4). One of the most important 
examples of constrained six-membered nucleosides has been represented by the 1',5'-
anhydro-arabino-D-hexitol nucleosides (hNAs, FIGURE 4).17 NMR studies first and X-
ray crystallographic studies then, have demonstrated that hNA monomer conformation 
has the heterocyclic base placed in an axial position, while both the primary and 
secondary hydroxyl are in an equatorial position resembling a distorted 4C1 conformation 
mimic of the 3E conformation (North, N) exhibited by natural deoxynucleosides. 
 
FIGURE 4. hNAs as mimics of natural nucleosides. 
hNAs equipped with natural and/or modified nucleobases demonstrated to be selectively 
phosphorylated by viral kinases (e.g. HSV-tk), determining a remarkable activity17 
against most Human Herpes Viruses (HHV) such as HSV-1 (HHV-1), HSV-2 (HHV-2), 
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VZV (HHV-3), EBV (HHV-4) and HCMV (HHV-5), comparable in vitro to that of the 
currently marketed anti-HHV agent, acyclovir (ACV, ZoviraxTM). On the other hand, 
hNAs were not incorporated by human kinases: this, on one side, determined a high 
selectivity of hNAs toward viral enzymes, on the other side, was responsible for their 
lack of activity against HIV-1 and HIV-2 viruses.18 The lesson learned from the study of 
hNAs was that the C3'-endo (N) conformation was that required for the enzymatic 
recognition processes leading to inhibition of HHV replication. In the further attempt to 
develop other bioactive NAs, cyclohexanyl nucleosides (cNAs, obtained by replacement 
of the endocyclic oxygen of hNAs with a methylene group) were later designed (FIGURE 
5),19 but, surprisingly, they displayed any antiviral activity. As revealed earlier by 
computational calculations and later by NMR and X-ray studies, cNAs, contrarily to 
hNAs, occurred in conformations with an equatorially-oriented nucleobase. This 
conformational preference was mainly ascribed to the unfavourable 1,3-diaxial 
interactions between the nucleobase and the hydrogen atoms (FIGURE 5), which did not 
occur in hNAs, owing to the presence of endocyclic oxygen. 
 
FIGURE 5. Conformational preferences of hNAs and cNAs. 
2.2.1.4 ANTIVIRAL STRATEGY: LETHAL MUTAGENESIS 
As already mentioned above, the lethal mutagenesis antiviral mechanism has been 
proposed as a novel chemotherapeutic strategy for drug resistance.20 It is widely known 
that the viruses survive on the basis of quasispecies theory which states that there is a 
maximum error rate (defined also “error threshold”) above which genetic information 
would not be effectively transmitted.21 So the viral genetic information may be lost (if 
the virus quasispecies exceeds the above mentioned threshold) or it may results in a 
lethal accumulation of errors, defined lethal mutagenesis (FIGURE 6). Therefore, this 
strategy may be effective in reducing the viral infection but also in weakening the 
capacity of the virus to the drug resistance. The hypermutation can be induced by direct 
or indirect22 mutagenesis; the direct approach, in which nucleoside analogues are 
incorporated in the growing viral DNA, represents the most efficient method to hamper 
its replication. It also results the most selective approach avoiding the inhibition of other 
biochemical pathways (as found for DNA alkylators or intercalators).23 
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FIGURE 6. Mutagenic nucleosides activation. 
Once accomplished the incorporation of mutagenic NA-TP in the viral transcript, the 
base mispairing can lead to increased mutation rate (FIGURE 6). The mentioned goal can 
be reached acting at nucleobase level on its (1) conformational flexibility, (2) chemical 
rearrangement, (3) existence as tautomeric forms, (4) pKa leading to the presence of both 
protonate and deprotonated forms at physiological pH. Ribavirin 1, is the best example 
to describe the first case, whose mutagenicity results from the rotation around the C3-
carbonyl bond to give the s-cis (able to give pair with uridine residues) and s-trans (able 
to give pair with cytidine residues) conformers (FIGURE 7). 
 
FIGURE 7. Examples of mutagenic NAs and their conformational 
flexibility inducing base mispairing. 
The Janus nucleoside 2, active against HBV,24 is another example of NA able to give 
nonselective base-pairing by conformational flexibility. 5-Hydroxycytidine 3 (FIGURE 
8) is suspected to be a mutagenic agent because of the presence of both the amino (3a) 
(resulting a cytidine analogue) and imino (3b) (resulting a thymidine analogue) 
tautomer.25 Besides, the increasing of the imino form with pH and temperature, 
suggested a possible deprotonation of the 5-hydroxyl moiety in this observed 
equilibrium. Finally, 5-halouridine derivatives (with 5-bromouracil or 5-fluorouracil as 
nucleobase), represent a classical example of NAs in which the base ionization (due to 
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the presence of an electrowithdrawing group in C5 position) seems to be responsible of 
the observed mispairing (FIGURE 8).26 
 
FIGURE 8. Tautomeric forms of 5-hydroxycytidine 
3 and ionized base-pairing of 5-halouridines. 
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2.2.2 RESULTS AND DISCUSSION 
2.2.2.1 SYNTHESIS AND ANTIVIRAL ACTIVITY OF NOVEL PIPERIDINYL 
NUCLEOSIDE ANALOGUES 
On the basis of the considerations made on the conformational requirements needed to 
ensure the efficacy and selectivity of NAs for the treatment of viral infections, this 
project has concerned the synthesis of novel iminosugar-based nucleosides as 4 and 5d 
(SCHEME 1). 
 
SCHEME 1. Target mutagenic NAs 4,5 and 
retrosynthetic pathway to prepare them. 
Piperidinyl nucleosides hold a very intriguing structure of the sugar moiety, enabling 
their potential use in a wide range of applications. Particularly, due to the close structural 
analogy with 1',5'-anhydro-D-arabino-hexitol nucleosides (they can be regarded as their 
aza-analogues, as the endocyclic oxygen of hNAs is formally replaced by an amino 
function, SCHEME 1), they have been tested as potential anti-HHV agents. Moreover, on 
the basis of the previous discussion on NAs conformation in relation to biological 
activity, a conformational analysis devoted to study of the connection between pH (i.e. 
nitrogen protonation) and preferred chair conformation (i.e. 4C1→1C4 inversion owing 
to occurring 1,3-diaxial interactions) has been undertaken. As depicted in the 
retrosynthetic analysis (SCHEME 1), our synthetic approach starts from the well-known 
glucosidase inhibitor 1-deoxynojirimycin (D-DNJ) from which the C-3 deoxygenated 
key intermediates 6a-c are readily synthetized. Nucleobase insertion is then performed 
                                                 
d In recent times, the fusion of the two concepts of glyco- and biomimetic, i.e. the structural 
mimicking (in terms of charge) of carbohydrate mimetics and the conformational mimicking of 
nucleoside mimetics, has resulted in the development of a new class of inhibitors, defined to as 
iminosugar-based nucleosides (see APPENDIX A). 
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by nucleophilic displacement of a good leaving group (from 7b) or by Mitsunobu 
procedure (from 7c, obtained by 7a), leading to the target piperidinyl NAs 4 and 5. 
2.2.2.2 PIPERIDINYL SKELETON SYNTHESIS 
A wide number of carbohydrate-based approaches are available in the literature for the 
synthesis of D-DNJ on large scale. To this aim, we used one of the most convenient 
procedures (also used for industrial preparations)27 which involves the use of 2,3,4,6-
tetra-O-benzyl-D-glucose (7) as starting material (SCHEME 2). The synthesis starts with 
LiAlH4-mediated reduction of 7 that led to the corresponding glucitol 8, consequently 
oxidized under classical Swern conditions [DMSO/(CO)2Cl2, then TEA] to yield the 
unstable ketoaldehyde 9 (SCHEME 2). The last is directly engaged in the next reductive 
amination step [NaBH3CN/AcONH4] to provide the 2,3,4,6-tetra-O-benzyl-D-1-
deoxynojirimycin (10) in a good overall yield (75%). 
 
SCHEME 2. Synthesis on large scale of 2,3,4,6-tetra-O-benzyl 
D-1-deoxynojirimycin (10). 
While standard hydrogenation with Pd/C under acidic conditions was unexpectedly 
unsuccessful,28 benzyl groups removal was efficiently accomplished by treatment of 10 
with boron trichloride (1M BCl3 in DCM, 3.5 eq) affording the corresponding 
unprotected D-DNJ∙HCl with an excellent yield (92%) (SCHEME 3). 
 
SCHEME 3. Efficient deprotection of 10 to afford D-DNJ hydrochloride. 
To prepare the target mutagenic nucleosides 4 and 5, DNJ⸱HCl was thus subjected to a 
series of carefully studied synthetic manipulations conceived to insert the nucleobase in 
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the desired C2 position and the correct axial orientation. First of all, the endocyclic 
amino group was protected with di-tert-butyl dicarbonate [(Boc)2O, pH~9-10], affording 
tert-butylcarbamate 11 (87% yield). Then, through a regioselective isopropylidenation 
reaction, N-Boc-DNJ (11) was treated with 2,2-dimethoxypropane, 2-methoxypropene 
and PTSA (pH~4.5) to protect the C6 primary and C4 secondary OH functions affording 
the corresponding 4,6-O-isopropylidene-N-Boc-DNJ (12) (76% yield) (SCHEME 4). 
 
SCHEME 4. Protective group chemistry of D-DNJ⸱HCl. 
However, an undesired double isopropylidenation byproduct 13 was also detected by 
NMR analysis of the crude mixture (~12%). Looking for more effective procedures, the 
long established isopropylidenation method,29 exploiting triphenylphosphine (PPh3) in 
combination with molecular iodine (I2) and imidazole and using anhydrous acetone as 
acetonide source, was alternatively employed (SCHEME 4). Under these conditions, a 
high-yielding (94%) conversion of 11 into the diol 12 was observed, while no traces of 
the side product 13 were detected. 
Subsequently, the development of a synthetic strategy leading to key C-3 deoxygenated 
intermediates 6a,b, required a first regioselective protection reaction by the stannylene 
method.30 To a solution of 12, in refluxing MeOH, dibutyltin oxide (DBTO) was added 
and the resulting dibutyilstannylene acetal intermediate treated with BzCl/TsCl and TEA 
afforded quantitatively esters 14a,b. Treatment with O-phenyl chlorothionoformate and 
DMAP gave xanthate intermediates 15a,b (83-90%) that under Barton-McCombie 
deoxygenation condition (Bu3SnH/AIBN)31 led to 6a,b with excellent yields (94-96%) 
(SCHEME 5). 
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SCHEME 5. Synthetic route to obtain the C-3 deoxygenated intermediates 6a,b. 
2.2.2.3 SYNTHESIS OF MUTAGENIC NUCLEOSIDES 
In order to obtain the mutagenic uracil nucleoside 4, the C-3 deoxygenated intermediate 
6b was at first subjected to nucleophilic displacement of the leaving group under slightly 
milder activating conditions (DBU/Uracil/DMF/SCHEME 6). Subsequent C-5 
iodination (I2, mCPBA) in anhydrous DMF then enabled conversion of 16 into 5-
iodouridine analogue 17 (77 %). Alternatively, in order to favour the direct introduction 
of 5-iodouracil on the sugar moiety, Mitsunobu conditions were attempted and 6c, 
(obtained by treatment of 6a with MeONa in MeOH, 90%), was reacted with N3-
benzoylated-5-iodouracil. The resulting nucleoside, as crude, was then treated with 1M 
NH3 in methanol to remove the Bz group leading to 17 but, unfortunately, with lower 
overall yields (43% yield over two steps). Final treatment of 17 with 1M HCl (60 °C) 
gave the desired free nucleoside 4 quantitatively (SCHEME 6). 
 
SCHEME 6. Synthesis of mutagenic nucleoside 4. 
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Similarly, the synthesis of the 5-fluorouracil derivative 5 was carried out starting from 
6c, always under Mitsunobu conditions, using N3-benzoyl-5-fluorouracil as nucleobase 
(SCHEME 7). Nucleoside 18, obtained in 50% yield, was then treated with phosphorus 
oxychloride and triazole, followed by treatment with a solution of NH4OH-1,4-dioxane 
(1:3) to allow the conversion of the uracil derivatives into the desired fluoro cytidine 
nucleoside 20 via the 4-triazolylpyrimidinone intermediate 1932 (SCHEME 7). 
 
SCHEME 7. Synthesis of mutegenic nucleoside 5. 
Removal of protecting groups, under the same reaction conditions reported above (HCl) 
finally afforded the desired nucleoside 5. 
2.2.3  CONFORMATIONAL ANALYSIS OF PIPERIDINYL NUCLEOSIDES 
NMR analysis has been performed to provide indications on the conformational profile 
of the synthetized nucleosides. NMR analysis of 4 (taken as model) was unfortunately 
hampered by the occurrence of a not so well resolved 1H spectrum (FIGURE 9). However, 
the large coupling constants relative to H2’ were indicative for a 1C4 conformation, with 
an equatorially oriented nucleobase (FIGURE 9). This conformational trend is opposite 
to the 4C1 conformation (axially oriented nucleobases) adopted by hNAs. 
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FIGURE 9. NMR conformational profile of 4 and its 1H NMR spectra in D2O. 
It is to underline that 1H NMR spectrum in D2O of 4 shows two signals at 7.94 ppm (s) 
and 8.04 ppm (s) (FIGURE 9), which suggest the presence of two species; even, 1H NMR 
spectra of 4 in DMSO-d6 shows the presence of two singlets at 11.72 and 11.89 ppm 
(FIGURE 10). On the basis of literature data reported for 5-halo-substituted uridines,33 
these signals seemed to be ascribed to the existence of two tautomeric species such as 
those depicted in FIGURE 10. In support of this assumption, HMBC experiments were 
performed, highlighting dipolar correlations between the H nucleus bound to nitrogen 
atom (3-NH) and ketone carbon (C-4) in the A form, and between the H nucleus of the 
enol function (4-OH) and C-4 in the B form. 
 
FIGURE 10. 1H NMR spectrum of 4 in DMSO-d6. 
2.2.4 ANTIVIRAL EVALUATION 
Piperidinyl nucleoside 4 was subjected to a preliminary antiviral screening at the Rega 
Institute for Medical Research (under the supervision of Prof. Graciela Andrei and Prof. 
Robert Snoeck), with the aim to study its capacity to interfere with the life cycles of 
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various Human Herpes Viruses (HHVs). Particularly, 4 was evaluated for its inhibitory 
effect on the cytopathicity of HSV-1 (strains KOS and KOS/ACVr), HSV-2 (strain G), 
VZV (strains OKA and O7-1) and CMV (strains AD 169 and Davis). All experiments 
were performed using HEL cells; well-known anti-HHV drugs were used as reference 
compounds, including Cidofovir (CDV), Acyclovir (ACV) and (E)-5-(2-bromo-vinyl)-
2’-deoxyuridine (BVDU) for HSV-1 and HSV-2 assays, CDV and GCV for VZV and 
ACV and BVDU for CMV assays. In all cases, the antiviral potential was measured 
calculating the concentration required to reduce the virus-induced cytophaticity (HSV) 
plaque formation (VZV, CMV) or cell growth by 50% (EC50). As summarized in TABLE 
1, only a weak activity of 4 as anti-HHV agent was found. Indeed, although 4 displayed 
activity in the micromolar range against all the examined viral infections, the observed 
EC50 values were always far higher than those reported by the reference drugs. These 
results are in agreement with the conformational analysis above discussed. As a matter 
of fact, nucleoside 4 adopts a sugar conformation (south-like) which makes it easily 
recognized by viral kinases, but not by viral polymerases, which typically recognize 
triphosphate nucleotides adopting north-like conformations. This makes 4 a poor 
substrate for these enzymes, and therefore not an efficient antiviral agent. One interesting 
observation from these assays is the activity of 4 against TK- strains. These mutated 
strains lack the viral kinases (e.g. HSV-TK) enabling nucleoside phosphorylation to the 
triphosphate form. While it is not clear why we observe activity in these cases, a 
conceivable hypothesis is that 4 is able to accurately mimic natural nucleosides frozen 
in the South-like conformation: accordingly, the nucleoside can be recognized by natural 
kinases despite their sophisticated control mechanisms. Although activity still needs to 
be improved, this observation suggests that this class of compounds may find useful 
application in the treatment of those viral infections not holding their own viral kinases, 
such as HIV.  
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TABLE 1. Antiviral evaluation of 4 against HHV infections (EC50, µM). 
 
aKOS strains. bG strains. cKOS/ACVr strains. dAD-169 strains. 
eDavis strains. f OKA strains. gO7-1 strains.   
 4 BVDU ACV GCV CDV 
HSV-1a 45 0,04 0,8 0,02 1,2 
HSV-2b 45 96 0,4 0,02 1,0 
HSVc (TK-) 34 3,8 126 0,8 1,0 
CMVd 76 ND ND 8,27 0,38 
CMVe 67 ND ND 0,63 0,51 
VZVf (TK+) 50 0,042 0,7 ND ND 
VZVg (TK-) 61 2,4 14,74 ND ND 
Vaccinia Virus 50 19 >250 >100 37 
Adeno-Virus 50 ND ND ND 22 
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2.2.5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
As described in the introductive section, study of the conformational requirements of 
NAs to be recognized as the natural counterparts by the corresponding hosts (i.e. 
enzymes, nucleic acid partners) has enabled the development of a wide amount of 
biomimetic agents (i.e. NAs and modified oligonucleotides, MOs) based on the concept 
of structural preorganization that showed remarkable improvement of selectivity 
associated to their enzymatic recognition processes. In the same context, but looking for 
antiviral agents, the development of mutagenic nucleoside analogues may be effective 
in reducing the viral infection but also in weakening the capacity of the virus to the drug 
resistance. One of the main topic of this PhD project arises from the fusion of the two 
above mentioned concepts and at the same time has the aim to explore novel inhibition 
modes for the treatment of viral infections exploiting the endocyclic amino group that 
replaces the oxygen atom in the iminosugars (see Chapter 1.1). The designed mutagenic 
piperidinyl nucleosides 4 and 5 are thus novel examples of iminosugar-based 
nucleosides (see APPENDIX A). For this reason, the preparation of the target nucleosides 
proper starts from the well-known glucosidase inhibitor 1-deoxynojirimicin (DNJ) as 
chiral building block, efficiently synthetized in large scale. Thanks to appropriate 
functionalization and orthogonal protections of the hydroxyl functions of DNJ, it was 
possible to synthesize the desired nucleosides through the key intermediates 6a-c, even 
if the final coupling reactions should be further studied in order to improve the low 
reaction yields. Conformational analysis of nucleoside 4 (taken as model molecule) 
underlined (despite the broadness of NMR spectra) the presence of an expected 
tautomeric equilibrium between two forms, already observed in 5-halouridine 
nucleosides. 
A preliminary screening aimed to study the capacity of 4 to interfere with the life cycles 
of various Human Herpes Viruses (HHVs) has been carried out at the Rega Institute for 
Medical Research (under the supervision of Prof. Graciela Andrei and Prof. Robert 
Snoeck). The biological data shows a substrate poorly recognized by polymerases; this 
process could be reasonably improved attempting 6’OH triphosphorylation (e.g. Protide 
Approach)34 in order to avoid this process in vivo and favour the nucleoside inversion 
toward the opposite 4C1 conformation, mimic of the North one, typically recognized by 
viral polymerases.  
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2.2.6 EXPERIMENTAL SECTION 
 
2,3,4,6-tetra-O-Benzyl-deoxynojirimycin (10). Reduction: To a solution of 2,3,4,6-
tetra-O-benzyl-D-glucopyranose 7 (15.0 g, 27.7 mmol) in anhydrous THF (150.0 mL), 
cooled to 0 °C, LiAlH4 (2.1 g, 55.5 mmol) was slowly added. The reaction mixture was 
kept to room temperature and magnetically stirred for 20h. LiAlH4 excess was quenched 
with H2O and EtOAc; the resulting suspension was extracted with EtOAc and brine. The 
organic layers were dried (Na2SO4) and concentrated under reduced pressure to obtain 
the corresponding glucitol 8 as a white oil. Oxidation: A solution of DMSO (9.0 mL, 
126.7 mmol) in DCM (75.0 mL) was slowly added to a stirred solution of (CO)2Cl2 (9.0 
mL, 104.8 mmol) in DCM (75.0 mL) at 78 °C. After 90 min., glucitol 8 (15.0 g, 30.8 
mmol) solution in DCM (75.0 mL) was slowly added dropwise. After further 90 min., 
Et3N (48.0 mL, 345.3 mmol) was added dropwise at  °C and the resulting mixture 
was stirred for 90 min. at 0 °C. Reductive amination: To a solution of NH4OAc (24.0 
g, 311.4 mmol) in MeOH (1.5 L), Na2SO4 (18.3 g, 128.8 mmol) and NaBH3CN (7.2 g, 
114.6 mmol) were added. The resulting suspension was added to the mixture previously 
obtained and stirred for 20h at room temperature. NaOH was then added until pH~10 
and the mixture extracted with DCM and brine. The organic layers were dried (Na2SO4), 
concentrated under reduced pressure and chromatographed over silica gel 
(hexane:EtOAc = 80:20) to give the pure 10 (10.9 g, 75% overall yield) as a white solid. 
[α]D +27.7, CHCl3. 1H NMR (400 MHz, CDCl3), δ: 1.95 (bs, 1H), 2.57 (dd, J= 12.3, 10.4 
Hz, 1H), 2.79 (ddd, J= 2.5 Hz, 9.2 Hz, 1H), 3.31 (dd, J= 4.8 Hz, 12.3 Hz, 1H), 3.42 (t, 
J= 9.2 Hz, 1H), 3.513.67 (m, 2H), 3.73 (dd, J= 2.5 Hz, 1H), 4.49 (d, J= 11.7 Hz, 1H), 
4.53 (d, J= 11.7 Hz, 1H), 4.56 (d, J= 10.9 Hz, 1H), 4.73 (d, J= 11.6 Hz, 1H), 4.77 (d, J= 
11.6 Hz, 1H), 4.92 (t, J= 10.3 Hz, 2H), 5.05 (d, J= 10.9 Hz, 1H), 7.25 (d, J= 7.0 Hz, 2H), 
7.287.46 (m, 18H). 13C NMR (100 MHz, CDCl3),  46.7, 59.1, 68.3, 73.0, 73.3, 75.3, 
75.6, 78.3, 78.7, 86.4, 127.5, 127.7, 127.8, 127.9, 128.3, 128.4, 137.4, 137.9, 138.0, 
138.5. 
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D-DNJ⸱HCl. To a solution of 2,3,4,6-tetra-O-benzyl-1-deoxynojirimicin 10 (6.8 g, 13.0 
mmol) in DCM (350.0 mL), cooled at 0 °C, BCl3 (1M, 45.5 mL, 45.5 mmol) was added. 
The mixture, stirred for 12h at 0 °C, was then quenched with MeOH (280.0 mL) at 0 °C 
and concentrated under reduced pressure. The crude was coevaporated with toluene and 
triturated with EtOAc to give pure DNJ∙HCl (2.4 g, 92% reaction yield) as a white solid; 
[α]D +34.7, MeOH. NMR analysis of D-DNJ⸱HCl is consistent with the NMR spectra 
reported for  
L-DNJ⸱HCl in the Chapter 1 of this thesis. 
 
N-tert-Butoxycarbonyl-deoxynojirimycin (11). To a solution of DNJ⸱HCl (2.3 g, 11.6 
mmol) in a mixture of water (38.0 mL) and 1,4-dioxane (38.0 mL) at 0°C, (Boc)2O (5.0 
g, 23.1 mmol) and NaOH (1N, until pH~9-10), were added. The reaction mixture stirred 
at room temperature for 16h, was then concentrated under reduced pressure and the crude 
purified by silica gel chromatography (CHCl3:MeOH=95:5) to obtain the pure 11 (2.6 g, 
87% reaction yield). [α]D +24.3, MeOH. 1H NMR (400 MHz, CD3OD), 1.47 (s, 9H), 
3.38 (dd, J= 13.9 Hz, 1H), 3.59 – 3.66 (m, 2H), 3.67 – 3.74 (m, 1H), 3.77 (dd, J= 5.6, 
11.4 Hz, 1H), 3.80 (dd, J= 9.3, 11.4 Hz, 1H), 3.90 (d, J= 13.9 Hz, 1H), 4.10 (dd, J= 5.6, 
9.3 Hz, 1H). 13C NMR (CD3OD, 100 MHz),  28.8, 44.3, 61.2, 61.3, 70.6, 71.5, 72.4, 
81.4, 158.2. 
 
4,6-O-Isopropylidene-N-tert-butoxycarbonyl-deoxynojirimycin (12). Procedure A: 
to a solution of 11 (2.0 g, 7.6 mmol) in DMF (40.0 mL), 2,2-dimethoxypropane (1.9 mL, 
15.2 mmol), 2-methoxypropene (1.5 mL, 15.2 mmol) and PTSA (to adjust the pH~4.5) 
were added. The reaction mixture was stirred at room temperature for 1h then aq. 
NaHCO3 was added and stirred for further 30 min.; the mixture was extracted with DCM 
and brine and the organic layers dried (Na2SO4). Solvent was evaporated under reduced 
pressure and the crude purified by silica gel chromatography (CHCl3:MeOH = 95:5) to 
provide 12 (1.8 g, 78% reaction yield). Procedure B: to a magnetically stirred solution 
of triphenyl phosphine (2.99 g, 11.4 mmol) in anhydrous acetone (50.0 mL) at rt, a 
solution of I2 (2.9 g, 11.4 mmol) in the same solvent (20.0 mL) was added dropwise in 
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the dark and under Ar atmosphere. After 5 min solid imidazole was added (1.55 g, 22.8 
mmol) and then 11 (2.0 g, 7.6 mmol) was added in one portion to the suspension. TLC 
monitoring (CHCl3:MeOH = 9:1) showed that the starting sugar was completely 
consumed within 10 min. The reaction mixture was first treated with sodium tiosulphate 
then extracted with EtOAc and washed with brine. The organic layer was dried (Na2SO4) 
and evaporated under reduced pressure to give a crude product that after chromatography 
over silica gel column gave 10 (2.2 g, 94% reaction yield). [α]D -28.9, CHCl3. 1H NMR 
(CDCl3, 400 MHz), δ: 1.42 (s, 3H), 1.45 (s, 9H), 1.52 (s, 3H), 2.49 (bs, 1H), 2.64 (dd, 
J= 13.3 Hz, 1H), 2.70 (bs, 1H), 3.00 (dt, J= 5.0 Hz, 1H), 3.43 (t, J= 9.0 Hz, 1H), 3.56 (t, 
J= 9.0 Hz, 1H), 3.59 3.65 (m, 1H), 4.25 (dd, J=13.3 Hz, 1H), 4.33 (dd, J= 5.0, 11.8 Hz, 
1H), 4.47 (t, J= 11.8 Hz, 1H). 13C NMR (100 MHz, CDCl3), δ: 21.1, 28.4, 28.6, 45.3, 
46.5, 62.2, 65.5, 67.2, 68.3, 80.6, 98.8, 158.7. 
 
2-O-Benzoyl-4,6-O-isopropylidene-N-tert-butoxycarbonyl-deoxynojirimycin (14a). 
To a solution of 4,6-O-isopropylidene-N-tert-butoxycarbonyl-1-deoxynojirimycin 12 
(0.50 g, 1.6 mmol) in anhydrous MeOH (5.5 mL), Bu2SnO (0.81 g, 3.3 mmol) was added 
under Ar atmosphere. Both 12 and Bu2SnO were pre-dried under vacuum over KOH 
overnight. The reaction mixture was stirred at reflux temperature for 12h. The solvent 
was then removed by coevaporation with toluene. The residue was dissolved in 
anhydrous DCM (5.5 mL) and dry Et3N (0.27 mL, 1.9 mmol), BzCl (0.19 mL, 1.6 mmol) 
were sequentially added. The resulting mixture was stirred for 1h at room temperature 
and aq. NaHCO3 was then added. The suspension was extracted (EtOAc) and washed 
(brine) and the organic layers dried (Na2SO4). The solvent was removed under reduced 
pressure and the chromatography of the residue (Hexane:EtOAc = 85:15) gave the pure 
14a (0.67 g, >99% reaction yield). 1H NMR (500 MHz, CDCl3), 1.48 (bs, 15H), 3.26 
(dt, J= 4.8 Hz, 1H), 3.45 (dd, J= 7.0, 14.0 Hz, 1H), 3.793.90 (m, 2H), 3.98 (dd, J= 3.0, 
14.0 Hz, 1H), 4.21 (dd, 1H), 4.39 (dd, J= 4.8 Hz, 1H), 5.02 (ddd, J= 3.0, 7.0 Hz, 1H), 
7.44 (t, J= 7.7 Hz, 2H), 7.56 (t, J= 7.5 Hz, 1H), 8.00 (d, J= 7.2 Hz, 2H). 13C NMR (125 
MHz, CDCl3),  19.2, 28.3, 44.7, 53.2, 62.6, 72.7, 73.9, 74.5, 81.0, 99.3, 128.4, 129.8, 
133.3, 155.0, 165.8. 2-O-p-toluensulfonyl-4,6-O-isopropylidene-N-tert-
butoxycarbonyl-1-deoxynojirimycin (14b). 18b has been prepared following the same 
procedure described above for 14a, replacing BzCl with TsCl (1.0 eq.). 
Chromatographic purification of the residue (hexane:EtOAc = 70:30) gave the pure 14b 
(>99% yield). [α]D -14.2, CHCl3. 1H NMR (400 MHz, CDCl3), δ: 1.39 (s, 3H), 1.44 (s, 
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9H), 1.48 (s, 3H), 2.44 (s, 3H), 2.94 (dd, J = 9.6, 14.0 Hz, 1H), 3.0 (dt, J = 4.9 Hz, 1H), 
3.59 (t, J = 8.8 Hz, 1H), 3.64 (dt, J = 1.8, 8.7 Hz, 1H), 4.19 (dd, J = 4.9, 13.6 Hz, 1H), 
4.26 (dd, J = 5.0, 11.7 Hz, 1H), 4.31-4.36 (m, 1H), 4.38 (t, J = 7.2 Hz, 1H), 7.34 (d, J = 
8.0 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H). 13C NMR (100 MHz, CDCl3), : 19.3, 21.8, 28.4, 
29.3, 47.6, 54.9, 62.1, 73.1, 74.7, 78.6, 81.5, 99.5, 128.1, 130.0, 133.6, 142.2, 154.2. 
 
2-O-Benzoyl-4,6-O-isopropylidene-3-O-phenylthionoformate-N-
tertbutoxycarbonyl-deoxynojirimycin (15a). To a stirring solution of 14a (0.44 g, 1.1 
mmol) in DCM (7.0 mL), O-phenyl chlorothionoformate (0.18 mL, 1.3 mmol) and 
DMAP (0.27 g, 2.2 mmol) were sequentially added. After stirring for 12h, the mixture 
was quenched with NH4Cl and extracted with DCM:Brine. The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. Chromatography of the residue 
(flash chromatography: DCM) gave 15a as pure product (0.53 g, 90% reaction yield). 
1H NMR (500 MHz, C6D6), δ: 1.26 (s, 3H), 1.27 (s, 9H), 1.45 (s, 3H), 3.33 – 3.43 (m, 
2H), 3.83 (dd, J= 2.9, 14.0 Hz, 1H), 4.14 (dd, J= 9.5, 11.0 Hz, 1H), 4.23 (t, J= 10.1 Hz, 
1H), 4.57 (dd, J= 5.0, 11.5 Hz, 1H), 5.48 (td, J= 3.5, 7.2 Hz, 1H), 6.06 (dd, J= 5.5, 9.0 
Hz, 1H), 6.70–6.75 (m, 2H), 6.76–6.81 (m, 1H), 6.87 (t, J= 7.8 Hz, 2H), 6.95–7.00 (m, 
2H), 7.02–7.08 (m, 1H), 8.16 (d, J= 7.2 Hz, 2H). 13C NMR (100 MHz, C6D6), δ: 18.68, 
27.71, 29.00, 44.91, 53.47, 62.60, 70.62, 71.61, 80.36, 84.02, 99.36, 121.81, 126.07, 
128.30, 129.20, 129.96, 133.01, 133.69, 153.70, 154.73, 164.82, 195.04. 2-O-p-
toluensulfonyl-4,6-O-isopropylidene-3-O-phenylthionoformate-N-
tertbutoxycarbonyl-deoxynojirimycin (15b). 15b has been prepared following the 
same procedure described above for 15a. Chromatographic purification of the residue 
(hexane:EtOAc = 85:15) gave the pure 15b (83% reaction yield). [α]D +8.06, CHCl3. 1H 
NMR (400 MHz, CDCl3), δ: 1.38 (s, 3H), 1.47 (s, 6H), 1.48 (s, 3H), 1.51 (s, 3H), 2.41 
(s, 3H), 3.14-3.24 (m, 1H), 3.52-3.63 (m, 1H), 3.92-4.05 (m, 2H), 4.24-4.43 (m, 2H), 
4.57-4.64 (m, 1H), 5.58-5.62 (m, 1H), 7.04 (d, J = 8.4 Hz, 2H), 7.28-7.36 (m, 3H), 7.39-
7.44 (m, 2H), 7.82 (d, J= 8.3 Hz, 2H). 13C NMR (100 MHz, CDCl3), δ: 21.9, 28.4, 31.2, 
60.0, 61.6, 68.2, 75.3, 82.3, 121.9, 125.1, 127.0, 128.2, 129.8, 129.9, 130.3, 133.3, 145.5, 
153.5, 155.6, 194.4, 207.2. 
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2-O-Benzoyl-3-deoxy-4,6-O-isopropylidene-N-tertbutoxycarbonyl-1-deoxynojirimycin 
(6a). To a boiling solution of 15a (0.50 g, 0.92 mmol) in anhydrous toluene (10.0 mL) a 
solution of Bu3SnH (0.47 mL, 1.8 mmol) and AIBN (0.030 g, 0.18 mmol) in toluene 
(10.0 mL) was added dropwise. The resulting mixture was stirred, under Ar, for 30 
minutes. The solvent was removed under reduced pressure and the crude was purified 
by silica gel chromatography (hexane:EtOAc = 90:10) to give 6a as pure product (0.32 
g, 96% reaction yield). 1H NMR (400 MHz, C6D6), δ: 1.29 (s, 3H), 1.35 (s, 9H), 1.48 (s, 
3H), 1.58–1.68 (m, 1H), 2.21–2.32 (m, 1H), 3.14 (dd, J= 7.4, 13.2 Hz, 1H), 3.18–3.24 
(m, 1H ), 3.62 (td, J= 5.1, 10.8 Hz, 1H), 3.79 (dd, J= 3.3, 13.4 Hz, 1H), 4.31 (t, J= 10.9 
Hz, 1H), 4.61 (dd, J= 4.7, 11.4 Hz, 1H), 5.03 (ddd, J= 3.6, 7.7, 14.2 Hz, 1H), 6.99–7.05 
(m, 2H), 7.13–7.08 (m, 1H), 8.05–8.09 (m, 2H). 13C NMR (100 MHz, C6D6), δ: 14.90, 
23.85, 25.33, 31.65, 43.10, 53.11, 58.91, 63.36, 63.67, 75.79, 94.52, 125.63, 128.65, 
150.77, 160. 99.  
2-O-p-toluensulfonyl-3-deoxy-4,6-O-isopropylidene-N-tertbutoxycarbonyl-1-
deoxynojirimycin (6b). 6b has been prepared following the same procedure described 
above for 6a. Chromatographic purification of the residue (hexane:EtOAc = 85:15) gave 
the pure 6b (94 % reaction yield). [α]D -1.26, CHCl3. 1H NMR (400 MHz, CDCl3), δ: 
1.35 (s, 3H), 1.40 (s, 9H), 1.45 (s, 3H), 2.21-2.28 (m, 1H), 2.44 (s, 3H), 2.82 (dd, J = 9.7, 
13.2 Hz, 1H), 2.90 (dt, J = 4.9 Hz, 1H), 3.66 (dt, J = 4.6 Hz, 1H), 4.08-4.14 (m, 2H), 
4.25 (dd, J = 4.9, 11.8 Hz, 1H), 4.35-4.46 (m, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 
8.3 Hz, 2H). 13C NMR (100 MHz, CDCl3), δ: 19.3, 21.8, 28.4, 29.4, 37.4, 49.9, 58.0, 
62.5, 67.9, 73.5, 81.2, 99.0, 127.9, 130.1, 134.0, 145.1, 154.2. 
 
3-deoxy-4,6-O-isopropylidene-N-tert-butoxycarbonyl-1-deoxynojirimycin (6c). To 
a solution of 6a (0.32 g, 0.82 mmol) in anhydrous MeOH (10.0 mL), MeONa (0.044 g, 
0.82 mmol) was added and the resulting suspension was heated to 50 °C. After stirring 
for 16h the mixture was extracted with DCM:Brine. The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. The resulting crude was 
chromatographed on silica gel (hexane:EtOAc = 70:30) to give 6c as pure product (0.21 
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g, 90% reaction yield). 1H NMR (400 MHz, C6D6), δ: 1.31 (s, 3H), 1.36 (s, 10H), 1.47 
(s, 3H), 2.11–2.16 (m, 1H), 2.41 (dd, J= 9.6, 12.9 Hz, 1H), 2.90 (dt, J= 7.8, 9.8 Hz, 1H), 
3.44 (bs, 1H), 3.49–3.58 (m, 1H), 4.07 (ddd, J= 1.6, 4.4,12.9 Hz, 1H), 4.55 (d, J= 7.5 Hz, 
2H). 13C NMR (100 MHz, C6D6), δ: 14.82, 23.96, 25.39, 36.28, 48.32, 54.11, 58.72, 
60.74, 64.29, 75.61, 94.17, 150.32. 
 
3’-deoxy-4’,6’-O-isopropylidene-2’(uracil-1-yl)-N-tert-butoxycarbonyl 
deoxynojirimycin (16). Uracil (0.038 g, 0.329 mmol) and 6b (0.063 g, 0.143 mmol) 
were suspensed in anhydrous DMF (3.0 mL) under N2 for 15 min at room temperature. 
Then 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU, 50.0 L, 0.329 mmol) was added and 
the reaction mixture heated at 90 °C for 72h, after which the reaction was cooled to RT, 
quenched with NH4Cl and concentrated. The residue was extracted with DCM and 
washed with brine. The organic layer was dried (Na2SO4) and the solvent evaporated 
under reduced pressure. Flash chromatography of the crude residue over silica gel 
(CH3Cl/MeOH = 98:2) gave the corresponding pure 16 (0.047 g, 87% reaction yield). 
[α]D -17.1, MeOH. 1H NMR (500 MHz, CDCl3), δ: 1.42 (s, 3H), 1.46 (s, 9H), 1.54 (s, 
3H). 1.92 – 2.04 (m, 1H), 2.16–2.24 (m, 1H), 3.18 (td, J= 10.0, 4.4 Hz, 1H), 3.60 (dd, J= 
14.1, 4.5 Hz, 1H), 3.98 (dd, J= 14.2, 6.5 Hz, 1H), 4.07 (t, J= 10.9 Hz, 1H), 4.21 (td, J= 
11.0, 4.9 Hz, 1H), 4.40 (dd, J= 11.4, 4.3 Hz, 1H), 4.51 (bs, 1H), 5.73 (d, J= 7.6 Hz, 1H), 
7.36 (d, J= 8.0 Hz, 1H). 13C NMR (100 MHz, DMSO-d6), δ: 20.03, 28.39, 29.67, 31.80, 
50.55, 55.44, 62.92, 66.38, 80.31, 99.21, 101.95, 143.53, 151.21, 154.68, 163. 70. 
 
3’-deoxy-4’,6’-O-isopropylidene-2’(5-iodouracil-1-yl)-N-tert-butoxycarbonyl 
deoxynojirimycin (17). Uracil Iodination: to a solution of 16 (30 mg, 0.079 mmol) in 
DMF (1.0 mL), iodine (0.012 g, 0.047 mmol) and mCPBA (0.018 g, 0.104 mmol) were 
added at room temperature. After 4h the residue was extracted with AcOEt and washed 
with brine. The organic layer was dried (Na2SO4) and the solvent removed under reduced 
pressure. Flash chromatography (EtOAc) gave the pure 17 (0.031 mg, 77% reaction 
yield). Mitsunobu Coupling: to a suspension of 6c (0.035 g, 0.13 mmol), N3-benzoyl-5-
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iodouracil (0.068 g, 0.20 mmol) and triphenylphosphine (0.052 g, 0.20 mmol) in 1,4-
dioxane (3.0 mL), a solution of DEAD (0.031 mL, 0.20 mmol) in 1,4-dioxane (0.2 mL) 
was added via a dropping funnel over a period of 200 min. The reaction mixture was 
stirred overnight at room temperature. Then the solvent was removed under reduced 
pressure and the crude was treated with NH3 in MeOH (1M, 1.5 mL). The mixture was 
stirred for 90 min at room temperature. The volatiles were removed, and the crude was 
coevaporated with toluene three times. Chromatography of the residue over silica gel 
(hexane:EtOA=50:50) gave the corresponding pure 17 (0.027 g, 43% overall yield). [α]D 
-14.0, DMSO. 1H NMR (500 MHz, acetone-d6), δ: 1.33 (s, 3H), 1.49 (s, 3H), 1.52 (s, 
9H), 2.01 (dt, J= 11.9, 10.7 Hz, 1H), 2.22–2.29 (m, 1H), 3.20–3.27 (m, 1H), 3.79–3.86 
(m, 1H), 3. 78–3.98 (m, 2H), 4.32–4.38 (m, 1H), 4.51 (td, J= 10.2, 5.4 Hz, 1H), 4.65–
4.72 (m, 1H), 8.12 (s, 1H). 13C NMR (125 MHz, acetone-d6), δ: 18.80, 27.62, 32.28, 
42.68, 51.97, 55.55, 62.93 66.52, 67.33, 80.20, 98.67, 147.61, 150.49, 154.68, 159.96. 
 
2’-(5-iodouracil-1-yl) deoxynojirimycin (4). To a solution of 17 (0.014 g, 0.023 mmol) 
in THF (0.9 mL), HCl (1M, 0.3 mL) was added and the reaction mixture was stirred to 
60°C for 4h. Then the solvent was evaporated under reduced pressure and the crude 
residue was triturated with Et2O to give the pure 4 as chlorohydrate salt (0.009 g, >99% 
yield). [α]D +19.6, DMSO.1H NMR (400 MHz, D2O), δ: 2.07-2.15 (m, 2H), 2.32-2.40 
(m, 2H), 3.40-3.56 (m, 6H), 3.91-3.95 (m, 4H), 4.30-4.33 (m, 2H), 4.88-4.98 (m, 2H), 
8.04 (s, 1H), 8.14 (s, 1H). 1H NMR (400 MHz, DMSO-d6), δ: 1.80–1.90 (m, 2H), 2.05–
2.17 (m, 2H), 3.08–3.44 (m, 6H), 3.73 (dd, J= 5.6, 11.8 Hz, 2H), 3.82–3.99 (m, 2H), 
4.96–5.13 (m, 2H), 5.77 (bs, 2H), 8.32 (s, 2H), 9.10 (bs, 2H), 9.31 (bs, 2H), 11.72 (s, 
1H), 11.89 (s, 1H). 13C NMR (100 MHz, DMSO-d6), δ: 27.16, 42.00, 52.64, 55.84, 
56.53, 59.21, 66.03, 73.19, 147.09, 149.28, 156.91. 
 
3’-deoxy-4’,6’-O-isopropylidene-2’(5-fluorouracil-1-yl)-N-tert-butoxycarbonyl 
deoxynojirimycin (18). To a suspension of 6c (0.070 g, 0.25 mmol), N3-benzoyl-5-
fluorouracil (0.086 g, 0.37 mmol) and triphenylphosphine (0.096 g, 0.37 mmol) in 1,4-
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dioxane (3.0 mL), a solution of DEAD (0.058 mL, 0.37 mmol) in 1,4-dioxane (0.3 mL) 
was added via a dropping funnel over a period of 200 min. The reaction mixture was 
stirred overnight at room temperature. Then the solvent was evaporated under reduced 
pressure and the crude residue was treated with NH3 in MeOH (1M, 1.5 mL). The mixture 
was stirred for 90 min at room temperature. The volatiles were removed and the crude 
coevaporated with toluene three times. Chromatography of the residue over silica gel 
(hexane:EtOAc = 50:50) gave the corresponding pure 18 (0.049 g, 50% overall yield). 
1H NMR (400 MHz, MeOD), δ: 1.32 (s, 9H), 1.36 (s, 3H), 1.55 (s, 3H), 1.78 (ddd, J= 
3.2, 11.1, 14.2 Hz, 1H), 2.21–2.26 (m, 1H), 3.04 (d, J= 15.1 Hz, 1H), 3.10 (dd, J= 10.5, 
4.8 Hz, 1H), 4.14–4.23 (m, 2H), 4.60 (dt, J= 14.7, 2.2 Hz, 1H), 4.74 (t, J= 11.3 Hz, 1H), 
5.22 (bs, 1H), δ 7.79 (d, J = 3.2 Hz, 1H). 13C NMR (100 MHz, MeOD), δ: 14.04, 23.07, 
24.33, 31.06, 55.01, 57.73, 62.14, 68.67, 76.13, 94.61, 141.34, 143.88, 149.61, 150.51. 
 
3’-deoxy-4’,6’-O-isopropylidene-2’(5-fluorocytosine-1-yl)-N-tert-butoxycarbonyl 
deoxynojirimycin (20). To a suspension of 1,2,4-triazole (0.040 g, 0.59 mmol) in dry 
ACN (0.3 mL), POCl3 (0.011 mL, 0.13 mmol) was added dropwise at 0 °C under Ar. 
After stirring for 5 min, TEA (0.081 mL, 0.59 mmol) was added dropwise and the 
mixture stirred for another 30 min at 0 °C. A solution of 18 (0.013 g, 0.033 mmol) in dry 
ACN (0.5 mL) was added slowly by cannula. The reaction mixture was stirred for 10 
min at 0 °C and for 3 h at room temperature. The reaction mixture was extracted with 
EtOAc and brine. The combined organic phases were dried (Na2SO4) and the solvent 
was removed under reduced pressure. The crude was dissolved in dioxane (0.6 mL) and 
aq NH3 (25%, 0.2 ml) was added. The mixture was stirred at room temperature for 3 h, 
then the solvent removed, and the residue purified by column chromatography 
(DCM:MeOH = 93:7) to yield cytidine derivates 20 as a white foam (0.005 g, 40% 
overall yield). [α]D -2.8, MeOH. 1H NMR (500 MHz, acetone d6), δ: 1.33 (s, 3H), 1.46 
(s, 9H), 1.52 (s, 3H), 1.96 (dt, J=10.6, 13.0 Hz, 1H), 2.20-2.24 (m, 1H,), 3.21 (m, 1H), 
3.71 (dd, J= 3.7, 13.6 Hz, 1H), 3.90 (dd, J= 8.3, 13.4 Hz, 1H), 4.02 (t, J= 10.4 Hz, 1H), 
4.32 (dd, J= 3.3, 11.1 Hz, 1H), 4.51 (td, J= 5.6, 10.8 Hz, 1H), 4.59–4.68 (m, 1H), 7.86 
(d, J= 5.5 Hz, 1H), 8.24 (bs, 2H). 13C NMR (100 MHz, acetone d6), δ: 14.85, 23.51, 
28.31, 39.27, 48.12, 51.86, 58.84, 58.84, 62.52, 75.92, 94.62, 124.12, 124.43, 149.77, 
150.61, 153.44. 
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2’-(5-fluorocytosine-1-yl) deoxynojirimycin (5). To a solution of 20 (0.005 g, 0.013 
mmol) in THF (0.6 mL), HCl (2M, 0.2 mL) was added and the reaction mixture was 
stirred to 60°C for 2h. Then the solvent was evaporated under reduced pressure and the 
crude residue was triturated with Et2O to give the pure 5 as chlorohydrate salt (0.003 g, 
>99% yield). 1H NMR (400 MHz, D2O), δ: 2.14-2.19 (m, 1H), 2.32-2.40 (m, 1H), 3.51-
5.53 (m, 2H), 3.57-3.61 (m, 1H), 3.94-4.00 (m, 2H), 4.36-4.38 (m, 1H), 4.92-5.00 (m, 
1H), 8.12 (d, J = 6.4 Hz, 1H), 9.10 (bs, 1H). 
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APPENDIX A 
IMINOSUGAR-BASED NUCLEOSIDES 
Among nucleoside analogues bearing a modified sugar moiety, the azanucleosides 
(iminosugars-based nucleosides) deserve a pivotal role. This class of compounds 
exhibits a broad-spectrum therapeutic potential, with some of them involved in advanced 
clinical trials as antitumoral or for the treatment of immune diseases, such as viral 
infections. Modifications based on replacement of endocyclic oxygen of the natural 
ribose with a nitrogen atom and natural hypoxanthine or adenine with the corresponding  
9-deazapurine have allowed to develop a new class of nucleoside analogues named the 
Immucillins (FIGURE A1).35 Immucillin-H (Forodesine®) [Imm-H, (1S)-1-(9-
deazahypoxantine-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol] is an excellent inhibitor of 
bovine (Ki = 23 pM) and human (Ki = 56 pM) PNPs.36 
 
FIGURE A1. The Immucillins. 
On the other hand, Immucillin-A (BCX4430) is another synthetic deazapurine 
iminosugar-C-nucleoside that has exhibited a broad-spectrum antiviral activity.37  
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2.3.1 INTRODUCTION 
The concepts explained in the introductive section of the last two chapters regarding the 
critical role of the conformation and of the configuration in the research and design of 
selective antiviral agents, can be even applied to another class of nucleoside analogues 
bearing a cyclohexenyl sugar moiety, which attracted considerable attention over the 
last years. A brief overview about carbocyclic nucleosides, the synthetic methodologies 
devoted to their preparation, as well as their biological activity and selectivity is 
reported below. 
2.3.1.1 CARBOCYCLIC ANALOGUES OF NUCLEOSIDES AND THEIR 
PHARMACOLOGICAL PROPERTIES 
Carbocyclic nucleosides (also referred as carbanucleosides) born from the replacement 
of the oxygen atom of natural nucleosides with a methylene unit (FIGURE 1).1 
 
FIGURE 1. Formal replacement of the oxygen atom in the carbanucleosides. 
Their cellular processing and mechanism of action are similar to those of natural 
nucleosides: progressive phosphorylation until their triphosphate forms and then 
interaction with viral polymerases leading, sometimes, to potent biological activity.2,3 In 
1966 it has been revealed the antibiotic and antitumor activity of two natural occurring 
carbocyclic nucleosides, Aristeomycin A and Neplanocin (FIGURE 2).4 Since then the 
research on carbocyclic nucleosides with biological activity has been the subject of 
intense efforts. As widely explained in the last chapters, the design of NAs working as 
non-toxic and especially selective inhibitors of kinases and polymerases for the control 
of viral diseases and cancer, has been the main goal of this research area and the 
carbocyclic nucleosides seems to meet some of these challenging features. They are good 
substrates of enzymes that normally respond to standard nucleosides, but at the same 
time they are highly resistant to phosphorylases and hydrolases; as consequence showing 
extreme stability towards sugar-base cleavage.5 For all the described reasons, their 
design and preparation represent an important topic in modern medicinal chemistry. 
2.3.1.1.1  ANTIVIRAL CARBOCYCLIC NUCLEOSIDES 
As above, after the discovery of the biological properties belonging to Aristeromycin A 
and Neplanocin A, other synthetic nucleosides with important therapeutic applications 
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were discovered.6 The synthetic cytosine analogue of Aristeromycin A, the 
cyclopentenylcytosine (CPE-C) was developed as a potent antitumor and antiviral 
agent.7 The displacement of the double bond to a different position relative to the 
neplanocins, has given rise to the potent and specific antiretroviral agent Carbovir 
(CBV)8 and then its structurally related Abacavir (ABC)9, approved drug to prevent and 
treat HIV/AIDS. Entecavir (ETV),10 a guanosine analogue, was approved by FDA in 
2005 for oral treatment of Hepatitis B infection (HBV); the homomethylene derivative 
of carbocyclic oxetanocin A ((-)-BCA) is a hybrid structure with excellent antiretroviral 
activity11 and finally, another active carbanucleoside is the new transposed antiherpetic 
guanine isonucleoside BMS-18116412. All above mentioned carbanucleosides are only 
a fraction of some new and fascinating structures that have been synthesized in recent 
years. 
 
FIGURE 2. Chemical structures of some antiviral carbanucleosides. 
2.3.1.2 BRIEF OVERVIEW ON THE MAIN ENANTIOSELECTIVE SYNTHETIC 
APPROACHES USED FOR THE CONSTRUCTION OF CARBOCYCLIC 
NUCLEOSIDES 
The intense search for clinically useful carbocyclic nucleosides has resulted in the 
development of novel approaches for their synthesis, and especially, by enantioselective 
methodologies. The carbanucleosides can be prepared mainly by two approaches: 1) the 
convergent insertion of the nucleobase on a functionalized carbocyclic ring; 2) synthesis 
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of the carbocycle functionalized with an amino group from which the nucleobase is 
linearly constructed. 
1) The direct coupling of the nucleobase with the carbocyclic pseudo sugar can be 
accomplished by several methods: from the SN2 nucleophilic displacement of a halide 
ions or activated alcohols13 to the epoxide ring opening,14 or more interestingly, by a 
palladium catalysed displacement of allylic esters or carbonates (namely the Tsuji-
Trost rearrangement)15 (SCHEME 1). In the latter method the allylic substrate is 
typically treated with a bulky Pd(0) catalyst [such as tetrakis-triphenylphosphine 
palladium, Pd(PPh3)4] to generate an intermediate allyl palladium complex, that 
undergoing nucleophilic attack from the less hindered carbon atom, releases the 
corresponding nucleoside. Since the process involves a double substitution 
(palladium coordination takes place on the opposite side with respect to substituents 
and nucleophilic attack occurs on the opposite side with respect to palladium 
complex), the reaction overall proceeds with retention of configuration, providing the 
only cis-product.16 Even if direct coupling of the nucleobase represents the most 
convergent approach, it suffers of some limitation due to the regioselectivity of base 
insertion. Indeed, with purines the attack can happen at the N9, N7 and N3 positions 
(SCHEME 1). 
 
SCHEME 1. Tsuji-Trost Pd(0) allylic rearrangement. 
2) The nucleobase can be literally constructed on the carbocyclic pseudo sugar moiety 
if the latter possess an exocyclic amino group, which becomes the N9 of a purine or 
the N1 of a pyrimidine (SCHEME 2).17 
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SCHEME 2. Purine: a) 2-amino-4,6-dichloropyrimidine, i-Pr2NEt, BuOH, reflux, 80%; 
b) 4-ClC6H4N2+Cl-, HOAc, NaOAc, H2O, 69%; c) Zn, HOAc, EtOH, H2O, 50%; d) 
(EtO)3CH, HCl, H2O; e) NaOH, H2O, reflux, 74%. Pyrimidine: a) TEA, dioxane; b) 2% 
2N HCl in dioxane. 80% o.y. 
2.3.1.3 LOCKED CARBOCYCLIC NUCLEOSIDES 
As widely highlighted in the Chapter 2.218 about the synthesis of North and South 
methano-carbathymidine, N-MCT and S-MCT, if the nucleoside sugar is structurally 
constrained into the optimal conformation required for the binding with the target 
enzyme, it could be endowed with high activity and, more interestingly, by a 
considerable selectivity.19 This study has been extended by Herdewijn et al. and applied 
to the synthesis of carbanucleosides with a six-membered sugar moiety. Several mono-, 
di- and tri-substituted cyclohexane nucleoside analogues (FIGURE 3) have been prepared 
and tested as antiviral agents,20 but none of them showed biological activity. Poor 
anabolism (phosphorylation) inside the cells could account for this lack of activity. 
 
FIGURE 3. Cyclohexanyl nucleosides. 
2.3.1.3.1 CYCLOHEXENYL NUCLEOSIDES 
Among bioactive nucleosides bearing six-membered sugar moiety, those obtained 
replacing the furanose ring with a cyclohexene unit holds a privileged position. A 
cyclohexene ring mainly exists in two half-chair forms (3H2 and 2H3), which interconvert 
via the symmetrical boat conformation (FIGURE 4). Differently from the furonase ring, 
for which all the possible forms are given by two-dimensional pseudorotational cycle,21 
the cylohexenyl moiety has a conformational behaviour described by a three-
dimensional conformational globe (FIGURE 4).22 The chair forms are located at the poles 
of the globe; the planar form is the highest energy form and it is located at the centre of 
the globe. The ellipsis represents the most stable conformers of cyclohexene, the half-
boat (E) and the half-chair (H) forms with the corresponding inverted forms, located at 
antipodes of the globe. 
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FIGURE 4 (taken from ref. 22). Conformational globe of cyclohexene. 
In FIGURE 5 is easy to identify the relationship between the pseudorotational cycle of 
furanose ring and the cyclohexene one; the 3T2 (North) and 2T3 (South) conformations 
of furanose find their structural equivalent in the 3H2 (North) and 2H3 (South) 
conformations of the cyclohexene ring. Therefore, the conformational profile of a 
cyclohexenyl ring is similar to that of a saturated five-member ring and this interesting 
finding explains why the cyclohexene ring demonstrated to be an efficient bioisostere of 
the natural furanose unit. Moreover, the energy gap required for the conformational 
change 3H2 2H3 is even lower (ΔG~10 kJ/mol) than that involving the 2T3 3T2 
interconversion (ΔG~20 kJ/mol; FIGURE 5). 
 
FIGURE 5 (adapted by ref. 22). Conformational relationships between natural deoxynucleosides 
and cyclohexenyl nucleosides. 
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Because of these considerations, Herdewijn et al.23 synthetized and investigated the 
properties of both enantiomeric forms of the cyclohexene guanine nucleosides 1 and ent-
1 (FIGURE 6). They were evaluated against a broad range of human infections and 
exhibited potent and selective antiviral activity against HSV-1 and 2, VZV and CMV 
comparable to that of the well-known antiviral drugs acyclovir and ganciclovir (FIGURE 
6). The above results highlighted how NAs bearing a six-membered moiety drew great 
attention, as they demonstrated to enable precise positioning of functional groups in the 
recognition events dealing with the metabolism of nucleosides and their incorporation 
into viral genomes. This justifies the longstanding efforts in the field, as well as the still 
ongoing studies aimed to explore other six-membered NAs endowed with even higher 
therapeutic activity. 
 
FIGURE 6. D- and L-cyclohexenyl guanine as anti-HHV agents. 
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2.3.2 RESULTS AND DISCUSSION 
2.3.2.1  ASYMMETRIC SYNTHESIS OF D- AND L-CYCLOHEXENYL 
NUCLEOSIDES 
On the basis of the promising biological potential exhibited by carbanucleosides (i.e. D- 
and L-cylohexenyl nucleosides)23 and discussed in the previous section, this project has 
been focused on the development of a synthetic approach aimed to the preparation of 
novel cyclohexenyl nucleosides (CeNAs), once again in both enantiomeric forms (2a,b 
and ent-2a,b; SCHEME 3). These, due to the inherent flexibility of the cyclohexenyl unit 
(rapidly interconverting between the 3H2 and 2H3 forms), are able to resemble both the N 
and S sugar ring puckers of natural nucleosides resulting suitable substrates either for 
kinases and polymerases. The main structural modification made on 2a,b and ent-2a,b, 
despite the previously reported examples of cyclohexenyl NAs 1 and ent-1,23 is the lack 
of sec-OH group at C5’ position conceived with the aim to keep the biomimetic 
properties of cyclohexene moiety while acting as chain terminators. As shown in 
SCHEME 3, the synthesis has started from the inexpensive cyclohexanone 3, 
enantioselectively hydroxymethylated (organocatalytic reaction catalysed by D- or L-
proline) and then manipulated to obtain the carbonate 4 from which, by the Tsuji-Trost 
rearrangement, the target nucleosides are efficiently prepared. 
 
SCHEME 3. Retrosynthetic pathway to target CeNAs 2a,b and ent-2a,b. 
At the moment 2a,b and ent-2a,b are involved in a wide antiviral screening (against 
HHVs, HIV and tropical viruses such as Chikungunya virus, Yellow Fever or 
Enterovirus71) ongoing at the Rega Institute for Medical Research (KU Leuven, 
Belgium) under the supervision of Prof. Robert Snoeck, Prof. Graciela Andrei, Prof. 
Cristophe Pannecouque and Prof. Johan Neytz. 
2.3.2.2 ENANTIOSELECTIVE SYNTHESIS OF THE CYCLOHEXENYL UNIT 
The enantioselective synthesis of optically active cyclohexenone 6, involving the 
organocatalyzed hydroxymethylation of cyclohexanone (3) (L-proline/CH2O), the 
protection of the resulting alcohol (TBDPSCl/Him) to give 5 and the subsequent Saegusa 
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dehydrogenation of ketone [LDA/TMSCl, then Pd(OAc)2], has been performed as 
already described (SCHEME 4).24 
 
SCHEME 4. Synthetic paths to obtain the carbonates 4 (in black) and ent-4 (in grey). 
Ketone 6 was then subjected to reduction with DIBAL-H (to give a 1:1 mixture of cis 
and trans stereoisomers) (SCHEME 4) followed by the alcohol protection step with 
MeOC(O)Cl affording the carbonate 4. The same synthetic path (but using D-proline as 
chiral catalyst in the first reaction step) described starting by 3 has been applied to finally 
obtain ent-4 (SCHEME 4). 
2.3.2.3 CARBANUCLEOSIDES SYNTHESIS 
The synthesis of the target carbanucleosides 2a,b and ent-2a,b was then approached 
exploiting the Tsuji-Trost rearrangement.16 As already described for cyclopentenyl 
substrates in the introductive section of the chapter, this reaction is typically based on 
the use of allylic esters or carbonates, which are treated with a bulky Pd(0) catalyst [such 
as tetrakis-triphenylphosphine palladium, Pd(PPh3)4] to generate an intermediate allyl 
palladium complex, then undergoing nucleophilic attack from the less hindered carbon 
atom, releasing the corresponding cyclopentenyl nucleosides. Since the process involves 
a double substitution (palladium coordination occurs on the opposite side with respect 
to substituents and nucleophilic attack on the opposite side with respect to palladium 
complex), the reaction overall proceeds with net retention of configuration, providing 
the only cis-products.25 At a glance, the study of the rearrangement of cyclohexene 4 
appeared a simple repetition, on a six-membered system, of the work on the synthesis of 
bioactive cyclopentenyl nucleosides, since the extra-methylene group was not expected 
to influence the reaction outcome. Accordingly, among the two cyclohexenyl carbonates 
cis- and trans-4, only the cis isomer was at first considered of synthetic utility. 
Conversely, treatment of the inseparable mixture of cis and trans-4 with 6-chloropurine 
8, Pd2(dba)3.CHCl3 and PPh3 in a 1:1 THF/DMSO mixture surprisingly led to the 
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formation of one main nucleoside, identified by 1H NMR as cis-9 [rr(N9:N7) = 6:1, entry 
1, TABLE 1). The reaction of cis and trans-4 with 2-amino-6-chloropurine 10 also 
furnished nucleoside cis-11 with high stereoselectivity (>20:1), although 
regioselectivities and reaction times were variable (entry 2) (TABLE 1). 
TABLE 1. Allylic rearrangement of cis and trans-4. 
 
Entry 
Carbonate Nucleobase Nucleoside t (h) 
Yielda 
(%) 
cis:trans 
N9:
N7 
1 trans/cis-4 8 9 20 76 (65)b >20:1 6:1 
2 trans/cis -4 10 11 18 83 (69)b >20:1 5:1 
aSum of regioisomeric N9 and N7 nucleosides. 
It is worthy to mention that, to the best of our knowledge, no precedents examples of 
stereoconvergent Tsuji-Trost rearrangement have ever been reported. Computational 
studies are indeed ongoing in order to elucidate the reaction mechanism that allow to 
explain stereochemical outcome of the reaction when performed on cyclohexenyl 
substrates. 
Protected nucleosides 9 and 11 were eventually deprotected (TBAF) to afford 12 and 13 
(89-92% yield); treatment of 12 with NH3 in MeOH afforded the adenine 
carbanucleoside 2b, while treatment of 13 with NaOH led to guanine derivative 2a 
(SCHEME 5). 
 
SCHEME 5. Final reaction steps to afford the target nucleosides 2a,b. 
The corresponding L-enantiomers ent-2a,b were prepared following the same synthetic 
route. 
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2.3.3  CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
This part of the PhD project has been devoted to the development of a highly regio- and 
stereoselective route to cyclohexenyl nucleosides 2a,b and ent-2a,b. The antiviral 
potential of these compounds relies on the high conformational flexibility of the 
pseudosaccharide units, enabling a close mimicry of the bioactive conformations (N and 
S) of natural D-nucleosides. In addition, the absence of any secondary hydroxyl function 
(which would resemble the OH group at the C3’ position of natural nucleosides) justifies 
their employ as chain terminators. From a synthetic standpoint the crucial steps are the 
hydroxymethylation organocatalytic reaction with D- or L-proline which allowed us to 
pre-establish the belonging steric series of the final nucleosides and, noteworthy, the 
allylic Tsuji-Trost rearrangement, an unprecedented example of stereoconvergent case. 
Because of the evident synthetic applications of this finding, especially if applied to the 
synthesis of other carbocyclic nucleosides including bioactive cyclopentenyl nucleosides 
(e.g. the marketed anti-HIV agent Abacavir), further investigation on this topic is 
currently ongoing. The earliest examples of cyclohexenyl nucleosides obtained are now 
object of a wide antiviral screening (against HHVs, HIV and tropical viruses such as 
Chikungunya virus, Yellow Fever or Enterovirus71) ongoing at the Rega Institute for 
Medical Research (KU Leuven, Belgium) under the supervision of Prof. Robert Snoeck, 
Prof. Graciela Andrei, Prof. Cristophe Pannecouque and Prof. Johan Neytz. The 
synthesis and the biological evaluation of the following and other D- and L-cyclohexenyl 
nucleosides will be object of a paper, that will publish in due course.  
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2.3.4 EXPERIMENTAL SECTION 
 
Silyl ether 5. To a stirred solution of 2-(S)-hydroxymethyl cyclohexanone24 (0.15 g, 1.17 
mmol) in anhydrous pyridine (3 mL), TBDPSCl (0.36 mL, 1.40 mmol) and imidazole 
(0.095 g, 1.40 mmol) were added. After stirring for 15’ at rt, the reaction mixture was 
diluted with CH2Cl2 and washed with brine until neutrality. The organic layers were 
dried with Na2SO4 and the solvent evaporated under reduced pressure. Chromatography 
of the crude residue over silica gel (hexane:EtOAc = 96:4) gave the pure (2S)-
[(silyloxy)methyl]-cyclohexanone (5) (0.36 g, 84% reaction yield) as an oil. [α]25D -17.6 
(c 0.57, CHCl3). 1H NMR (500 MHz, CDCl3), δ: 1.04 (s, 9H), 1.42-1.52 (m, 1H), 1.61-
1.72 (m, 2H), 1.85-1.93 (m, 1H), 1.99-2.08 (m, 1H), 2.23-2.40 (m, 3H), 2.49-2.58 (m, 
1H), 3.67 (dd, J = 7.8, 10.5 Hz, 1H), 4.00 (dd, J = 4.6, 10.5 Hz, 1H), 7.32-7.45 (m, 6H), 
7.66 (d, J = 7.7 Hz, 4H). 13C NMR (100 MHz, CDCl3), ppm: 24.6, 26.5, 26.8, 27.6, 30.9, 
42.1, 52.8, 63.0, 127.7, 129.6, 133.6, 134.8, 135.5, 211.9. Anal. calcd for C23H30O2Si: C 
75.36, H 8.25, O 8.73. Found: C 75.27, H 8.28, O 8.76. 
 
Cyclohexenone 6:. n-BuLi (2.5 M in hexane, 0.40 mL, 1.00 mmol) was added to a 
solution of freshly distilled DIPA (0.16 mL, 1.14 mmol) in anhydrous THF (2 mL), 
stirred at -78°C under nitrogen atmosphere. After 20’, a solution of 5 (0.348 g, 0.95 
mmol) in anhydrous THF (1.6 mL) was added dropwise to the mixture. After 1h, TMSCl 
[2.2 mL, previously distilled and deacidified with a solution of freshly dried 
triethylamine (TEA) in anhydrous THF] was added and the resulting mixture stirred for 
1h at –78°C. After control TLC indicated complete conversion of the starting ketone into 
the corresponding trimethylsilyl enol ether, the solvent was evaporated under reduced 
pressure and the mixture filtered on a celite pad washing with pentane (10.5 mL). To a 
stirring solution of the crude trimethylsilyl enol ether in anhydrous CH3CN (14 mL), 
Pd(OAc)2 (0.21 g, 0.95 mmol) was added at rt and the reaction was stirred at the same 
temperature for 16h. The mixture was then filtered on a celite pad washing with CH2Cl2. 
The filtrate was washed with brine. The organic layer was dried (Na2SO4) and evaporated 
under reduced pressure. Chromatography of the crude residue over silica gel 
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(hexane:Et2O = 95:5) gave the pure 6 (0.298 g, 86% o.y.) as an oil. []25D +20.3 (c 0.57, 
CHCl3. 1H NMR (400 MHz, CDCl3), δ: 1.04 (s, 9H), 1.94-2.04 (m, 1H), 2.26-2.32 (m, 
1H) 2.37-2.45 (m, 2H), 2.49-2.56 (m, 1H), 3.88 (dd, J = 7.2, 10.2 Hz, 1H), 3.99 (dd, J = 
4.2, 10.2 Hz, 1H), 5.99 (dt, J = 2.2, 10.1 Hz, 1H), 6.96 (dddd, J = 1.2, 3.1, 4.9, 10.1 Hz, 
1H), 7.35-7.44 (m, 6H), 7.65 (dd, J = 1.8, 8.0 Hz, 2H), 7.68 (dd, J = 1.5, 7.6 Hz, 2H). 13C 
NMR (100 MHz, CDCl3), ppm: 19.3, 25.2, 25.6, 26.9, 48.9, 62.8, 127.7, 129.6, 129.9, 
133.5, 135.6, 135.7, 150.3, 199.4. Anal. calcd for C23H28O2Si: C 75.78, H 7.74, O 8.78. 
Found: C 75.70, H 7.76, O 8.81. 
 
Carbonate 4.  
Reduction step: to a stirred solution of unsaturated ketone 6 (0.269 g, 0.74 mmol) in 
anhydrous toluene (8 mL), DIBAL-H (1.5 M in toluene, 0.59 mL, 0.89 mmol) was added 
at -78°C. After 15’, the reaction mixture was warmed to 0°C, methanol and sodium 
potassium tartrate were added and the resulting mixture was extracted with EtOAc and 
washed with brine. The organic layer was dried (Na2SO4) and the solvent evaporated 
under reduced pressure. 
Protection step: to a solution of the crude allylic alcohol (0.74 mmol) in anhydrous 
CH2Cl2 (14 mL), stirred at 0°C under nitrogen atmosphere, TMEDA (0.11 ml, 0.74 
mmol) and ClCO2Me (0.11 mL, 1.48 mmol) were added. The reaction was stirred for 1 
h at the same temperature; afterwards aq. NH4Cl was added and the resulting mixture 
extracted with CH2Cl2 and washed with brine. The organic layers were dried (Na2SO4) 
and concentrated under reduced pressure. The compound 4 (0.337 g, 93% o.y.) was 
obtained as inseparable 1:1 mixture of cis and trans stereoisomers. 1H NMR (400 MHz, 
CDCl3), δ: 1.03 (s, 4.5H), 1.05 (s, 4.5H), 1.65-1.76 (m, 1H), 1.85-2.16 (m, 4H), 3.56 (dd, 
J = 6.4, 9.9 Hz, 0.5H), 3.64 (dd, J = 4.3, 10.2 Hz, 0.5H), 3.67 (dd, J = 5.1, 10.2 Hz, 0.5H), 
3.72-3.78 (m, 3.5H), 5.23 (dt, J = 2.0, 7.9 Hz, 0.5H), 5.28 (bt, J = 3.8 Hz, 0.5H), 5.69 
(dq, J = 2.4, 10.1 Hz, 0.5H), 5.88 (bd, J = 10.1 Hz, 0.5H), 5.97-6.03 (m, 1H), 7.31-7.43 
(m, 6H), 7.58-7.67 (m, 4H). 13C NMR (125 MHz, CDCl3), δ: 19.2, 19.6, 25.2, 26.6, 26.7, 
29.6, 40.2, 40.6, 54.4, 54.5, 63.8, 64.0, 70.2, 73.8, 124.0, 125.4, 127.5, 127.6, 129.5, 
131.8, 134.2, 135.5, 135.6, 155.4, 155.6. Anal. calcd for C25H32O4Si: C 70.72, H 7.60, 
O 15.07. Found: C 70.67, H 7.63, O 15.12. 
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Nucleoside 9. To a solution of 6-chloropurine 8 (35 mg, 0.23 mmol) in anhydrous 
DMSO (1.6 mL) stirred at rt under nitrogen atmosphere, Pd2(dba)3·CHCl3 (31 mg, 30 
μmol) and PPh3 (60 mg, 0.23 mmol) were sequentially added. A solution of 4 (0.10 g, 
0.23 mmol, mixture of cis- and trans-isomers) in anhydrous THF (1.6 mL) was added 
dropwise and reaction mixture was further stirred for 20 h. The resulting mixture was 
then washed with brine and extracted with EtOAc. The organic layers were dried 
(Na2SO4) and concentrated. Chromatography of the crude residue over silica gel 
(hexane:EtOAc = 70:30) gave nucleoside 9 (0.075 g, 65% reaction yield; dr(cis:trans) > 
20:1, rr(N9:N7) = 6:1). 1H NMR (400 MHz, CDCl3), δ: 1.09 (s, 9H), 1.39-1.49 (m, 1H), 
1.75, 1.83 (m, 1H), 1.99-2.12 (m, 2H), 2.44-2.52 (m, 1H), 3.65 (dd, J = 6.1, 9.9 Hz, 1H), 
3.69 (dd, J = 6.4, 9.9 Hz, 1H), 5.28-5.33 (m, 1H), 5.89 (dq, J = 2.5, 10.1 Hz, 1H), 6.30 
(dt, J = 1.9, 10.1 Hz, 1H), 7.38-7.46 (m, 6H), 7.64-7.69 (m, 4H), 8.11 (s, 1H), 8.75 (s, 
1H). 13C NMR (125 MHz, CDCl3), ppm: 19.4, 21.0, 27.1, 28.0, 38.2, 49.9, 66.9, 123.8, 
127.9, 130.0, 132.3, 133.4, 135.7, 137.5, 144.6, 151.1, 151.5, 151.8. Anal. calcd for 
C28H31ClN4OSi: C 66.84, H 6.21, Cl 7.05, N 11.14, O 3.18. Found: C 66.74, H 6.23, Cl 
7.07, N 11.17, O 3.17. 
 
Nucleoside 11. To a solution of 2-amino-6-chloropurine 10 (24 mg, 0.14 mmol) in 
anhydrous DMSO (2 mL) stirred at rt under nitrogen atmosphere, Pd2(dba)3 CHCl3 (19 
mg, 18 μmol) and PPh3 (37 mg, 0.14 mmol) were sequentially added. A solution of 4 
(60 mg, 0.14 mmol, mixture of cis- and trans-isomers) in anhydrous THF (2 mL) was 
added dropwise and reaction mixture was further stirred for 18 h. The resulting mixture 
was then washed with brine and extracted with EtOAc. The organic layers were dried 
(Na2SO4) and concentrated. Chromatography of the crude residue over silica gel 
(hexane:EtOAc = 70:30) gave nucleoside 11 (50 mg, 69% reaction yield; d.r (cis:trans) 
> 10:1, r.r (N9:N7) = 5:1). []25D +66.7 (c 0.32, CHCl3). 1H NMR (400 MHz, CDCl3), δ: 
1.08 (s, 9H), 1.38-1.49 (m, 1H), 1.71-1.79 (m, 1H), 1.93-2.01 (m, 2H), 2.43-2.49 (m, 
1H), 3.64 (dd, J = 6.3, 9.9 Hz, 1H), 3.68 (dd, J = 6.6, 9.9 Hz, 1H), 5.02-5.06 (m, 1H), 
5.82 (dq, J = 2.3, 10.1 Hz, 1H), 6.22 (dt, J = 1.9, 10.1 Hz, 1H), 7.37-7.46 (m, 6H), 7.66-
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7.68 (m, 4H), 7.75 (s, 1H). 13C NMR (100 MHz, CDCl3), ppm: 19.8, 20.9, 26.9, 27.6, 
38.0, 49.2, 66.8, 124.2, 125.7, 127.8, 129.8, 133.4, 135.6, 136.6, 141.5, 151.2, 153.2, 
158.9. Anal. calcd for C28H32ClN5OSi: C 64.91, H 6.23, Cl 6.84, N 13.52, O 3.09. Found: 
C 64.80, H 6.25, Cl 6.85, N 13.57, O 3.10, Si 5.53. 
 
Nucleoside 12. To a solution of 9 (70 mg, 0.14 mmol) in THF (4.4 mL), 
tetrabutylammonium fluoride (1M solution in THF, 0.14 mL, 0.14 mmol) was added at 
0°C. The reaction mixture was stirred at the same temperature for 1.5 h; afterwards the 
solvent was removed under reduced pressure. Chromatography of the crude residue on 
silica gel (hexane:EtOAc = 20:80) gave the pure 12 (33 mg, 89% reaction yield). []25D 
-6.0 (c 0.12, CH3OH). 1H NMR (400 MHz, CD3OD), δ: 1.48-1.59 (m, 1H), 1.78-1.85 
(m, 1H), 2.07-2.20 (m, 2H), 2.37-2.46 (m, 1H), 3.62 (dd, J = 5.3, 10.7 Hz, 1H), 3.69 (dd, 
J = 6.0, 10.7 Hz, 1H), 5.34-5.40 (m, 1H), 6.00 (ddd, J = 2.4, 4.0, 10.1 Hz, 1H), 6.28 (dt, 
J = 1.8, 10.1 Hz, 1H), 8.56 (s, 1H), 8.74 (s, 1H). 13C NMR (100 MHz, CD3OD), ppm: 
21.7, 28.5, 39.4, 51.6, 65.8, 125.3, 132.8, 138.1, 146.9, 147.3, 151.2, 152.8. Anal. calcd 
for C12H13ClN4O: C 54.45, H 4.95, Cl 13.39, N 21.17. Found: C 54.30, H 4.97, Cl 13.44, 
N 21.23. 
 
Nucleoside 13. To a solution of 11 (50 mg, 96 mol) in THF (2.6 mL), 
tetrabutylammonium fluoride (1 M solution in THF, 96 L, 96 mol) was added at 0°C. 
The reaction mixture was stirred at the same temperature for 1.5 h; afterwards the solvent 
was removed under reduced pressure. Chromatography of the crude residue on silica gel 
(CHCl3/MeOH = 95:5) gave the pure 13 (0.025 g, 92% reaction yield). []25D -74.9 (c 
0.65, CH3OH). 1H NMR (400 MHz, CD3OD), δ: 1.51 (dddd, J = 3.9, 8.7, 10.8, 15.4 Hz, 
1H), 1.73-1.82 (m, 1H), 1.97-2.13 (m, 2H), 2.33-2.43 (m, 1H), 3.60 (dd, J = 5.5, 10.8 Hz, 
1H), 3.66 (dd, J = 6.0, 10.8 Hz, 1H), 5.09-5.14 (m, 1H), 5.94 (dddd, J = 0.5, 2.4, 3.6, 10.1 
Hz, 1H), 6.22 (dt, J = 1.9, 10.1 Hz, 1H), 8.06 (s, 1H). 13C NMR (100 MHz, CD3OD), 
ppm: 21.8, 28.4, 39.4, 50.5, 65.9, 125.3, 125.7, 137.6, 143.4, 151.5.8, 154.8, 161.5. Anal. 
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calcd for C12H14ClN5O: C 51.53, H 5.04, Cl 12.67, N 25.04. Found: C 51.36, H 5.06, Cl 
12.752, N 25.12. 
 
Nucleoside 2b. Nucleoside 12 (20 mg, 0.07 mmol) was treated with a solution of 
ammonia in MeOH (7 M, 2.4 mL) and heated in a steel bomb for 20 h at 90°C. After 
cooling, the solvent was removed under reduced pressure. Chromatography of the crude 
residue over silica gel (CH2Cl2:MeOH = 85:15) gave the pure 2b (17 mg, 92% reaction 
yield). []25D -3.5 (c 0.10, CH3OH). 1H NMR (400 MHz, CD3OD), δ: 1.44-1.55 (m, 1H), 
1.73-1.83 (m, 1H), 2.03-2.11 (m, 2H), 2.35-2.44 (m, 1H), 3.60 (dd, J = 5.5, 10.8 Hz, 1H), 
3.66 (dd, J = 6.0, 10.8 Hz, 1H), 5.16-5.23 (m, 1H), 5.95 (ddd, J = 2.4, 4.0, 10.0 Hz, 1H), 
6.23 (dt, J = 1.7, 10.0 Hz, 1H), 8.12 (s, 1H), 8.23 (s, 1H). 13C NMR (500 MHz, CD3OD), 
ppm: 21.7, 28.9, 39.4, 50.6, 65.9, 125.7, 128.05, 134.9, 137.6, 141.8, 153.6, 157.4. Anal. 
calcd for C12H15N5O: C 58.76, H 6.16, N 28.55. Found C 58.66, H 6.18, N 28.62. 
 
Nucleoside 2a. Nucleoside 13 (45 mg, 0.16 mmol) was refluxed for 2 h in a 0.5 N aq 
NaOH solution (2.9 mL). Then the reaction mixture was cooled to 0 °C, and 0.5 N HCl 
was carefully added until neutral. The solvent was removed under reduced pressure and 
the crude residue was chromatographed over silica gel (CHCl3/MeOH = 80:20) affording 
the pure 2a (31 mg, 75% reaction yield). 1H NMR (400 MHz, CD3OD), δ: 1.46-1.56 (m, 
1H), 1.72-1.81 (m, 1H), 1.95-2.07 (m, 2H), 2.34-2.42 (m, 1H), 3.60 (dd, J = 5.6, 10.8 Hz, 
1H), 3.63 (dd, J = 6.2, 10.8 Hz, 1H), 4.96-5.03 (m, 1H), 5.91 (ddd, J = 2.4, 4.0, 10.0 Hz, 
1H), 6.18 (dt, J = 1.9, 10.0 Hz, 1H), 7.70 (s, 1H). 13C NMR (100 MHz, CD3OD), ppm: 
21.8, 28.8, 39.4, 50.1, 66.0, 117.9, 126.0, 137.0, 138.5, 152.6, 155.2, 159.5. Anal. calcd 
for C12H15N5O2: C 55.16, H 5.79, N 26.80. Found: C 55.04, H 5.81, N 26.86.  
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MODIFIED OLIGONUCLEOTIDES 
The concept of using synthetic oligonucleotides (ODNs) to control the expression of 
specific genes dates back to the late 1970s, when from several studies emerged the 
‘‘antisense’’ approach for targeted gene silencing. AON (antisense oligonucleotides)-
based therapeutics have been under clinical investigation for more than 30 years, 
achieving one approved drug (Fomivirsen, Vitravene). Subsequent to antisense strategy, 
RNA interference (RNAi) and small interfering RNAs (siRNAs) were introduced as 
alternative gene silencing strategies. Although siRNAs and AONs are perhaps the most 
commonly discussed ODN-based agents under development, new systems such as 
microRNA-targeting ODNs (antimiRNAs), aptamers and DNA/RNAzymes have recently 
emerged for relevant and ambitious applications. Particularly aptamers are ONs that 
can specifically bind to a molecular target; by SELEX process, thousands of aptamers 
have been generated against a wide range of targets, including organic molecules, 
proteins, peptides, viruses and bacteria. Their medical applications include chemical 
sensors, imaging molecules, diagnostic assays and therapeutic purposes. However, the 
most significant obstacles impeding the approvals of ODNs as drugs (aptamers 
included) are their poor extracellular and intracellular stability, low efficiency of 
intracellular delivery to targets cells or tissues and onset of side effects. In attempts to 
overcome their therapeutically limiting features, a wide array of chemical modifications 
has been developed leading to modified oligonucleotides (MOs). These are rationally 
designed, allowing specific alterations to many of the inherent properties of ODNs 
affecting their biological application and potency. The challenge of chemists is the 
construction of modified oligonucleotides (MOs) endowed with deep structural changes 
compared to natural ODNs, able to hold the potential for selective cross communication, 
as well as to enhance nuclease stability, target binding affinity, enzyme interaction, 
hybridization properties, cellular uptake and pharmacokinetic/pharmacodynamic 
properties. In this context, replacement of natural (deoxy)ribose moiety with a six-
membered ring has led to highly preorganized structures, resulting in potentially 
excellent candidates for cross pairing with natural/modified complements.  
Particularly, the oligonucleotide system composed of (6'→4')-linked  
1',5'-anhydro-D-arabino-hexitol nucleotides (HNA) has represented one of the most 
prominent examples of hexose NAs with capability for cross-communication with 
natural complements. Thus, on the basis of the above-mentioned considerations, during 
this PhD research project the attention has been focused on the preparation of MOs 
containing hNAs (1',5'-anhydro-D-arabino-hexitol nucleosides). The aim was to study 
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the influence of hNAs in the ability of resulting modified oligonucelotides to bind the 
thrombin acting as its aptamers and then as anticoagulant agents. 
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3.1.1 INTRODUCTION 
3.1.1.1 DNA AND RNA OLIGONUCLEOTIDES AS APTAMERS 
Ellington1 in 1990 coined the term aptamer from the combination of the latin word aptus 
(‘to fit’) and the greek word meros (‘part’). Nucleic acids aptamers are indeed, short, 
single stranded DNA or RNA molecules (20-100 nucleotides) that can specifically bind 
to a molecular target via three-dimensional structures defined by the perfect shape 
complementarity between the two parts.2 Aptamers are usually selected on the basis of 
their affinities for a target molecule in a selection process called SELEX3 (Systematic 
Evolution of Ligands by EXponential enrichment) whose experimental simplified 
principle is illustrated in FIGURE 1. Typically, the libraries used in SELEX process4 
contain about 1014-1015 sequences that in the first phase are incubated in presence of the 
molecular target. The interacting sequences are separated from the others and then 
amplified (by RT or PCR); this process is repeated several times (8-15 rounds) until the 
highly specific oligonucleotide with great affinity for the target is identified. The 
aptamers can fold with various secondary structures (stem, loop, G-quadruplex or 
kissing hairpins) that finally form a unique three-dimensional structure capable of 
specific interactions with the target, discriminating against conformational isomers, 
different functional groups or even amino acid mutations. 
 
FIGURE 1. Simplifed scheme of the SELEX Process. 
By SELEX process, thousands of aptamers have been generated5 against a wide range 
of targets, including organic molecules, proteins, peptides, viruses and bacteria. Their 
medical applications6 include chemical sensors, imaging molecules, diagnostic assays 
and therapeutic purposes. However, the pharmaceutical application of aptamers is 
hampered by the use of therapeutic antibodies which still dominate the global market. 
The only approved aptamer drug is Pegaptanib (Macugen; Pfizer/Eyetech) targeted 
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against the VEGF (Vascular Endothelial Growth Factor); many other aptamers are still 
in clinical trials7 mainly due to their in vivo limitations, such as the metabolic instability 
(high nuclease degradation susceptibility), rapid renal filtration and rapid distribution 
into tissues (liver or spleen). Various chemical modifications and conjugations have 
therefore been developed with the aim to improve their pharmacokinetic properties.5 
3.1.1.1.1 THROMBIN BINDING APTAMERS 
An elective field in which DNA and RNA aptamers are used is represented by 
thrombotic syndromes, whose disorders lead to significant morbidity and mortality.8 
Hemostatic proteases are obvious enzymatic targets for anticoagulant and 
antithrombotics agents; thrombin, factor IXa and factor Xa constitute crucial trypsin-like 
serine proteases involved in the coagulation cascade. Thrombin particularly is the 
terminal enzyme involved in such cascade; it is directly responsible for the conversion 
of fibrinogen to fibrin9 and, on the basis of its multifunctional nature,10 it has soon been 
recognized as the major target for the development of inhibitors or modulators. 
Thrombin-Binding Aptamer (TBA), also named ARC183 (Archemix Corp.) or HD1, a 
15-mer DNA structure d(GGTTGGTGTGGTTGG) (FIGURE 2b) discovered11 with 
SELEX12 process, represents the best-known example among thrombin inhibitors. TBA 
is characterized by a chair-like quadruplex structure consisting of two G-tetrads 
connected by two TT loops (T3T4 and T12T13) and a single TGT loop (T7G8T9). NMR13 
(TBA in solution) and the X-ray14 (complex of TBA with thrombin) studies, after several 
ambiguities, have confirmed that the aptamer interacts with the fibrinogen recognition 
site (exosite I) of a first molecule of thrombin through the two TT loops, while the TGT 
loop is involved in the interaction with the heparin-binding site (exosite II) of a second 
distinct thrombin molecule (FIGURE 2a).15 These interactions reflect the strong TBA in 
vitro anticoagulant activity (Kd = 34 nM);11 its in vivo properties were evaluated on 
cynomolgus monkeys and sheep first,16 then it was admnistered by infusion in a short-
term canine cardiopulmonary bypass model17 and the promising results obtained thus led 
TBA in Phase I of clinical trials. However, because of suboptimal dosing profile, 
primarily caused by the restricted binding affinity of the aptamer, the trials were halted 
in 2005. Over the years, many studies have been devoted to the development of more 
potent derivatives with improved pharmacological activity with the aim to improve the 
properties of TBA and overcome the drawbacks arising from its use (especially the short 
in vivo half-life, t1/2 =1.8 min). Modifications of the original structure18 have concerned 
substitutions in the nucleoside residues (i.e. LNA, UNA, RNA, FIGURE 3) or in the 
internucleoside linkages19 (methylphosphonate or phosphorothioate), inversion of the 
TBA polarity with 5’-5’ internucleoside linkage20 or the changing of the loops 
sequence/length.21 
 142 
 
 
FIGURE 2. a) TBA-thrombin complex; b) schematic representation  
of the structure of TBA (adapted from ref.8 and ref.25). 
LNA (2'-O-4'-C-methylene-linked ribonucleotide nucleic acid analogues) substitutions22 
(FIGURE 3) at loop region interestingly demonstrated a position dependent effect on the 
stability of the TBA; indeed, the substitution of G8 with G-LNA increased the stability, 
whereas, the substitution of T7 decreased it and substitution of T4 disrupted the aptamer. 
In terms of activity, LNA substitutions did not lead to interesting improvement and only 
LNA-G2 thrombin aptamer, one of the least stable quadruplexes, demonstrated activity 
equal to the control aptamer. Modified TBA carrying 2’-deoxyguanine (dG) residues 
with locked North or South-bicyclo[3.1.0]hexane pseudosugars (FIGURE 3) were 
prepared23 by Eritja et al.; substitutions at 5, 10 and 14 positions with a locked South/syn-
dG nucleoside produced aptamers with the same stability of the unmodified one. 
Replacement at 15 position, on the contrary, induced a strong destabilization of the 
aptamer, while substitution with the antipodal North/anti-dG nucleoside caused a minor 
destabilization. Remarkably, the insertion of a North/anti-dG nucleoside at position 14, 
where both pseudosugar conformation and glycosyl torsion angle are opposite with 
respect to the native structure, led to the complete disruption of the G-tetraplex structure 
supporting the concept that the glycosyl conformation is more restrictive for TBA 
stability than the sugar puckering. 
 
FIGURE 3. Chemical structures of modified carbohydrate moiety in the guanine TBA tetrads. 
Second generation DNA aptamers were next synthetized and a great interest was focused 
on bimodular oligonucleotides24 encompassing both a duplex and a quadruplex module, 
adopting a so-called duplex/quadruplex (DQ) conformation. They, because of their 
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peculiar structure, represent better therapeutic agents compared with those containing a 
single G-quadruplex domain.25 RE31, NU172, HD22_27mer and HD22_29mer (see 
TABLE 1 for the sequences) belong to the class of anti-thrombin DQ aptamers; on one 
side RE3125 and NU172 are both hexosite I inhibitors, while the two HD22 variants are 
able to bind exosite II of thrombin. RE31 showed a structure (FIGURE 4) in which the 
two domains are strictly interconnected with a continuous stacking of the bases and, 
particularly, fifteen residues adopt the same antiparallel G-quadruplex structure 
observed for TBA. Noteworthy, both domains of RE31 interact with the same thrombin 
molecule but the binding involves only the quadruplex one, as observed, once again, for 
TBA. The presence of the duplex domain, however, may contribute to make more 
compact the structure and it is probably involved in the enhancing of the protein affinity 
which is greater for RE31 with respect to TBA. Altough the high resolution structure of 
NU172 is not still available, the hypotized structure26 (FIGURE 4) seems to be very 
similiar to that of RE31; NU172 is able to bind the thrombin at picomolar concentration 
(Kd= 0.1 nM) and it is in Phase II27 of clinical trials as anticoagulant agent in patients 
undergoing coronary artery bypass graft surgery. On the other hand, the HD22 variants 
present a structure28 in which the perpedicular orientation of the two domains does not 
allow a continuous stacking of the bases; however, this peculiar steric combination 
favours the binding with the exosite II, with which both motifs are able to interact. 
Name Sequence (5’-3’)  
TBA GGTTGGTGTGGTTGG  
RE31 GTGACGTAGGTTGGTGTGGTTGGGGCGTCAC  
NU172 CGCCTAGGTTGGGTAGGGTGGTGGCG  
HD22_27 GTCCGTGGTAGGGCAGGTTGGGGTGAC  
HD22_29 AGTCCGTGGTAGGGCAGGTTGGGGTGACT  
TABLE 1. Sequences of thrombin binding aptamers. 
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FIGURE 4. DQ aptamers exosite I inhibitors. 
3.1.1.2 PREORGANIZED NUCLEIC ACIDS 
The desired goals of molecular design (i.e. aptamer design) are the binding affinity and 
selectivity. High affinity often means slow dissociation from the biological target and 
therefore a long time for the inhibition of the biological process; the substrate 
concentration with which it typically occurs is very low. High selectivity means great 
ability of the substrate in discriminating among different biological targets, thus 
enhancing the mismatch possibilities. Even if high affinity sometimes does not mean 
also high selectivity, in several cases, the two goals are simultaneously reached. One of 
this case occurs when the structural preorganization concepte is applied designing 
modifications which freeze the substrate (i.e. the aptamer) prior to fit, in order to adopt 
the binding conformation. This event reduces the number of frozen bond rotations during 
the entropically disfavoured complexation, enhancing thus the affinity. At the same time, 
the substrate is spatially “organized” with that shape complementary to the desired 
biological target than the undesired ones, increasing thus the selectivity. One of the 
strategies used to preorganize helical structures is represented by the design of hexose-
DNAs or RNAs. Oligonucleotide analogues bearing a six-membered ring in the 
backbone hold a central position among conformationally restricted ODNs. Indeed, 
replacement of a furanose ring with a six-membered unit (e.g. a pyranose ring) involves 
dramatic differences in flexibility, causing conformational preorganization of the 
corresponding nucleotide system. This has justified the design of a wide number of 
                                                 
e The concept of structural preorganization has been fully introduced in the Chapter 2.2 (see 
2.2.1.3. Conformationally Constrained Nucleoside Analogues in “Novel Piperidinyl Iminosugar-
Based Nucleosides as Selective Pharmacological Tools”)  
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hexopyranosyl and other six-membered NAs, whose structures have long been 
investigated to consider their potential in therapy,29 diagnostics,30 synthetic biology31 and 
etiology-oriented studies on the structure of natural nucleic acids32. 
3.1.1.2.1 HNA – HEXITOL NUCLEIC ACIDS 
In this context, the oligonucleotide system composed of (6'→4')-linked 1',5'-anhydro-D-
arabino-hexitol nucleotides (hereafter HNA; FIGURE 5) has represented one of the most 
prominent examples of hexose NAs with capability for cross-communication with 
natural complements (DNA: ∆Tmf/mod up to +1.3 °C; RNA: ∆Tm/mod up to +3 °C).33 
The order of duplex stability is HNA:HNA > HNA:RNA > HNA:DNA. Pairing studies 
of HNA with RNA and DNA showed that the resulting duplexes behave as A-type 
(RNA) mimics34 in which the hexitol sugar backbone resembles the conformation of 
natural D-(deoxy)ribonucleotides frozen in a C3'-endo pucker (FIGURE 5). 
 
FIGURE 5. Pairing properties of the oligonucleotide system composed of  
(6'→4')-linked 1',5'-anhydro-D-arabino-hexitol nucleotides (HNA). 
From a biological point of view, in vitro experiments showed that HNA are incorporated 
by polymerase models35, by HIV-1 reverse transcriptase36 and they are not recognized 
by ligases, methylases and terminal transferases37. Moreover, the HNA⸱RNA hybrid 
resulted to be a very poor substrate for RNaseH. These results and other38 highlighted 
how, among the most relevant examples of conformationally restricted nucleic acids, 
those bearing a six-membered moiety drew most attention. This justifies the 
longstanding efforts in the field, as well as the still ongoing studies, aimed to explore 
their potential therapeutic application (e.g. antisense ODNs, siRNA, aptamers).   
                                                 
f The melting temperature (Tm) is defined as the temperature at which two complementary 
oligonucleotides occur to 50% as single strands and as duplex. Typically these data are extracted 
from UV–melting curves as the maximum of the first derivative. Although Tm data do not reflect 
necessarily thermodynamic stability, they are a reliable and widely used measure for thermal 
stability of duplexes. 
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3.1.2 RESULTS AND DISCUSSION 
3.1.2.1 SYNTHESIS OF MODIFIED THROMBIN APTAMERS AS POTENTIAL 
ANTICOAGULANT AGENTS 
On the basis of the discussed therapeutic properties exhibited by modifed oligonucletides 
(MOs) as aptamers and by HNA in terms of target affinity and selectivity, aim of this 
project was the synthesis and biological evaluation of conformationally preorganized 
MOs containing hNA monomers as new NU172 analogues (FIGURE 6). Guanosine 
monomer 1 has been synthetized as described in the next paragraph, while thymdine 
analogue 2 has been furnished by Piet Herdewijn Lab. 
 
FIGURE 6. NU172 and its analogues containing hNAs. 
As discussed in the introductive section, NU172, probably thanks to its peculiar 
structure, has revealed strong inhibitory activity toward thrombin (Kd = 100 pM)2 and it 
is now in Phase II of clinical trials as anticoagulant agent.39 The project arises from the 
collaboration with Prof. Piet Herdewijn and his research group (Rega Institute for 
Medical Reasearch, KU Leuven Belgium) in order to preliminary test the ability of hNA 
modified sequences to bind thrombin and exert anticoagulant properties. The synthesis 
of monomer 1 has been performed in our laboratories, whereas oligonucleotide 
synthesis, thrombin binding affinity studies and stability in human serum were carried 
out at Rega Institute. 
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3.1.2.2 GUANOSINE MONOMER SYNTHESIS 
The building block 1 has been synthetized as described in the Current Protocols in 
Nucleic Acid Chemistry (CPNAC);40 however, some of the procedures have been tuned 
up or changed to improve the overall reaction yield. The synthesis started from penta-O-
acetyl-α-D-glucose 3 which was converted in the corresponding 2,3,4,6-O-acetyl-α-D-
bromoglucose 4 by treatment with HBr (33% in AcOH); the subsequent dehalogenation 
reaction was performed by use of Et3SiH in presence of catalytic amount (10%) of PdCl2 
(SCHEME 1). Final deprotection step of 5 was then accomplished in typical conditions 
(MeONa/MeOH) affording 1,5-anhydroglucitol 6. 
 
SCHEME 1. Synthetic route to 1,5-anhydroglucitol 6. 
The regioselective benzylidene introduction in O4 and O6 positions was performed with 
a procedure different to that reported40 leading to 7 (SCHEME 2) with a higher reaction 
yield (87% - CPNAC 75%). Particularly, 6 was subjected to treatment with 
benzaldehyde dimethyl acetal in presence of catalytic amount (5%) of CSA in DMF 
(SCHEME 2). At this point, in order to remove the secondary hydroxyl function in C3 
position and promote the axial nucleobase insertion in C2 position, a protection of C2-
OH position as p-toluensulfonyl ester (8) was choosen (by stannylene method, 84% 
reaction yield over two steps) and subsequent OH removal from C3 postion (Barton-
McCombie methodology) was carried out. The latter reaction (TBSH/AIBN/toluene) 
was conducted on xanthate 9, in turn obtained by treatment of 8 with phenyl 
chlorothionoformate (SCHEME 2). 
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SCHEME 2. Regioselective protections and C3 deoxygenation. 
Installation of p-toluensulfonyl group at C2 position was planned to stereoselectively 
introduce the nucleobase by its nucleophilic displacement; this strategy, once again, 
differs from that reported.40 2-Amino-6-chloropurine has been introduced with mild 
reaction conditions (DBU/DMF/90 °C) affording the desired nucleoside 11 after 48h 
(SCHEME 3). Subsequent acidic treatment contemporary allowed the conversion to the 
corresponding guanine derivative and the removal of benzylidene group to give 1. At 
this point, in order to favour the modified oligomers preparation, it was necessary to 
promote the conversion of nucleoside 1 into 13. Therefore, 1 was subjected to a transient 
O4 and O6-silylation (BSA/pyridine) followed by treatment with isobutyric anhydride 
to promote the bis-protection of the exocyclic nucleobase amino function; subsequent 
treatment with ammonia and then water, allowed the single removal of isobutyryl group 
to afford 12 (SCHEME 3). Finally, tritylation of primary hydroxyl function O6 in typical 
conditions (MMTrCl/DMF/Py) led to desired 13, ready to undergo to automatized 
oligonucleotide assembly. 
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SCHEME 3. Synthetic route to final guanine oligo building block 13. 
3.1.2.3 OLIGONUCLEOTIDES SYNTHESIS 
The five anti-thrombin NU172 aptamers analogues containing hexitol nucleotides (hNA) 
have been prepared with a DNA synthesizer by using the phosphoramidite approach (see 
Experimental Section for details) (FIGURE 7). 
 
FIGURE 7. NU172DNA sequence and NU172 hNA-containing sequences. 
Single and multiple substitutions have been considered to evaluate how a preorganized 
nucleotide is able to influence the aptamer binding affinity with the protein and its 
susceptibility to nucleases action. 
3.1.2.4 BINDING AND STABILITY ASSAYS 
We first analyzed the ability of the aptamers to bind to human -thrombin by 
electrophoretic gel mobility assay (FIGURE 8). Each aptamer was mixed with an 
equivalent amount of thrombin or incubation buffer (see Experimental Section) and then 
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analyzed in a native polyacrylamide gel. Compared to unmodified aptamer 
(NU172DNA), the binding ability of NU172A0618 aptamer resulted interestingly 
improved of  23%; the affinities of NU172C0618 and NU172D0618 were almost 
equivalent to the native aptamer while in NU172B0618, the hexitol modification led to 
a binding reduction of two times. Finally, for the aptamer NU172E0618 the total loss of 
the aptamer binding ability to thrombin has been observed (FIGURE 8). 
 
 
FIGURE 8. Binding analysis by EMSA. Human thrombin (200 nM) was incubated with (+) or 
without (-) aptamer samples (200 nM) at 37 C for 2 h. The aptamer-thrombin complexes were 
separated from the free aptamers on a 6% native PAGE. The relative binding abilities were 
calculated from their band intensities, normalized by that of unmodified aptamer NU172DNA. 
Next, we examined the stability of the variants against nuclease digestion, using 90% 
human serum at 37 C (FIGURE 9). After 6h, NU172A0618 showed an higher residual 
activity than NU172DNA (93% and 83 % respectively); after 24h the modified aptamer 
residual activity resulted once again 1.7 times higher than NU172DNA. On the other 
hand, NU172C0618, if firstly showed less stability than native aptamer, after 24h and 
then 48h, exhibited higher residual activity (even more higher of that showed by 
NU172A0618). In the remaining cases, such as NU172B0618, NU172D0618 and 
NU172E0618, the aptamer resistance to nuclease degradation was even reduced by 
incorporation of the modified nucleotides. Finally, we can detect some correlation 
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between aptamer affinity to thrombin and stability in serum; the tighter binding aptamers 
(NU172A0618 and NU172C0618) have indeed higher resistance to nuclease hydrolysis. 
 
FIGURE 9. Aptamer stability assay in human serum. Unmodified and modified aptamer variants 
were incubated in 90% human serum at 37 C for up to 72 h.  
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3.1.3 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
The research of a biological application for the HNA was the main aim of the above 
described project. The high affinity and selectivity demonstrated by preorganized 
systems, such as HNA, led us to conceive the possibility to plan precise modifications 
of an oligonucleotide sequence that showed interesting biological activity. NU172 is 
now the most promising thrombin aptamer, now in Phase II of clinical trials, probably 
adopting a bimodular structure (duplex/quadruplex conformation; DQ aptamer). The 
most interesting result ragards the aptamer NU172A0618 for which the binding ability 
resulted improved of  23%; the affinities of NU172C0618 and NU172D0618 were 
almost equivalent to the native aptamer while for the aptamer NU172E0618 the total 
loss of the aptamer binding ability to thrombin has been observed. The stability studies 
in human serum revealed, once again, an extra stabilization for the aptamer 
NU172A0618 while an equal or reduced stability has been observed in the remaining 
cases. Taking into account the results obtained, further modifications on the NU172 
sequence are currently ongoing aimed to fully establish the role of the key residues 
involved and absolutely required for the effective binding to the thrombin and 
furthermore able to improve the stability of aptamers to nucleases degradation.  
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3.1.4 EXPERIMENTAL SECTION 
GUANOSINE MONOMER SYNTHESIS 
The 1,5-anhydrohexitol building block 13 for oligonucleotide synthesis (1 mmol, 0.62 
g) has been prepared as described in details in the CPNAC40; however, some procedures 
were changed and, noteworthy, the reaction yields sometimes improved. The present 
experimental section contains thus only the new procedures and the new compounds, 
fully characterized. 
 
Compound 5: 4 (10 g, 0.024 mol) was dissolved in dry toluene (70.0 mL), then Et3SiH 
(0.24 mol, 38.0 mL) was added. The mixture was cooled to 0°C and PdCl2 (catalytic 
amount, 10%) carefully added (0.430 g, 2,44 mmol); after that the mixture was warmed 
to RT and stirred for 24h. Once filtered on a Celite pad (and washed with EtOAc), the 
crude was concentrated under reduced pressure and purified by flash cromatography 
(hexane:EtOAc=80:20) affording 5 as a white solid (6.4 g, 79% reaction yield). The 
spectroscopic properties of 5 are fully in line with those described in the CPNAC. 
 
Compound 7: 6 (5.8 g, 0.035 mol) was dissolved in dry DMF (60.0 mL) under nitrogen 
atmosphere; then benzaldehyde dimethyl acetal was dropwise added (6.9 mL, 0.048 
mol). The pH was led to 4 by adding CSA (5%) (0.41 g, 1.76 mmol). The mixture was 
stirred for 30’ at RT, quenched with TEA until neutral and then extracted with 
DCM:MeOH (95:5) and brine; organic layers were dried (Na2SO4) and solvent 
evaporated under reduced pressure. Flash chromatography over silica gel of the crude 
(chloroform:MeOH=97:3) affords the pure 7 as a white solid (7.1 g, 87% reaction yield). 
The spectroscopic properties of 7 are fully in line with those described in the CPNAC. 
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Compound 9: once dissolved 8 (10.4 g, 0.026 mol) in dry DCM (150.0 mL), O-phenyl 
chlorothionoformate (4.2 mL, 0.031 mol) and DMAP (6.4 g, 0.051 mol) were added. 
After 30’ the mixture was extracted with DCM and brine, the organic layers dried 
(Na2SO4) and concentrated under reduced pressure. Cromatography over silica gel of the 
crude (hexane:EtOAc=50:50) afforded the pure 9 as white solid (9.5 g, 71% reaction 
yield). 1H NMR (400 MHz, CDCl3), δ: 2.41 (s, 3H), 3.48-3.54 (m, 1H), 3.61 (t, J =10.8 
Hz, 1H), 3.69-3.75 (m, 2H), 4.29 (dd, J=6.3, 11.6 Hz, 1H), 4.36 (dd, J= 4.6, 10.4 Hz,1H), 
4.72-4.79 (m, 1H), 5.50 (s, 1H), 5.94 (t, J=9.5 Hz, 1H), 6.98 (d, J =7.6 Hz, 2H), 7.29-
7.42 (m, 3H), 7.85 (d, J=7.7 Hz, 2H). 13C NMR (100 MHz, CDCl3), δ: 21.8, 68.4, 68.6, 
71.4, 75.2, 79.0, 81.0, 101.6, 121.8, 126.2, 126.9, 128.1, 128.4, 129.2, 129.6, 130.2, 
133.0, 136.7, 145.6, 153.6, 194.3. 
 
Nucleoside 11: once dissolved 10 (4.8 g, 0.012 mol) in dry DMF (190.0 mL), 2-amino-
6-chloropurine (4.9 g, 0.028 mol) was added. The mixture was stirred under nitrogen 
atmosphere for 15’; then DBU (4.3 g, 0.03 mol) was gently added and the mixture was 
warmed to 90 °C. After 72h at the same temperature, the mixture was extracted with 
EtOAc and brine, the organic layers dried (Na2SO4) and concentrated  
under reduced pressure. Flash cromatography of the crude (chloroform:MeOH=97:3) 
afforded the pure 11 as a white solid (2.1 g, 45 % reaction yield). 1H NMR (400 MHz, 
CDCl3), δ: 2.11-2.20 (m, 1H), 2.59-2.64 (m, 1H), 3.57-3.68 (m, 2H), 3.79 (t, J=9.8 
Hz,1H), 4.09-4.15 (m, 1H), 4.37 (dd, J =4.6, 10.7 Hz, 1H), 4.41-4.45 (m, 1H), 4.82 (bs, 
1H), 4.98-5.30 (m, 2H), 5.50 (s, 1H), 7.33-7.36 (m, 3H), 7.41-7.44 (m, 2H), 8.31 (s, 1H). 
13C NMR (100 MHz, CDCl3), δ: 31.3, 32.9, 51.0, 69.0, 61.5, 73.9, 74.8, 102.2, 126.2, 
128.3, 129.3, 137.2, 141.5, 151.7, 153.7, 159.2. 
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OLIGONUCLEOTIDE SYNTHESIS 
Oligonucleotide assembly was performed with an Expedite DNA synthesizer (Applied 
Biosystems) by phosphoramidite approach. The oligomers were deprotected and cleaved 
from the solid support by treatment with aqueous ammonia (33%) for 2 h. After gel 
filtration on a NAP-25 column (Sephadex G25-DNA grade from GE Healthcare) with 
water as eluent, the crude mixture was analyzed by using a Mono-Q HR 5/5 anion 
exchange column, after which purification was achieved by using a Mono-Q HR 10/100 
GL column (Pharmacia) with the following gradient system: buffer A (10 mM NaOH in 
0.1 M NaCl, pH 12.0) and buffer B (10 mM NaOH in 0.9 M NaCl, pH 12.0). After gel 
filtration on a NAP-25 column with water as eluent, the oligo was re-purified with the 
following gradient system: buffer A (0.1 M TEAA with 5% CH3CN, pH 7.5) and buffer 
B (0.1 M TEAA with 80% CH3CN, pH 7.5). The low-pressure liquid chromatography 
system consisted of a HITACHI Primaide organizer with a HITACHI Primaide 1410 
UV detector and with a HITACHI Primaide 1110 pump and a Mono-Q HR 10/100 GL 
column (Pharmacia). The product-containing fraction was desalted on a NAP-25 column 
and lyophilized. Analysis by mass spectrometry was subsequently performed. Before 
each analysis, all anti-thrombin aptamers were first folded in the SB buffer (TABLE 3) 
by heating to 95 °C for 5 min followed by slow cooling to 8 °C and equilibration to room 
temperature. 
BINDING AND STABILITY ASSAYS 
Electrophoretic mobility shift assay (EMSA). In this assay, 50 µL of the total reaction 
volume containing 200 nM of renatured anti-thrombin aptamer solution without or with 
200 nM of human -thrombin in SB was incubated for 2 h at room temperature upon 
shaking at 300 rpm. After incubation, 10 µL of 6× gel loading buffer was added to the 
samples, and 20 µL of the final solutions was run on a 6% Native PAGE (see TABLE 3 
for details) with 0.5× TBE (running buffer) at 150 V and  18 °C until the bromophenol 
blue dye was  3 cm below the bottom of the gel wells ( 1.5 h). The gels were incubated 
in 1× SYBR Gold Nucleic Acid Gel Stain for 10 min and scanned using the Typhoon 
9500 imaging system (Cy2-channel) and quantified with the ImageQuant TL v8.1 
software (both from GE Healthcare Life Science). Band intensities of each aptamer 
variant were measured, normalized by that of unmodified thrombin aptamer and the 
relative binding abilities were calculated. The EMSA experiment was repeated three 
times, and the average data are plotted on the graph in FIGURE 8. 
Stability of unmodified and modified aptamers in human serum. Unmodified and HNA-
modified aptamer variants (2 µM each) were incubated in 90% whole human serum at 
37 C in 100 µL total reaction volume. Aliquots (10 µL) of each reaction were taken at 
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different time intervals (0, 1, 6, 24, 48, and 72 h). Then 10 µL of H2O was added to each 
aliquot together with 20 µL of 2× quenching buffer. The samples were denatured at 95 
C for 10 min, then were kept at -20C until analysis by denaturing 15% PAGE. The 
gels were incubated in 1× SYBR Gold Nucleic Acid Gel Stain for 10 min followed by 
visualization using the Typhoon 9500 imaging system (Cy2-channel) and the 
ImageQuant TL v8.1 software. The analysis was performed two times and average band 
intensities corresponding to full-size aptamer in each time point (normalized by that at 0 
h point) were plotted on the graph in FIGURE 9. 
TABLE 3. Buffer and solutions used in the studies 
Buffer/Solution Composition Purpose 
SB 40 mM Tris-HCl (pH 7.4), 2 mM MgCl2, 
2 mM KCl, 100 mM NaCl, 1 mM CaCl2 
Aptamer – Thrombin 
incubation buffer  
1× gel loading buffer 2.5% Ficoll 400, 40 mM Tris-HCl (pH 
7.4), 2 mM MgCl2, 2 mM KCl, 100 mM 
NaCl, 1 mM CaCl2, 0.02% bromophenol 
blue and xylene cyanol FF 
Gel loading buffer for 
Native PAGE analysis 
6% Native PAGE For 100 mL, 15 mL 40% 
Acrylamide/Bis-acrylamide (29:1) 
solution, 5 mL 10× TBE (final 0.5×), 80 
mL H2O 
Electrophoretic mobility 
shift assay of aptamer-
thrombin samples 
2× quenching buffer 95% formamide, 18 mM EDTA, 0.25% 
SDS, 0.05% bromophenol blue 
Gel loading buffer for 
15% denaturing PAGE 
15% PAGE For 100 mL, 37.5 mL 40% 
Acrylamide/Bis-acrylamide (19:1) 
solution, 10 mL 10× TBE (final 1×), 
52.5 mL H2O 
Analysis of samples after 
human serum stability 
assay 
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GENERAL CONCLUSIONS 
The reader will have noticed that every chapter of this PhD thesis already contains its 
conclusions about the experimental results obtained and the potential future 
perspectives. However, I would give you more general conclusions trying to explain how 
the selectivity associated to biomolecular recognition processes is a concept sometimes 
independent from those “chemical rules” that we have learned over the years. We 
usually identify the molecules in terms of atoms and of their periodic properties, 
connectivity and bound strength, R or S stereocenters configuration, conformational 
behaviour, in terms of contained functional groups and resultant reactivity and thus in 
terms of nucleophilicity or electrophilicity. The biomolecular recognition processes can 
be also viewed as chemical reactions between the guests (the enzymes) and the hosts 
(substrates). However, independently from the nature of the catalysed reaction, the 
molecular symmetry of the two involved counterparts has a central role into the 
development of most biological and physiological processes. We know that the 
“l’Univers est dissymétrique”, but the questions about the dissymetrization process at 
the origin of life, are still unanswered. Proteins made of L-aminoacids and sugars 
belonging to the D-series are the main result of such a process. The dissymmetry of 
nature is the reason why until few years ago, the attention was mainly focused only on 
the use of D-sugars as convenient source of starting material for organic synthesis of 
complex natural products and for biological investigations. Even, the reason why for a 
long period it was assumed that nucleoside analogues having only a natural D-
configuration, by analogy with the natural ones, could exert biological activity. 
 Then, the identification of L-sugars as constituents of biologically relevant 
compounds (i.e. oligosaccharides, antibiotics, glycopeptides and terpene glycosides) 
has moved the attention toward their synthetic preparation and, on the same line, the 
discovery of (-)-3TC has challenged the same paradigm in the field of nucleoside 
analogues discovery as antiviral and anticancer agents. 
 In other words, these more and more frequent examples of molecules with 
unconventional chirality but with biological/pharmacological interest, suggested us the 
idea to view the molecules as chemical entities made of electronic densities which, 
independently by the above-mentioned classifications, are able to fit the target enzymatic 
site and furnish biological activity. In this way, as accomplished during this PhD 
research project, the biological selectivity concept can be revised and in several not 
accidental cases (as shown), can be useful to reach interesting results in the field of drug 
discovery. 
“If it fits, it sits”. 
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PhD Courses 
• Glicoscienza (Prof. Michelangelo Parrilli and Dr Emiliano Bedini), July 5th-
12th, 2016. 
• Corso avanzato di Spettrometria di Massa (Prof. Piero Pucci), July 11th-15th, 
2016. 
• Chimica fisica degli acidi nucleici (Dr Luigi Petraccone), May 17th-19th, 2017. 
• Synthesis, structure and applications of natural and modified oligonucleotides 
(Prof. Daniela Montesarchio), July 17th-20th, 2017. 
• Produzione ricombinante di proteine naturali e mutanti (Prof. Angela Duilio), 
July 18th-20th, 2017. 
 
Publications 
• D’Alonzo, D.;* De Fenza, M.; Palumbo, G.; Romanucci, V.; Zarrelli, A.; Di 
Fabio, G. Guaragna, A. Synthesis of β-L-2'-Fluoro-3'-Thiacytidine (F-3TC) 
Stereoisomers: Toward a New Class of Oxathiolanyl Nucleosides? Synthesis 
2017, 49, 998-1008.  
• D’Alonzo, D.;* De Fenza, M.; Porto, C.; Iacono, R.; Huebecker, M.; Cobucci 
Ponzano, B.; Moracci, M.; Parenti, G.; Priestman, D.; Platt, F.; Palumbo, G.; 
Guaragna, A. N-Butyl-L-Deoxynojirimycin (L-NBDNJ): Synthesis of an 
Allosteric Enhancer of a-Glucosidase Activity for the Treatment of Pompe 
Disease J. Med. Chem. 2017, 60, 9462-6469. 
• De Fenza, M.; D' Alonzo, D.;* Esposito, A.; Munari, S.; Loberto, N.; 
Santangelo, A.; Lampronti, I.; Tamanini, A.; Rossi, A.; Ranucci, S.; De Fino, I.; 
Bragonzi, A.; Aureli, M.; Sonnino, A.; Lippi, G.; Gambari, R.; Cabrini, G.; 
Palumbo, G.; Dechecchi, M.C.; Guaragna, A. Anti-Inflammatory Treatment of 
Cystic Fibrosis Lung Disease: Exploring the Effect of Chirality on the 
Therapeutic Potential of N-Alkyl-Deoxyiminosugars. Manuscript submitted. 
 
Training Courses 
• NMR Advanced Course, May 3rd-5th, 2017, Bruker Italia S.r.l. Milano. 
 
Congress Schools 
• 43rd Edition of the “A. Corbella” International summer school on organic 
Synthesis (ISOS 2018), June 10th-14th, 2018, Gargnano (Brescia, Italy) 
. 
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Seminaries 
• “1,1,2,2-Tetraethoxybutyne - Exciting to Make and Work with” – Prof. Leiv K. 
Sydnes, January 14th, 2016, Dipartimento di Scienze Chimiche, Università degli 
Studi di Napoli Federico II. 
• “Multimodal Approaches for Preclinical Molecular Imaging” – Prof. Luca 
Menichetti and Prof. Mario Chiariello, February 5th, 2016, Dipartimento di 
Scienze Chimiche, Università degli Studi di Napoli Federico II. 
• “The Importance of Catalysis in the Synthesis of Active Pharmaceutical 
Ingredients" – Dr Michelangelo Scalone, November 25th, 2016, Dipartimento di 
Scienze Chimiche, Università degli Studi di Napoli Federico II. 
• “Chemical biology and medicinal chemistry of glycosphingolipid metabolism” 
– Prof. H. Overkleeft, December 19th, 2016, Dipartimento di Scienze Chimiche, 
Università degli Studi di Napoli Federico II. 
• “The future of chemistry written in unconventional reaction media” – Prof. Vito 
Capriati, February 28th, 2018, Dipartimento di Scienze Chimiche, Università 
degli Studi di Napoli Federico II. 
• “Chemical Synthesis and Characterization of Chondroitin Sulfate” – Prof. 
Tamura, July 23th, 2018, Dipartimento di Scienze Chimiche, Università degli 
Studi di Napoli Federico II. 
• “The golden age of Glycoscience – new tools in synthesis and analysis” – Prof. 
S. Flitch, September 24th, 2018, Dipartimento di Scienze Chimiche, Università 
degli Studi di Napoli Federico II. 
 
Congress Participations 
• Challenges in Organic Synthesis: Efficient Processes for Novel Applications, 
11th-12th December 2015, Naples (Italy). 
• XXII International Roundtable on Nucleosides, Nucleotides and Nucleic Acids, 
18th-22th July 2016, Paris (France).  
• XVIIth Symposium on Chemistry of Nucleic Acid Components, 4th-9th June 2017, 
Český Krumlov (Czech Republic). 
• Prospettive e sfide della moderna chimica organica. In ricordo di Alessandro 
Ballio, Gian Paolo Chiusoli e Giorgio Modena, 26th May 2017, Accademia 
Nazionale dei Lincei, Roma (Italy). 
• SCI 2017–XXVI Congresso Nazionale della Società Chimica Italiana, 10th-14th 
September 2017, Paestum (Italy). 
• XLIII "A. Corbella" International Summer School on Organic Synthesis, 10th-
14th June 2018, Gargnano (Italy). 
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• SISOC XII–12th Spanish-Italian Symposium on Organic Chemistry, 2nd-4th July 
2018, Ferrara (Italy). 
Oral Presentations 
• Maria De Fenza, Anna Esposito, Graciela Andrei, Robert Snoeck, Annalisa 
Guaragna, Daniele D’Alonzo. “Novel Piperidinyl Iminosugar-Based 
Nucleosides as Selective Pharmacological Tools”, XVIIth Symposium on 
Chemistry of Nucleic Acid Components, Cesky Krumlov, Czech Republic, 4th-
9th June 2017.  
• Maria De Fenza, Anna Esposito, Daniele D’Alonzo, Annalisa Guaragna. 
“Highly stereocontrolled de novo synthesis of N-alkyl L-deoxynojirimycin 
derivatives and their pharmacological applications in rare diseases”, XLIII "A. 
Corbella" International Summer School on Organic Synthesis, Gargnano, Italy, 
10th-14th June 2018.  
• Anna Esposito, Maria De Fenza, Daniele D’Alonzo, Annalisa Guaragna. “De 
novo synthesis of L-DNJ and its N-alkylated derivatives”, XVI Convegno-
Scuola sulla chimica dei carboidrati, Certosa di Pontignano, Siena, Italy, 17th-
20th June 2018.  
• D'Alonzo, D.; De Fenza, M.; Esposito, A.; Munari, S.; Loberto, N.; Santangelo, 
A.; Lampronti, I.; Tamanini, A.; Rossi, A.; Ranucci, S.; De Fino, I.; Bragonzi, 
A.; Aureli, M.; Sonnino, A.; Lippi, G.; Gambari, R.; Cabrini, G.; Palumbo, G.; 
Dechecchi, M.C.; Guaragna, A. “Synthesis of N-Alkylated-L-Iminosugars and 
their Therapeutic Application in Cystic Fibrosis Lung Disease”, XXXVIII 
Convegno Nazionale della Divisione di Chimica Organica della Società 
Chimica Italiana, Milano, Italy, 9th-13th September 2018. 
Poster Presentations 
• De Fenza, M.; Guaragna, A.; Esposito, A.; Andrei, G.; Snoeck, R.; Di Fabio, G.; 
Zarrelli, A.; D’Alonzo, D.; “Novel D- and L-Cyclohexenyl Nucleosides: 
Asymmetric Synthesis and Antiviral Activity”-XXII International Roundtable on 
Nucleosides, Nucleotides and Nucleic Acids, Paris (France), 18th-22th July 2016.  
• Esposito, A.; De Fenza, M.; Guaragna, A.; Andrei, G.; Snoeck, R.; Talarico, G.; 
D’Alonzo, D.; “Synthesis and Biological Evaluation of D- and L-Cyclohexenyl 
Nucleosides” - XVIIth Symposium on Chemistry of Nucleic Acid Components, 
Cesky Krumlov, Czech Republic, 4th–9th June 2017.  
• De Fenza, M.; Esposito, A.; Andrei, G.; Snoeck, R.; Guaragna, G.; D’Alonzo, 
D.; “Synthesis and Biological Evaluation of Novel Piperidinyl Iminosugar-
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Based Nucleosides”, XXVI SCI – Congresso Societaà Chimica Italiana, 
Paestum (Italy), 10th-14th September, 2017. 
• Esposito, A.; De Fenza, M.; Andrei, G.; Snoeck, R.; Talarico, G.; Guaragna, G.; 
D’Alonzo, D.; “Asymmetric Synthesis and Antiviral Activity of Novel 
Carbocyclic Nucleosides”, XXVI SCI – Congresso Societaà Chimica Italiana, 
Paestum (Italy), 10th-14th September 2017.  
• Maria De Fenza, Anna Esposito, Daniele D’Alonzo, Annalisa Guaragna. 
“Highly stereocontrolled de novo synthesis of N-alkyl L-deoxynojirimycin 
derivatives and their pharmacological applications in rare diseases”, XLIII "A. 
Corbella" International Summer School on Organic Synthesis, Gargnano, Italy, 
10th-14th June 2018. 
• Anna Esposito, Maria De Fenza, Giuseppe Punzo, Daniele D’Alonzo, Annalisa 
Guaragna. “New O-Glycosidation methods for the synthesis of unnatural 
oligosaccharides”, XLIII "A. Corbella" International Summer School on 
Organic Synthesis, Gargnano, Italy, 10th-14th June 2018. 
• Maria De Fenza, Anna Esposito, Daniele D’Alonzo, Annalisa Guaragna. “A 
novel synthetic approach to N-alkyl iminosugars with broad therapeutic 
potential”, SISOC XII – 12th Spanish-Italian Symposium on Organic 
Chemistry, Ferrara, Italy, 2nd-4th July 2018.  
• Daniele D'Alonzo, Maria De Fenza, Anna Esposito, Silvia Munari, Nicoletta 
Loberto, Alessandra Santangelo, Ilaria Lampronti, Anna Tamanini, Alice Rossi, 
Serena Ranucci, Ida De Fino, Alessandra Bragonzi, Massimo Aureli, 
Alessandro Sonnino, Giuseppe Lippi, Roberto Gambari, Giulio Cabrini, Maria 
Cristina Dechecchi, Annalisa Guaragna. “Synthesis of N-Alkylated L-
Iminosugars and their Therapeutic Application in Cystic Fibrosis Lung 
Disease”, SISOC XII – 12th Spanish-Italian Symposium on Organic Chemistry, 
Ferrara, Italy, 2nd-4th July 2018. 
 
Grants and awards 
• Travel Grant to attend: “Prospettive e sfide della moderna chimica organica. In 
ricordo di Alessandro Ballio, Gian Paolo Chiusoli e Giorgio Modena” – 
Accademia Nazionale dei Lincei, Roma, Italy, 26th May 2017.  
• Fellowship to attend: XLIII "A. Corbella" International Summer School on 
Organic Synthesis, Gargnano, Italy, 10th-14th June 2018. 
• Fellowship to attend: SISOC XII – 12th Spanish-Italian Symposium on Organic 
Chemistry, Ferrara, Italy, 2nd-4th July 2018. 
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• Poster Award IS3NA Antonin Holy, XXII International Roundtable on 
Nucleosides, Nucleotides and Nucleic Acids, 18th-22th July 2016, Paris 
(Francia) – De Fenza, M.; Guaragna, A.; Esposito, A.; Andrei, G.; Snoeck, R.; 
Di Fabio, G.; Zarrelli, A.; D’Alonzo, D. “Novel D- and L-Cyclohexenyl 
Nucleosides: Asymmetric Synthesis and Antiviral Activity”.  
Abroad research periods 
•  9th April-31st May 2018 – PhD Visiting Scholar at Department of Biochemistry 
(Supervisor: Prof. Nicole Zitzmann), University of Oxford. 
• 1st June-20th July 2018 - PhD Visiting Scholar at Department of Pharmacology 
(Supervisors: Prof. Frances Platt, Dr David A. Priestman), University of Oxford. 
 
